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A mi hermano 
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  Los tónicos de la voluntad: Reglas y consejos sobre 
investigación científica. 1899
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Abstract
The complex interactome of GRK2 points to this kinase as a key node in the signal transduction network of the cell, contributing to the proper functioning of basic cellular processes such as cellular migration, cell cycle progression or angiogenesis. 
Both GRK2 expression levels and activity are frequently found unbalanced in diverse diseases, 
thus suggesting a role for this kinase in aberrant cellular processes related to the onset or 
development of these pathologies. In the present work, we have extensively characterized the 
role of GRK2 as a novel onco-modulator of breast tumoural transformation, with particular 
focus on its impact in the Mdm2/p53 axis and /or in  HDAC6-mediated responses. We 
have determined that high-amplification of ErbB receptors such as EGFR or Her2 and 
over-activation of the PI3K/AKT axis as a result of mutations in PI3K-p110, PTEN or 
AKT genes (all frequent molecular features of luminal types of breast tumours) converge in 
promoting GRK2 accumulation. Enhanced GRK2 levels are also triggered by the amplified 
oestrogen signalling characteristic of luminal tumours. Increased GRK2 expression, which 
is detected in transformed breast cell lines, in two murine mammary tumor models and in 
patients, would in turn activate two key regulatory axis /signalling modules with either 
Mdm2 or HDAC6 (also up-regulated in luminal breast cancer), leading to promotion of  cell 
proliferation, survival and invasion in transformed cells. We find that ERK1/2-mediated 
modification of GRK2 at S670 enables GRK2-mediated HDAC6 phosphorylation and 
stimulation of its tubulin-deacetylase activity and microtubule dynamics, what results 
in higher persistence growth factor-dependent signalling and increased duration and 
extent of downstream stimulation of mitogenic and pro-survival molecules such as Ras, 
MAPK, AKT and Pin1. Moreover, our findings suggest that in breast tumoral contexts, 
GRK2 can act  as a positive modulator of Mdm2 functionality. We describe herein that 
GRK2 specifically phosphorylates Mdm2 and potentiates the Mdm2-dependent wild-
type p53 downmodulation, resulting in enhanced cell survival. On the other hand, the 
phosphorylation of GRK2 at S670 seems to cause a switch on the sub-cellular distribution 
of this kinase in tumour cells harboring mutant p53 (as luminal T47D, basal-A MDA-
MB-468 or basal MDA-MB-231 cells), what could amplify oncogenic functions by means 
of the increased functional competence of Ras/Pin1 and HDAC6, which are involved in 
protecting mutant p53 from degradation and supporting its functionality. In fact, our data 
show that GRK2 function is required (in a p53 status-independent fashion) for enhanced 
proliferation, anchorage-independent growth, survival and invasion of tumoral breast cells 
“in vitro” and for tumor progression “in vivo”, thus suggesting a relevant and general role 
for GRK2 as an onco-modulator of key processes involved in breast tumor development.
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Resumen en castellano
E
l complejo interactoma de GRK2 señala a esta quinasa como un nodo clave para la red 
de transducción de señales de la célula, participando en procesos básicos tales como la 
migración celular,  la progresión del ciclo celular o la angiogénesis. Tanto los niveles 
de expresión de GRK2 como su actividad están sometidos a estrictos mecanismos de control 
que frecuentemente se ven alterados en diversos contextos fisiopatológicos, sugierendo un papel 
relevante de esta quinasa en la aparición o el desarrollo de estas patologías. En el presente trabajo 
se ha identificado a GRK2 como un nuevo onco-modulador de la transformación tumoral, 
responsable de estimular la adquisición de proliferación sostenida, crecimiento independiente de 
anclaje, supervivencia e invasividad de células de mama. Hemos caracterizado los mecanismos 
moleculares de la función onco-moduladora de GRK2, demostrando el papel crucial de esta 
quinasa en la regulación de la ligasa Mdm2 y la deacetilasa HDAC6 y sus consecuencias en la 
actividad de los módulos celulares de señalización de p53 y de Ras, cuya alteración  es clave para la 
transformación celular. Nuestros resultados indican que la co-regulación al alza de GRK2/Mdm2/
HDCA6 es una nueva característica molecular de los tumores de mama de tipo luminal que podría 
estar asociada a una mayor agresividad y peor prognosis. Hemos determinado que el exceso de 
actividad de la cascada de PI3K/Akt, como resultado de mutaciones en PI3K p110, PTEN o 
AKT o de la amplificación/sobre-estimulación de receptores ErbB, así como la sobre-activación de 
receptores de estrógenos, convergen en la acumulación de GRK2 en modelos celulares y animales 
y en pacientes. El aumento de la proteína GRK2 en líneas tumorales de mama luminales, junto 
con el de su fosforilación por ERK1/2 en el residuo S670 (característica también común a las 
líneas celulares derivadas de tumores basales) facilita y permite, respectivamente, la modificación 
por GRK2 de HDAC6, lo que conduce a  la estimulación de  la actividad tubulina deacetilasa 
y de la dinámica de microtúbulos, que a su vez lleva a potenciar la duración e intensidad de las 
señales mitogénicas y de supervivencia, así como a promover un fenotipo migratorio invasivo, 
estimulando la formación y funcionalidad de invadopodios. Por otro lado, nuestros resultados 
sugieren un nuevo mecanismo de regulación negativa del supresor tumoral p53 mediada por 
GRK2 a través del control directo de Mdm2. En contextos oncogénicos de mayor actividad Ras/
ERK1/2 y/o PI3K/Akt, la interacción entre GRK2 y Mdm2 se reprograma con consecuencias 
funcionales distintas: estabilización de GRK2 y modulación de Mdm2 como nuevo sustrato de 
GRK2. Hemos identificado los sitios de fosforilación de Mdm2 por GRK2 y demostrado que estas 
modificaciones aumentan la estabilidad de la ligasa, promueven la interacción de la proteína con 
p53 causando la desestabilización de p53 y disminuyen las respuestas apoptóticas dependientes 
de este factor transcripcional. Además, la interrelación de GRK2 con Mdm2 y HDAC6 atenúa la 
capacidad citotóxica tumoral y anti-proliferativa de compuestos inhibidores de Mdm2 (Nutlin-3a) 
y de HDAC6 (tubacina, SAHA). Por último, la contribución de GRK2 a las respuestas mitogénicas 
y de supervivencia a través de la modulación de la actividad de Ras/Pin1 y de p53 vía Mdm2 
y HDAC6 es necesaria para el crecimiento y progresión de tumores de mama “in vivo” tanto 
basales como luminales, sugiriendo un papel clave y global de GRK2 como onco-modulador de los 
diferentes procesos que dan lugar al desarrollo del cáncer de mama.
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1. 
Hallmarks of cancer
Advances in Molecular Biology have revolutionized our understanding and knowledge of the pathogenesis of cancer, a disease that, until the 1990s, was mostly studied in purely descriptive terms. Nowadays, cancer is understood as a 
process caused by sequential genetic and epigenetic alterations that deregulate the activities 
of pathways mediating normal cellular functions, thus disrupting the regulatory circuits 
that govern normal cell proliferation and cell homeostasis. This multi-step process does not 
result from an abrupt transition from a normal to malignant condition, but instead involves 
progressive and gradual occurrence of molecular modifications and cellular adaptations 
by selective pressure over many years, what leads to considerable heterogeneity and 
variability among cancers. However, it has been proposed that most and perhaps all types 
of human tumours must acquire a succession of common capabilities that enable normal 
cells to become tumorigenic and ultimately malignant.  These capabilities represent six 
essential alterations in cell physiology that collectively dictate malignant transformation 
and have been termed as “hallmarks of cancer” (Hanahan et al., 2000; Hanahan & 
Weinberg, 2011). These hallmarks were initially defined as: maintained proliferative 
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signalling, insensitivity to growth-inhibitory signals, resistance to cell death, limitless 
replicative potential, induction of angiogenesis and tissue invasion and metastasis. In 
the last decade two emerging hallmarks were added to this list: metabolic reprogramming 
and evading immune response (FIG. I.1). None of these hallmarks is sufficient by itself 
to promote transformation, but their intertwinement profoundly modifies the normal 
cellular behaviour and allows cells to survive, proliferate and disseminate. In addition, 
two transversal characteristics are permissive for the acquisition of these tumoural traits, 
thereby functioning as driving forces of cellular transformation.  Such “tumour-enabling” 
properties include development of genomic instability and the chronic inflammation linked 
to pre-malignant and tumoural lesions.  Impaired functionality of genome maintenance 
pathways underpins the increased mutation rate of cancer cells, what permits the rise of 
genetic changes that may orchestrate tumoural hallmarks.  In turn, immune cells and 
inflammatory mediators can contribute to debilitate genomic surveillance mechanisms 
and to foster cancer progression by providing cell survival and proliferation support 
through direct impact on tumour cells or indirect remodelling of the surrounding stroma. 
Indeed, contributions of non-tumoural components (extracellular matrix, fibroblasts, 
resident immune cell types or vascular cells) are important for tumour growth, and feed-
back reciprocal interactions between the neoplastic cells and the supporting stromal cells 
are at the root of high-grade malignancies.  Therefore, tumour biology cannot be longer 
build on a simple recapitulation of capabilities but instead must consider contributions 
of the ‘‘tumour microenvironment’, what adds another dimension of complexity in the 
acquisition of cancer traits. 
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Figure I.1. Hallmarks of cancer. 
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2. 
Physiology and complexity of breast cancer
Breast cancer is one of the most common cancers with more than 1,300,000 cases and 450,000 deaths each year world-wide and the most frequently diagnosed neoplastic process in women (Banin Hirata et al., 2014). Breast cancer is not 
a simple or uniform disease, but represents a heterogeneous disease including different 
histopathological entities with different molecular signatures, genetic and genomic 
variations (Ellsworth et al., 2009.).
 Physiologically, the breast is an organ which structure reflects its special function: 
the production of milk for lactation.  Mammary glands consist of 15–20 epithelial lobes, 
each of which develops numerous milk-producing lobules upon pregnancy (Fig I2A). Each 
lobule and lobe is connected to the nipple via ducts that transport milk. The lobules and 
ducts consist of a bi-layered epithelium comprising an inner layer of milk-producing luminal 
epithelial cells and an outer layer of myoepithelium that contracts to generate milk flow. 
Besides this function, breast myoepithelial cells play an important role in the suppression of 
tumour invasion as they form a natural fence separating the menstrual-cycling proliferative 
epithelial cells from the stroma. Nutrients are supplied to the breast tissue through a rich-
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network of blood vessels, primarily derived from the internal mammary artery, while the 
interstitial protein-rich fluid is returned to the bloodstream by the lymphatic vessels of the 
breast that follow blood vessels in an opposite flow direction, to drain into lymph nodes. 
 
The first classification of  breast cancer is based on the identity of the tissue component 
that gives raise to the tumour. According to that, carcinomas and sarcomas are the two 
main groups. Carcinomas arise from the epithelial component of the breast (i.e., cells that 
form the lobules and terminal ducts) and comprise the vast majority of all breast cancers, 
whereas sarcomas are less common cancers that originate from the stromal (connective 
tissue) component of the mammary gland. The most common type of breast carcinoma 
is the ductal carcinoma in situ (DCIS), a non-invasive lesion that contains abnormal cells 
inside of the pre-existing normal ducts, which precursor is thought to be the Atypical ductal 
hyperplasia (ADH), a pre-malignant lesion characterized by monotonous proliferation of 
regularly arranged cells within the duct or lobule. In those hyperplasias that are associated 
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Figure I.2. Breast cancer classification. A) Schematized view of the tissue organization in mammary 
gland with an expansion of the cell types that develop breast cancer. B) Classification of breast cancer 
according to the molecular features of each tumour, showing the different proportions of mutations in key 
genes deregulated in the onset of the disease. 
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with an increased incidence of malignancy, it appears that the luminal epithelial cells or 
the still-uncharacterized basal stem cells are the targets for transformation. Interestingly, 
myoepithelial cells have the property of self-renewal and it has been proposed that halt of 
stem cell differentiation into this cell type contributes to tumorigenesis (Pandey, 2011). 
In situ carcinoma has significant potential to become invasive and develop an infiltrating 
ductal carcinoma (IDC), with cancer cells infiltrating outside the normal breast ducts and 
growing into the breast connective tissue until they finally spread to other sites of the body. 
In such dissemination process the lymphatic drainages of the breast and the intercostal 
veins plus the vertebral plexus are of great importance to colonize in the form of metastasis 
lymph nodes and bones or the nervous system, respectively, among other organs (Vargo-
Gogola & Rosen, 2007). 
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3.  
Molecular classification of breast cancer.  
Based on distinctive molecular profiling, breast ductal carcinomas, that comprise 80% of all breast cancers, can be grouped according to the Perou’s classification in luminal A, luminal B, ERBB2+ (or HER2+) and basal-like, also referred as 
triple negative because they are negative for ER, PR and ERBB2 and associated with 
poor outcome and prognosis (Holliday & Speirs, 2011) (Fig 2.B). Luminal and basal 
subtypes display molecular similarities to the luminal and myoepithelial cells of the 
normal mammary gland, respectively. Thus, basal-type breast cancers are enriched in 
myoepithelial cytokeratins 5/6, 14 and 16, whereas luminal-type tumours harbour luminal 
markers (estrogen receptor-alpha, GATA-3 and cytokeratins 8/18), what would suggest 
that the former tumours arise from the underlying basal (myoepithelial) layer of normal 
breast ducts and the latter from the luminal secretory layer. However, this simplistic notion 
has been called into question since the previously accepted basal-layer origin for Brca1 
mutant breast cancer has turned into ER-negative luminal origin (Molyneux et al., 2010), 
suggesting that luminal progenitor cells might trans-differentiate into basal cells or de-
differentiate to a bipotent progenitor/ stem cell. 
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 Irrespective of the histological origin of the transformed cell, both A and B luminal 
types of breast cancer are positive for expression of ER, but luminal B is enriched in 
ERBB2 and p53 mutations, thereby exhibiting increased proliferation and worse prognosis. 
In contrast, 80% of basal-like tumours present mutations in TP53 (mostly non-sense 
mutations). Together with the RAS/MAPK pathway triggered by high-level amplification/
upregulation of growth factor receptors (ERBB2, IGF1R, EGFR), the PI3K pathway is 
also a major contributor to the uncoupled cellular proliferation and increased survival of 
breast tumour cells (Banerji et al., 2012; Cancer genome atlas network, 2012). A significant 
proportion of human breast tumours of luminal origin displays increased activity of the 
PI3K/AKT signalling axis by means of mutations in PIK3CA and AKT genes, while the 
remaining basal-like display only 9% PI3KCa mutations. However, genomic loss of PTEN 
is a common feature for basal-like tumours. The ERBB2 subtype presents Her2/ErbB 
family amplification and frequent p53 and PI3KCa mutations or loss of PTEN (Banerji 
et al., 2012; Cancer genome atlas network, 2012). Moreover, CyclinD1 amplification 
occurs with high incidence in luminal tumours, mostly in luminal B subtypes (Holliday & 
Speirs, 2011), whereas a novel subtype was recently described based on the low levels of 
claudin (Herschkowitz et al., 2007).  This last group displays all the features of the basal 
tumours but differs from the latter in the distinctive downregulation of claudin-3 and 4, 
low expression of the KI67 proliferation marker and enrichment for markers associated 
with the epithelial–mesenchymal transition and with mammary cancer stem cells, making 
these tumours more aggressive and highly metastatic (Holliday & Speirs, 2011; Kao et 
al., 2009). Breast tumour cell lines often mirrors the heterogeneity of the different types of 
tumours from which they derive, but basal cells lines can be additionally stratified in two 
subgroups, A and B as well (Kao et al., 2009). Interestingly, although tumours of the basal 
A subtype are triple-negative (ER-, PR- and ERBB2-), they share some luminal epithelial 
markers, what leads to a tumoural behaviour closest to that of luminal groups than to the 
more related basal B cell lines. 
 From a clinical point of view, breast tumour oestrogen receptor-positive patients 
are the more “treatable” group, since they can respond to endocrine therapies based on 
antagonists of the ER pathway. On the other hand, the HER2/ERBB2-amplified group of 
patients also can undergo successful clinical treatments with anti-ErbB2 therapy, whereas 
triple negative breast cancers lack specific molecular-targeted treatments and patients 
can only receive classical chemotherapy (Kao et al., 2009). However, some tumours can 
develop resistance to known therapies or, as mentioned before, relative resistance appears 
from cross talk between signalling pathways. Thus, a deep characterization of the molecular 
features and behaviour of the tumours is essential to find a specific directed therapy against 
each tumour. 
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4.  
Most relevant oncogenic pathways in breast cancer
To better understand breast cancer, a detailed study about the molecular changes that are taking place in cells as they become malignant is absolutely required. As mentioned before, there are several hallmarks common to cancer cells, but 
the underlying molecular mechanisms and signalling pathways engaged to promote these 
tumoural capabilities vary from one tumour to another. On the basis of gene expression 
signatures several modules within the cellular signalling network can be identified as core 
oncogenic signalling pathways and as those carrying frequently mutated genes. Such 
modules include the Ras, p53 and TGFb signalling blocks with their related transducing 
hubs and regulatory loops (Cui et al., 2007). These oncogenic blocks control key tumour-
related functions such as cell cycle control, cell proliferation and apoptosis. In this section, 
we summarize the most relevant signalling pathways related to these blocks in breast 
cancer, with a particular focus on their contribution to the acquisition of cancer hallmarks. 
It is worth noting that the functionality and competence of these blocks is also determined 
by the extent of post-translational modifications, including phosphorylation, acetylation, 
ubiquitination or SUMOylation of regulatory and signaling hubs.  In this context, the goal 
Introduction
53
of this thesis project is to gain insight into the functional interplay of the serine-threonine 
kinase GRK2 and the ubiquitin-ligase Mdm2 and the relevance of such interplay in breast 
tumour biology.
4.1. Oncogenic pathways controlling sustained proliferative signalling and cell 
survival
 It is worth noting that the most fundamental feature of cancer cells is their ability 
to sustain chronic proliferation. Normal tissues finely control the production and release 
of growth-promoting signals that direct entry into and progression through the cell cycle, 
thereby ensuring cell number homeostasis (Hanahan & Weinberg, 2011). However, cancer 
cells deregulate these signals through the over-expression or the acquisition of activating 
mutations on several proteins (encoded in so-called oncogenes), what leads to uncontrolled 
cell growth.
 Oncogene-driven proliferation of tumoural cells is assisted by various mechanisms. 
First, cells can produce their own growth factors or stimulate the continuous release of 
such factors by neighbouring normal cells within the tumour-associated stroma (Cheng et 
al., 2008; Bhowmick et al., 2004) . Alternatively, growth factor-receptor proteins displayed 
at the cancer cell surface can also be mutated or over-expressed, rendering such cells hyper-
responsive to otherwise-limiting amounts of growth factor ligands. Constitutive activation 
of signalling components operating downstream to these receptors may drive cellular 
growth factor-independent proliferation, thus overcoming the need of ligand-mediated 
receptor activation (Hanahan & Weinberg, 2011). Consequently, growth factor receptors, 
protein kinases regulators, GTP-protein signalling switchers, and transcription factors of 
specific signal transduction pathways for which particular cells display mitogenic-addiction 
are common targets for oncogenic transformation. 
a. Growth factor receptor signalling: tyrosine kinase receptors as a common platform for 
multiple oncogenic pathways
 Cell surface receptors that transduce growth-stimulatory signals into the cell are 
themselves targets of deregulation during tumour pathogenesis. Growth Factor (GF) 
receptors, often harbouring tyrosine kinase activities in their cytoplasmic domains, are 
hyper-activated in approximately 20–30% of human breast cancers (Iglehart et al., 1990). 
In particular, gene-amplification or over-expression of members of the human ErbB 
receptor family (constituted by four members: ErbB1 (EGFR/ HER1), the orphan receptor 
ErbB2 (HER2 or Neu), ErbB3 (HER3), and ErbB4 (HER4)) and the increased expression 
of activating growth factors such as EGF (ErbB1 ligand) or heregulin/neuregulin (ErbB3/
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ErbB4 ligands) are commonly observed and their occurrence has been closely associated 
to the incidence and poor prognosis of breast cancer (Citri, 2003; Hynes & Lane, 2005). 
 Upon agonist binding to their extracellular domains, ErbB receptors can homo- 
or hetero-dimerize. Their combinatorial dimerization and subsequent phosphorylation 
together with their distinct coupling to signalling adaptors (through SH2 domains) and 
effectors create a complex network of signalling events (Sosa et al., 2010). Regarding the 
ErbB2 receptor, no physiological selective ligands have been identified, but it is activated 
by cognate ligands of the other members of the EGFR receptor family by means of their 
heterodimerization (Olayioye et al., 2000). ErbB receptors can signal through AKT, 
MAPK, and many other pathways to regulate cell proliferation, differentiation, apoptosis, 
and cell motility (Fig. I.3). 
Figure I.3. Oncogenic signalling governing breast tumour transformation. Growth factors receptors, 
G-protein coupled receptors and Oestrogen receptors are the main mediators of the growth and survival 
signals that trigger oncogenic transformation. In this scheme, the main down-stream signalling pathways 
and the inter-relations between them are represented. 
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b. Signal transduction mediated by the ErbB receptor family: Mutations and/or alterations 
of  the Ras-Raf-MEK-ERK and PI3K/AKT signalling modules
 It is well established that members of the family of small GTP-binding proteins such 
as Ras mediate most of the ErbB responses. Upon ligand-induced trans-phosphorylation, 
the ErbB receptor associates with the growth factor receptor bound 2 (GBR2) adaptor, 
which triggers the recruitment of the protein SOS. Subsequently, SOS acts as a GEF 
(guanine nucleotide exchange factor) and catalyzes the exchange of GDP for GTP in 
the nucleotide-binding pocket of RAS-GTPases, thus resulting in their activation. In the 
activated GTP-bound state, Ras is able to bind to and activate several effectors proteins, 
such as the kinase b-Raf and the p110 catalytic subunit of PI3K (Rodriguez-Viciana et al., 
1994; Steelman et al., 2011) (Fig. I.3). Genetic abnormalities associated with breast cancer 
include gain-of-function mutations of ErbB effectors. Moreover, PI3KCA gene mutations 
or PTEN deletions are common features in many cases of breast cancer (Banerji et al., 
2012). Most notably, many Ras responses depend on cross-talking connections between 
both RAS/MAPK and PI3K pathways, increasing the likelihood and robustness of cell 
proliferation and survival (Cully et al., 2006; DeNicola & Tuveson, 2009; Eckert et al., 
2004; Margolis & Skolnik, 1994). Ras mutations are rarely seen in breast cancers (5%) but, 
still, there is considerable experimental evidence that aberrant Ras activation and signalling 
can promote breast cancer development (Eckert et al., 2004). Thus, in breast cancers Ras 
may be activated by persistent upstream signalling instead of through direct mutational 
activation. Defective EGFR downregulation and intracellular misrouting can drive such 
signalling persistence. Indeed, balance between recycling and degradation is determined by 
a regulatory cluster of Ser and Thr residues in the EGFR that is modified by several kinases 
including ERK1/2 and p38 or by the less characterized GRK2 (Freedman et al., 2002; 
Zhang et al., 2011). Thus, post-translational modifications including phosphorylation or 
ubiquitination and protein-protein interactions directly modulate EGFR functionality and 
can contribute to neoplastic cell transformation.
 i. The ErbB-dependent mitogenic signalling 
 Downstream ErbB receptors, active b-Raf phosphorylates and stimulates mitogen-
activated kinases (MEK) 1 and 2, which in turn phosphorylate the kinases ERK1 and 2 
(Margolis & Skolnik, 1994) (Fig I.3). Finally, the kinase cascade leads to the activation of 
transcription factors of the AP1 family among others, promoting the expression of many 
genes that encode growth factors, cyclins and cytokines which, collectively, trigger cellular 
proliferation (Mechta et al., 1997).  One of the most important final effectors of the Ras/
Raf/ERK pathway is Cyclin D1, which is in fact amplified in most human breast cancers, 
playing a pivotal role in the development of the disease by promoting cell cycle progression 
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(Caldon et al., 2010; Lee et al., 2000; Liu et al., 1995; Zeng et al., 2010). Additionally, it has 
been recently shown that the prolyl-isomerase Pin1, also frequently up-regulated in breast 
cancer, is another downstream target of the oncogenic Neu/Ras signalling and essential for 
Neu/Ras-induced cyclin D1 activation and cell transformation. Indeed, the upregulation 
of Pin1 in the context of Neu/Ras signalling was reported to enhance b-catenin and c-Jun 
signalling, leading to transactivation of the cyclin D1 gene. Furthermore, Pin1 is also able to 
directly bind cyclin D1 and to stabilize it via post-transcriptional mechanisms (Ryo, 2003; 
Ryo et al., 2002; Wulf et al., 2001) (Fig. I.3). It is possible that cyclin D1 also regulates 
Pin1 expression via E2F in a positive feedback loop (Ryo et al., 2002). Moreover, Pin1 
can also amplify EGF signalling in breast cancer cells through its interaction with MEK1 
thereby enhancing HER-2 expression, in another positive feedback loop (Khanal et al., 
2010). Finally, it is well known that Pin1 acts on various cell cycle proteins to coordinate 
progression through the cell cycle (Wulf et al., 2001). Thus, Pin1 operates as a novel 
molecular key of the Neu-Raf-Ras-MAPK signal pathway by acting on multiple targets at 
various steps of the signal network to promote cell proliferation and transformation. 
 ii. PI3K/AKT pathway
The PI3K/AKT pathway is a highly intertwined network that arises as an integrator 
of multiple inputs derived from RTKs and other membrane receptor types during breast 
tumorigenesis (Cully et al., 2006). Besides the Ras-dependent activation of PI3K that 
might be common to different receptor systems, tyrosine-phosphorylated RTKs act as 
docking platforms for direct or Grb2-Gab1-mediated indirect engagement of the regulatory 
p85 subunit of PI3K and subsequent kinase activation (Fig.I3). Active PI3K catalyses the 
transformation of membrane-bound phosphatidylinositol (4,5) bisphosphate (PIP2) into the 
second messenger phophatidylinositol-(3,4,5) tris-phosphate (PIP3). Since PIP3 is restricted 
to the plasma membrane, this results in the translocation of the serine-threonine kinase 
AKT (also called PKB) to the plasma membrane, where it is activated by phosphorylation 
in Thr308 by PDK1 and in Ser473 by PDK1, mTOR or AKT itself  (Cidado & Park, 
2012; Steelman et al., 2011) (Fig.I.3). Recently, a novel mechanism accounting for full 
AKT activation through S477/T479 modification by mTOR and CDK2/cyclinA has been 
described in response to DNA damage that allows cell cycle progression and chemoresistance 
(Liu et al., 2014).  AKT is a proto-oncoprotein with multiple effectors (Bad, Ikb, GSK3, 
mTOR....) that control crucial biological processes such as apoptosis, protein synthesis or 
translation, proliferation and cell survival (Kim & Chung, 2002). Therefore, the activity 
of AKT is tightly regulated in physiological conditions. The multifunctional phosphatase 
PTEN acts as a negative regulator of the pathway through the transformation of PIP3 to 
PIP2, blocking the activation of AKT. PTEN can also interact with and dephosphorylate 
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ERK1/2, thereby inhibiting cell proliferation (Cully et al., 2006). AKT-1 kinase activity 
contributes to the development of breast cancer and to therapeutic responses as tumour 
cells with acquired resistance to anti-tumour agents may display higher AKT activation 
and treatments based on molecular-directed targeting can often activate feed-back loops 
involving AKT (Cancer genome atlas network, 2012).  
c. G-Protein coupled receptors(GPCRs) as drivers of  breast cancer proliferation and 
growth: RTK-transactivation- dependent and independent mechanisms.
 G protein-coupled receptors (GPCRs), also known as seven-transmembrane domain 
receptors or 7TM receptors, constitute the other major protein family of receptors which 
deregulated activity have been linked to aberrant proliferation and metastatic progression 
of tumours of different nature (Dorsam & Gutkind, 2007; Lappano & Maggiolini, 2011). 
The first evidence of the potential oncogenic roles of GPCRs came from the identification 
of activating oncogenic mutations in the thyroid stimulating hormone receptor (TSHR) 
and from the connexion of virally-encoded GPCRs with tumorigenesis. In addition, potent 
mitogens such as thrombin or PGE2 regulate tumour cell proliferation and/or invasion 
through binding to their cognate GPCRs (PAR1 and EP2/EP4) and the stimulation of 
Rho/Rac modules and of MAPK cascades including ERK, JNK, p38 and ERK5 (O’Hayre 
et al., 2014). Interestingly, these receptors are usually over-expressed or their regulatory 
processes altered in breast tumours (Boire et al., 2005; Chang et al., 2005; Filardo et al., 
2008). GPCRs lack intrinsic catalytic activities but couple to heterotrimeric G proteins, 
molecular transducers composed of bγ dimers and α subunits of four subfamilies, each 
of which directly modulates a specific set of enzymes (adenylase cyclases activated or 
inhibited by Gαs or Gαi, phospholipases activated by Gαq and small GTPases activated 
by G12/13, among others) to generate second messengers and stimulate diverse signalling 
cascades. Both G protein-dependent signalling and receptor/G protein coupling ability 
are tightly controlled by the heterotrimeric G protein cycle and the receptor homologous 
desensitization process, respectively (Fig. I3).  Ligand-bound GPCRs act as GEFs for 
Gα subunits, facilitating the GDP/GTP exchange process.  GTP-bound α subunits 
dissociate from the bγ dimer, and both G protein subunits regulate an ever-expanding list 
of independent effectors. Finally, GTP hydrolysis, a process known to be increased by 
RGS (Regulator of G-protein signalling) and GAP (GTPase-activating proteins) proteins, 
causes re-association of G protein subunits and termination of signal transduction.  Besides 
this regulatory G protein cycle, receptor signalling is also curtailed by the ligand-induced 
engagement of the desensitizing factors GRKs and arrestins. Phosphorylation of agonist-
bound GPCRs by GRKs leads to the translocation and high affinity binding of the cytosolic 
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proteins b-arrestins to the receptors (Benovic et al., 1986; Premont et al. 1995). This event 
not only inhibits further G protein-receptor interactions, but also allows the recruitment of 
the endocytic machinery, ultimately leading to receptor internalization, which can promote 
either GPCR-resensitization or receptor degradation.
 Besides the stimulation of mitogenic pathways by G-protein and second messengers-
dependent mechanisms (for instance activation of ERK1/2 by cAMP- and PKA-stimulated 
Rap1 or by Calcium-stimulated calmodulin kinase), several other signaling mechanisms 
appear to contribute to GPCR-mediated MAPK activation (Fig.I.3). These include 
transactivation of the EGFR via either the autocrine/paracrine release of EGF-like ligands 
at the cell surface or the direct Src-mediated activation of the receptor (independently 
of EGF ligand shedding). For instance, EGFR are transactivated by oestrogen via the 
G-protein-coupled receptor GPR30 (Filardo et al., 2008; Prossnitz et al., 2007), defining 
a novel signalling pathway with potential significance for proliferation of (ERα)-negative 
human breast cancer cells. Another mechanism involves G protein-independent, b-arrestin-
mediated activation of MAPK cascades, what means that beyond its classical desensitization 
function, b-arrestins have the ability to scaffold diverse signaling complexes including the 
Raf-MEK-ERK1/2 module in a c-Src-mediated manner and the ASK1/MKK4/JNK3 
module. Activation of b-arrestin signalling is biased by particular GPCR ligands and 
linked to specific patterns of GRK-mediated receptor phosphorylation that trigger different 
receptor conformations for b-arrestin docking. ERK activated via b-arrestins differs from 
the G protein-activated one in several aspects as mitogenic potency, intracellular location 
or signalling time-course. Therefore, it is not surprising that changes in the expression and 
localisation of arrestins (and of GRKs, see section 6) may occur during cancer progression. 
In this regard, high levels of both b-arrestins have been described in advanced-stage breast 
cancer, correlating with reduced patient survival (Sobolesky & Moussa, 2013). Another 
layer of complexity derives from the fact that RTKs and GPCRs can form platforms in which 
protein signalling components specific for each receptor are shared to produce an integrated 
response upon engagement of ligands (Pyne & Pyne, 2011).  For instance, PDFGbR might 
use G proteins to transmit signals to effectors upon formation of membrane complexes 
with the GPCR S1P1. On the other hand, heregulin binding to ErbB2 activates a b-arrestin-
biased CXCR4 signalling, independently of its cognate CXCL12 ligand, through a direct 
tyrosine receptor trans-phosphorylation (Sosa et al., 2010), while CXCR4 can associate 
with other RTK, such as IGF-RI, in response to IGF, leading to preferential coupling of 
CXCR4 to Gαi proteins (Akekawatchai et al., 2005). Overall, combined receptor platforms 
and reciprocal hijacking of signal transducers have the potential to reprogram intracellular 
signalling and to alter the outcome of conventional pharmacological receptor antagonists 
in the context of cancer. 
Introduction
59
d. Oestrogen receptors: the endocrine contribution
 Oestrogen-induced proliferation of normal cells has been considered a milestone 
for the initiation and promotion of tumorigenesis (Blanco-Aparicio et al., 2007). Cellular 
actions of oestrogenic compounds are mediated by two “classical” nuclear estrogen receptors 
α(ERα) and b (ERb), which expression is present in 75% of breast cancers (Fig.I.3). Nuclear 
ERs act as  transcriptional factors regulating the expression of genes required for cell division 
and survival (Frasor et al., 2004). Upon oestrogen binding, ER homo or hetero-dimerizes 
and attracts a complex of co-activators and co-repressors to specific sites on DNA (oestrogen 
response elements, EREs) (Klinge, 2001).  ER can also bind to other transcription factors 
such as AP-1 and SP-1 at their specific sites on DNA, thereby functioning as a co-regulator 
(Babu et al., 2013; Bartella et al., 2012). However, a non-genomic ER activity has been 
suggested, since the rapid oestrogen-dependent activation of PI3K/AKT and Ras/ERK1-
2 pathways (Osborne et al., 2013) is not compatible with the slower time-course of ER-
triggered transcriptional changes (Soltysik & Czekaj, 2013).  These non-genomic effects 
are mediated by plasma membrane-associated estrogen receptors (mER), and the cellular 
transmembrane G protein-coupled estrogen receptor (GPER/GPR30). Although mERs 
do not have intrinsic kinase activity, they can orchestrate a membrane “signalosome” 
(Moriarty et al., 2006), where numerous molecules potentially important for mediating 
rapid signalling cascades, such as G-proteins, tyrosine kinase c-Src, modulator of non-
genomic activity of the ER (MNAR), caveolin-1, and heat shock protein 90 (Hsp90) 
interact in response to estrogens.  In this context a robust crosstalk between mER and 
co-recruited growth factor receptors has been described. Moreover, oestrogen receptor can 
increase the expression of ligands such as transforming growth factor-α (TGFα) and IGF1 
or directly increase IGF1-R levels (Hawsawi et al., 2013; Vyhlidal et al., 2000) which can 
then activate the growth factor receptor pathway  (Giuliano et al., 2013; Nicholson et 
al., 2005; Osborne et al., 2013) In the absence of ER expression, oestrogens can activate 
GPR30 and stimulate MAPK and PI3K/AKT signaling  through either G protein and 
adenylyl cyclase-mediated or EFGR transactivation-dependent mechanisms  (Filardo et 
al., 2008; Prossnitz et al., 2007). 
4.2) Oncogenes and neutralization of tumour suppressors by loss-of-function 
mutations/loss-of-expression provides cells with death resistance features: the p53 / 
Mdm2 axis 
 Cancer cells are insensitive to anti-growth signals, displaying unlimited replication, 
and usually harbour inactivating mutations in tumour suppressor genes whose products 
normally contribute to DNA repair processes. Indeed, the most common cause of hereditary 
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breast cancer is related to mutations in one of such genes, Brca1. In addition, tumour 
suppressors may be also involved in the detection of genomic and metabolic stresses or in 
the activation of cell-cycle checkpoints and proliferation arrest.  Their inactivation involves 
considerable vulnerability, since cumulative replication cycles increase the frequency of 
single- or double-strand DNA breaks and chemical modifications (intrinsic replicative stress) 
on cells that have deficient mechanisms to cope with them. However, in contrast to normal 
cells which undergo apoptosis when are unable to repair DNA insults and damage become 
excessive for genomic integrity, transformed cells disconnect the cellular death response 
by inactivating additional tumour suppressors that either act as pro-apoptotic regulators 
(Chk2) or negative regulators of survival pathways (PTEN by blocking the PI3K/AKT 
pathway). Consequently, cells continue to grow and divide as they accumulate mutations, 
thus contributing to the process of tumoural transformation (Alexander & Friedl, 2012). 
 The most widely impaired tumour suppressor in human cancer is p53, a potent 
transcription factor also known as “the guardian of genome” that is activated in response 
to diverse types of stress and environmental insults, leading to the induction of cell-cycle 
arrest, apoptosis or senescence (Fuster et al., 2007; Levine & Oren, 2009; Vogelstein et al., 
2000) . The p53 protein possesses an acidic N-terminal transactivation domain with an 
intervening hydrophobic conserved box I (aa 13-18), a proline-rich domain, and a centrally 
located sequence-specific DNA-binding domain bearing conserved boxes II-V, followed by 
an oligomerization domain and a basic C-terminal regulatory domain (Fig.I.4).  Wild-type 
p53 functions as a homo-tetramer in cells, binding to p53 response elements in a myriad 
of genes. Among the regulatory mechanisms controlling p53, the proteasome-dependent 
degradation appears to be the most relevant, since the knock-out mice for Mdm2, the 
main E3 ligase responsible for p53 ubiquitination and degradation through the proteasome 
pathway (Finlay, 1993; Vogelstein & Kinzler, 1992), is embryonic lethal due to an 
exacerbated expression of p53 (de Rozieres et al., 2000). However, many other ubiquitin 
ligases including Pirh2, COP1, CHIP and ARF-BP1 have been identified as regulators 
of p53 in response to different signalling pathways, thus underscoring the importance of 
keeping at bay p53 levels in unstressed conditions (reviewed at Carter and Vousden, 2009). 
In contrast, upon cellular stresses p53 undergoes phosphorylation, acetylation and other 
types of modifications that prevent ligase action. Such modifications also affect protein 
activity and subcellular localization, leading to p53 up-regulation and activation (Bode 
& Dong, 2004). The extent and repertoire of such posttranslational modifications is 
proportionate to the severity and nature of the stress and serves to direct p53’s actions toward 
particular sets of gene responders and protein partners. p53 activated by milder DNA-
damages transactivates components of the mismatch and the nucleotide excision repair 
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system and of cell cycle arrest like p21Cip1 or GADD45 (Menendez et al., 2009), whereas 
stronger DNA damage or persistent lesions trigger a p53-mediated programmed cell death 
by inducing the transcription of pro-apoptotic proteins such as Noxa, Bax and PUMA 
among others (reviewed in (Nag et al., 2013; Riley et al., 2008; Vousden & Lu, 2002)). p53 
is also involved in the ATM-mediated induction of senescence (Armata et al., 2007; Efeyan 
et al., 2009). In addition, p53 can also act as a transcriptional repressor of oncogenes that 
promote cell growth, survival or angiogenesis, such as c-fos, myc or VEGF-A (Nag et al., 
2013) . Recently, new functions of p53 have been discovered including p53 roles in energy 
metabolism (Maddocks & Vousden, 2011), immune response, cell differentiation, motility 
and migration and cell-cell communication, that, together with the well known functions 
in apoptosis, cell cycle regulation, senescence and angiogenesis makes this transcription 
factor a master regulator of the cell biology (Fuster et al., 2007; Muller et al., 2011; Riley 
et al., 2008). Thus, it is not surprising that in over 50% of all human cancers TP53 gene is 
mutated or deleted, while in the remaining tumours the wild-type p53 function is inhibited 
by several other mechanisms, as DNA tumour viruses encoding proteins that can inactivate 
p53, or  up-regulation/activation of negative modulators such as Mdm2 leading to p53 
downmodulation (Cancer genome atlas network, 2012).  
Figure I.4. p53 structure and post-transcriptional modifications. A) Linear representation of 
p53 sequence with relevant domains and the main post-transcriptional modifications. B) Several 
stresses lead to p53 activation, which can result in different cellular responses.
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a.The functional interplay between Mdm2 and p53 
Mdm2 is a multidomain protein endowed with multiple functional activities that go 
beyond the mere ubiquitination of p53. The most N-terminal part of Mdm2 harbours the 
lid domain (aa 1-24), a flexible region that folds over and regulates in a pseudosubstrate-
like fashion the hydrophobic pocket (aa 25–108), which binds p53, among other partners. 
The central region of Mdm2 includes nuclear localisation (NLS; aa 179–185) and nuclear 
export signals (NES; aa 190–202), followed by an acidic domain (CAD, aa 243–301) that 
partially overlaps with the zinc finger domain (aa 290–335).  In the very C-terminus is 
located the RING (for “really interesting new gene”) domain (aa 432–491) that promotes 
its E3 ubiquitin ligase activity, harbours its nucleotide binding site and also encompasses 
the nucleolar localisation signal (Fig.I.5). 
Figure I.5. Mdm2 structure and post-transcriptional regulation. Linear representation of Mdm2 
sequence with relevant domains and the main post-transcriptional modifications, showing the functional 
consequences of these alterations.  
Introduction
63
Mdm2 and p53 form a unique negative-feedback loop, in which p53 induces the 
expression of Mdm2 by binding to its promoter (Vousden & Prives, 2009), while Mdm2 
quenches cellular p53 activity by altering its stability, localization and transactivation 
activity (Nag et al., 2013) (Fig.I6).  Thus, the mutual binding of Mdm2 and p53 via the 
N-terminal hydrophobic domain and the box1 region, respectively, directly blocks the 
p53 transactivation domain.  This first interaction is followed by subsequent contacts 
involving the acidic domain of Mdm2 and the Box V region of p53, which produce 
allosteric conformational changes that allow the RING domain of Mdm2 to either mono-
ubiquitinate or poly-ubiquitinate p53. In fact, the interaction between the N-terminal 
domains of Mdm2 and p53 is not required for the Mdm2-catalyzed p53 ubiquitination, 
but instead the second interaction is critical for such modification (Ma et al., 2006). Mono-
ubiquitination of several Lys residues in the p53 C-terminus acts as a signal for p53 nuclear 
export to the cytosol, wherein it displays scaffolding regulatory functions on apoptotic 
proteins (Fig. I.4 and I.6). On the other hand, poly-ubiquitinated p53 is quickly degraded 
by the proteasome pathway (Lai et al., 2001).  Potential ubiquitin acceptor sites in p53 
also includes other regions of the protein and poly-ubiquitination within the DNA-binding 
domain seems to be responsible for protein destabilization (Chan et al., 2006). It is reported 
that the Mdm2 capability of catalyzing both mono-ubiquitination and poly-ubiquitination 
of p53 is dependent on the levels of Mdm2, with poly-ubiquitination occurring at high doses 
of Mdm2 (Lai et al., 2001). By its own, Mdm2 is a poor ligase for p53 poly-ubiquitination, 
thus requiring the assistance of additional factors to form ternary complexes in which 
the RING domain of Mdm2 is competent to elicit such modification on p53.  Among 
these factors, MdmX (or Mdm4), a paralog of Mdm2, is an essential, non-redundant, p53 
regulatory protein. Although the RING domain of MdmX is unable to ubiquitinate p53, it 
is involved in the activation of the Mdm2-dependent poly-ubiquitination of p53 via hetero-
dimerization with the RING domain of Mdm2 (Wade et al., 2010) (Fig. I.5).  Other factors 
engaged in ternary activating complexes related to p53 regulation are the proteasome 
activator PA28y protein, which increases Mdm2-p53 interaction (Zhang & Zhang, 2008) 
or UBE4B, an E4 factor of the E3 U-box family that binds to Mdm2 and p53 and facilitate 
poly-ubiquitination.  Recently, the p53-acetylating protein p300 was reported to be also an 
E4 ligase that mediates by itself poly-ubiquitination on previously mono-ubiquitinated and 
cytosol-exported p53 (Shia et al., 2009) . 
Beyond the well-known role of Mdm2 in the ubiquitination and degradation of p53 
through the proteasome pathway, other levels of p53 regulation have been reported, as 
binding of Mdm2 impedes p53 interaction with transcriptional co-activators or recruits 
transcriptional co-repressors to p53. It has also been described a chaperone-like function 
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of ATP-loaded Mdm2 that assists p53 assembly on the p21 promoter (Wawrzynow et 
al., 2007). Moreover, the RING domain bears a conserved Walker A or P-loop motif 
characteristic of nucleotide binding proteins that allows binding of Mdm2 to the nuclear p53 
mRNA under genotoxic stress. This prevents MDM2 from targeting p53 for degradation 
while increases the rate of p53 mRNA translation. 
 b. Regulation of  the ability of  Mdm2 to target p53
Regulation of p53 by Mdm2 is a crucial step in cell homeostasis and, consequently, 
Mdm2 is a target of a wide variety of tumour suppressors and oncoproteins and modifying 
enzymes. Mdm2 displays multiple post-transcriptional modifications that affect protein 
functionality (Coutts et al., 2009). First of all, Mdm2 promotes its own ubiquitination and 
subsequent degradation when it homodimerizes in the absence of MdmX (Lai et al., 2001), 
whereas sumoylation has the opposite effect on stability and regulates ligase nuclear and 
nucleolar localization. Neddilation has been described as a novel modification in Mdm2 
that blocks the function of Mdm2 as transcriptional suppressor of p53, resulting in increased 
expression of p53 (Xirodimas et al., 2004). In addition, acetylation of lysine clusters within 
Figure I.6. Mdm2/p53 axis.  p53 and MDM2 form an auto-regulatory feedback loop.  Different cellular 
stresses such as DNA damage induce p53 activation by preventing its MDM2-mediated degradation. 
Consequently, p53 stimulates the expression of p53 targets and iniciates its tumour suppressor activities. 
Interestingly, and as a regulatory mechanism, it also promotes the transcriptional expression of Mdm2, 
which in turn inhibits p53 activity, by mono- or poly-ubiquitinating p53 and favouring its nuclear export 
and its degradation, respectively. Moreover, Mdm2 is also able to block p53 transcriptional activity. 
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the MDM2 RING domain has been shown to attenuate the E3 ligase activity of MDM2 
towards p53 (Fig.I5). 
Extremely important is the modification of Mdm2 by different kinases, what 
may “reprogram” the functionality of Mdm2 in particular cellular settings. Most of the 
phosphorylation sites of Mdm2 are clustered in the central acidic domain. Importantly, 
some phosphorylation events in this region are related to allosteric conformational changes 
in Mdm2 required for an efficient p53 binding to the N-terminal domain of the ligase 
and for full ubiquitination activity towards p53 (Meek & Knippschild, 2003). However, 
phosphorylation sites lie also on other unstructured and inter-domain regions of the ligase, 
such as between the Zinc and RING finger or around NLS and NES localization signals, 
which modification can impose conformational changes to modify/stabilize interacting 
interfaces. Thus, DNA damage-response kinases (ATM, ATR) or the kinases responsible 
for the detection of replicative failure (Chk2 and c-Abl) phosphorylate Mdm2 near the 
RING domain, inhibiting the oligomerization of Mdm2 important for its E3 ligase 
activity and unmasking RNA-binding sites in the ligase, what overall contributes to p53 
accumulation (Chehab et al., 2000; Maya et al., 2001; Shinozaki et al., 2003). On the other 
hand, IGF1R or HER2-induced AKT-mediated phosphorylation of Mdm2 in serines 166 
and 186 promotes Mdm2 nuclear translocation (Jackson et al., 2006) and increases the 
ligase function against p53  (Ogawara et al., 2002). 
Finally, subcellular distribution of Mdm2 is strongly regulated through interactions 
with several proteins such as p14ARF or PML among others (Bernardi et al., 2004; 
Pan et al., 2011; Reed et al., 2014; Xirodimas et al., 2004). The ARF-Mdm2 interaction 
sequesters Mdm2 in the nucleolus, while 14-3-3σ causes translocation of the ligase to the 
cytosol (Bernardi et al., 2004; Lee & Lozano, 2006). Moreover, Mdm2 association with 
oligomers of b-arrestin2 promotes Mdm2 trafficking from nucleus to cytosol, and upon 
ligand challenge Mdm2 is brought via b-arrestins into the vicinity of activated GPCRs 
and RTKs such as IGF1R (Boularan et al., 2007; Wang et al., 2003), allowing the access 
of the ligase to other substrates. Furthermore, the serine 166 has a role in controlling the 
p53 and ARRB1 ternary complex that is induced via the b2-adrenoreceptors to suppress 
DNA damage-induced stress response (Hara et al., 2011). On the other hand, a subset of 
Ribosomal proteins (RPLs) bind to the CAD and Zn-finger domains of Mdm2 to inhibit its 
ligase activity toward p53 as part of the nucleolar response pathway activated by metabolic 
stress (Deisenroth & Zhang, 2011).
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c. P53-independent functions of  Mdm2
It is well established that over-expression of Mdm2 provides cells with a growth 
advantage, promotes tumorigenesis, and correlates with worse clinical prognosis and 
poor response to cancer therapy (Manfredi, 2010). In fact, Mdm2 over-expression or its 
functional amplification is a frequent event in neoplastic diseases (5% of all human tumours 
and more elevated percentage in the case of breast cancer) (Efeyan et al., 2007). Moreover, 
the higher incidence of breast tumours in p53 knockout mice that are also transgenic for 
Mdm2, and the occurrence of high levels of Mdm2 in the presence of mutant p53 or even 
in the absence of p53 gene expression in patients with worse prognostic suggests additional 
roles of Mdm2 in the oncogenic transformation that are independent of p53 regulation 
(Manfredi, 2010). 
Mdm2 can interact with at least 70 different protein partners by means of its different 
domains, and regulate the functionality of many of those, even in an ubiquitination- or 
catalytic-independent way (Shi & Gu, 2012) (Fig.I.7). The functional MDM2 interactome 
involves factors that divert its E3 ligase activity towards other substrates but in a way 
still affecting p53 activity, such as MDMX, also a substrate of Mdm2.  Other interactions 
can affect MDM2 E3 ligase activity unrelated to p53 modulation, whether others may 
alter Mdm2 functions not depending on E3 ligase activities. Indeed, Mdm2 is able to 
catalyze other modifications such as protein neddylation on itself and on other substrates 
such as p53 or HuR (Embade et al., 2012). This versatility might be related to the fact 
Figure I.7. p53-independent functions of Mdm2. Besides its function as a negative modulator of p53 
response, Mdm2 also participate in a wide variety of biological processes through the ubiquitination of 
other sustrates. 
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that the Mdm2 RING domain is atypical when compared to canonical RING ligase 
domains. Its conformational plasticity allows this region to couple to E2 activities for 
ubiquitin and Nedd8, to engage mRNA sequences leading to stabilization of VEGF or 
MYCN transcripts and bind nucleotides such as ATP in order to behave as a molecular 
chaperone of transcriptional complexes of ER or E2F1 factors with certain promoters 
(Slack et al., 2005; Stevens et al., 2008; Wawrzynow et al., 2007; Xirodimas et al., 2004; 
Zhou et al., 2011),  Moreover, the diverse conformations that Mdm2 can adopt induced 
by different combinations of protein modifications or regulatory interactions, the different 
subcellular localizations and the occurrence of splice variants and hetero-oligomerization 
can contribute to govern the specificity of Mdm2 partner interactions and their functional 
outcomes.  
The complex interactome of Mmd2 underpins the influence of this protein in 
several signalling pathways and different biological responses (Fig.I.7). Mdm2 might 
participate in the cell transformation by regulating nuclear proteins such as p73, p63, 
p21, pRb, p300, E2F, PCAF (Gu et al., 2001; Jin et al., 2003, 2004; Miwa et al., 2006; 
Uchida et al., 2005; Zeng et al., 2003) or membrane proteins such as the  IGF-1R receptor 
(Girnita et al., 2003; Yin et al., 2011) or E-cadherin (Yang et al., 2006). Recently, novel 
Mdm2 substrates have been described, what increases the possibility of finding novel 
p53-independent functions for Mdm2. For example, ERK dependent-phosphorylation of 
Foxo3a turns Foxo3a into a target for Mdm2-dependent ubiquitination and degradation. 
As Foxo3A regulates expression of genes that encode cell cycle regulators such as p27, 
this leads to a Mdm2-mediated control of cell cycle progression in response to oncogenic 
growth factor signalling or Ras activation in a p53-independent way (Yang et al., 2008). 
Mdm2 has also been shown to regulate the expression of the anti-apoptotic protein XIAP 
by a novel mechanism, which involves the binding of Mdm2 to the mRNA that encodes 
XIAP, thus enhancing its translation (Gu et al., 2009). Interestingly, oestrogens are found 
to be transcriptional effectors of Mdm2 up-regulation in breast cancer cells (Brekman et al., 
2011; Okoro et al., 2013). Interestingly, oestrogen can also activate cell proliferation using 
Mdm2 to repress multiple cell cycle checkpoints without the involvement of p53 (Brekman 
et al., 2011). Overall, available data indicate that Mdm2 can regulate key aspects of cell 
proliferation and apoptosis in both a p53-dependent and independent manner. 
d. TP53 mutations: Gain of  oncogenic functions 
 TP53 is the second most frequently mutated gene after the PI3KCA proto-oncogene 
in mammary tumours, becoming a key-driving factor in triple negative breast cancer.  Most 
of the alterations in TP53 are missense mutations that are overrepresented in the central 
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DNA-binding domain, affecting in spontaneous tumours mainly to codons R175, C220, 
G245, R248, R273 and R280 (Fig.I.8). Mutation of p53 not only hampers the tumour 
suppressor functions of this factor, but also leads to the acquisition of oncogenic properties 
by gain-of-function mechanisms. While some hotspot mutations impede contact between 
p53 and DNA, others distort the DNA-binding domain resulting in an altered promoter 
activation spectrum that involves both abnormal transactivation of particular p53 wt-
dependent genes (such as p21 or Mdm2) that are useful for tumour cell maintenance, as 
well as targeting of additional genes lacking p53-reponse elements that favour tumour 
progression by increasing invasiveness and chemoresistance. Mutant p53 can also directly 
activate transcription of specific micro–RNAs and attenuate micro-RNA processing 
(Suzuki et al., 2009). Moreover, mutant p53 cooperation with different transcription factors 
such as NFkB, NF-Y or E2F1 may be an important route to execute its gain-of-function 
activity.  Finally, although wt p53 does not hetero-oligomerize with its paralogs p73 and 
p63, mutant p53 can via its DNA-binding domain, what presumably attenuates the anti-
tumorigenic functions of these related factors, further contributing to cell transformation. 
Signalling pathways controlling mutant p53 levels are not entirely understood. 
The activity of mutant p53 is regulated through upstream signal transducers as well as 
regulators of transcription, stability and structure. While ER-alpha was shown to inhibit 
wt p53-dependent transcription, hormone-triggered complexes involving mutant p53 
may potentially influence the transcriptional spectrum of cells expressing mutant p53. 
On the other hand, the prolyl-isomerase Pin1, a component of checkpoints mechanisms 
Figure I.8. Location of tumour-associated p53 mutations. Almost all of the point mutations that are 
found in cancers occur within the central DNA-binding core of p53; the percentage of mutations within 
each region detected in cancers to date is indicated below and the most relevant mutated residues are 
highlighted.  
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that increases wt p53 stability upon DNA damage (Ryo, 2003) also plays a role in the 
stabilization and gain of function of mutant p53 by means of the enhancement of p53 
pro-migration and invasion activities, in a mechanism that involves the p53 paralog p63 
(Girardini et al., 2011; Muller et al., 2011; Wulf et al., 2002).  
e. Mdm2 and mutant p53 protein stability: Oncogen or tumour suppressor?
Oncogenic and genotoxic stresses can modify mutant p53 on the same regulatory 
sites as on wt p53, leading to similar stabilization mechanisms. However, even though 
mutant p53 can be efficiently ubiquitinated and targeted for degradation by MDM2 as well 
as by other E3 ligases, several mechanisms seem to counteract theses processes in tumoural 
contexts. The interaction between the chaperone Hsp90 and mutant p53 stabilizes protein 
conformations and blocks its degradation by inhibiting Mdm2 activity (Li et al., 2011a). 
Moreover, p16INK4 downmodulation, a common event in tumour progression, also cause 
mutant p53 stabilization (Terzian et al., 2008). In this context, opposite to its function as 
oncogene, growing evidence argues for the remarkable possibility that Mdm2 has tumour 
suppressor functions by means of either the promotion of mutant p53 degradation (Prives & 
White, 2008; Suh et al., 2011) or the nuclear export of wild-type p53, which facilitates p53 
binding to members of the Bcl2-family in the mitochondria, activation of mitochondria-
dependent apoptosis and cell death (Vaseva et al., 2009; Vaseva & Moll, 2009).   
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5. 
Cell Invasion and Metastasis: 
From cell migration to invadopodia formation 
Tumour cell invasion into host tissues and local and metastatic dissemination underlay the poor prognosis of certain breast cancers. Cellular invasiveness is dependent on the capacity of cancer cells to migrate from the tumour mass, to 
disrupt the basement membrane and remodel the extracellular matrix (ECM), followed by 
intravasation into blood or lymphatic vessels and subsequent metastasis to distant organs 
(Fig.I.9). Many cell types are able to undergo molecular and morphological polarization 
and to trigger motion in response to chemotactic gradients. Such oriented migration or 
chemotaxis is fundamental for embryogenesis, immunity and wound healing (Petrie 
et al., 2009). However, it also contributes to pathological conditions such as cancer or 
inflammatory diseases (Müller et al., 2001). Directed cell migration is dependent on a 
dynamic sequence of cell-substrate attachment at the leading edge of the cell coordinated 
with cell-substrate detachment at the rear (Frame et al., 2002). For a cell to migrate, it must 
initially sense and respond to a stimulus by developing filopodia and lamellipodia structures 
at the leading edge. Cell lamellipodium builds strong adhesion points with the substrate 
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and protrudes its membrane forward by polymerizing actin in the direction of movement. 
The formation of focal adhesions close to the leading edge of the cell provides the traction 
required to move the cell body forward. At the back, the actomyosin cytoskeleton contracts 
the cell body and breaks the adhesion points. Forward cell movement is then accompanied 
by focal-adhesion disassembly and cell-surface detachment at the rear of the cell, which 
permits retraction of the tail during active migration. 
  Cancer cells may adopt different ways of invasion depending on the cell type, 
the environment and the intrinsic molecular signature (Poincloux et al., 2009). The first 
detectable evidence of invasion is the degradation of the basal membrane, a thin layer that 
separates the epithelium from the stroma and that is basically formed by Collagen Type 
IV. This can be produced by the formation of protrusive structures called invadopodia. 
Invadopodia formation requires dynamic remodelling of f-actin and cortactin to transport 
metalloproteinases (mostly MT1-MMP) to the cell surface, where they are able to degrade 
the matrix. Invadopodia are generated by formation of dendritic actin networks but 
elongate as a result of extension of bundled longitudinal actin fibers. This elongation is 
Figure I.9. The metastatic cascade. Mechanisms of tumor invasion and metastatic dissemination. After 
tumour formation (1) at the primary site, single cell or collective invasion lead to the breakdown of 
the basement membrane  and intravasation into local vessels. Tumoural cells can also go through the 
membrane using a contraction- based amoeboid motility (2). Whereas the mesenchymal invasion requires 
the formation of protusive structures called invadopodia and MT1-MMP-dependent matrix proteolysis, 
amoeboid invasion relies in RhoA/ROCK/MyosinII-mediated actomyosin contractility. Before arrest 
in secondary organs, tumor cells extravasate (3) and regrow to macroscopic metastases (4). In both 
primary tumor and metastasis, reactive stromal cells such as fibroblasts, macrophages, myeloid- derived 
suppressor cells and regulatory T cells (Treg) contribute to cell growth, survival and invasion by the 
release of soluble factors and extracellular matrix remodeling. Abbreviations: BM, basement membrane; 
ECM, extracellular matrix; MDSC, myeloid-derived suppressor cell.
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accompanied by contact with microtubules and vimentin intermediate filaments, both of 
which support the maturation of the structure (Linder et al., 2011). 
 Pericellular proteolysis mediated by metalloproteinases, particularly by MT1-
MMP, allows tumour cells to remodel the matrix, supporting invasive migration through 
the 3D fibrillar collagen network (Poincloux et al., 2009). Proteolytic tracks left behind by 
invasive cells might support the migration of other cells.  A second strategy used by cancer 
cells to invade relies on collective cell migration, in which cells migrate as a multicellular 
sheet, strands, files or clusters, maintaining cell-cell contacts. Recently, a novel invasion 
mechanism was characterized based on an amoeboid motion (Poincloux et al., 2011). This 
kind of invasion does not depend on metalloproteinase activity and matrix proteolysis, 
but rather it is driven by RhoA/ROCK and MyosinII-dependent contractility, allowing 
cells to acquire a rounded morphology and to squeeze between gaps in the 3D matrix 
(Fig.I.9).  Epithelial tumours commonly use collective migration mechanisms, although 
both single cell invasion and collective moves are found simultaneously in many tumours, 
depending on their differentiation stage (the more un-differentiated, the less collective), 
their molecular signature or the environmental cues, in response to which cells might 
adopt different invasiveness strategies. This “plasticity” allows cells to shift from highly 
adhesive to low adhesive migration, from proteolytic or mesenchymal to non-proteolytic 
(amoeboid), from collective to individual migration and vice versa (Friedl & Wolf, 2003). 
Interestingly, signalling pathways controlling tumour cell growth and survival such 
as p53, RasGTPases, small Rho GTPases, integrins, growth factor receptors and cadherins 
(some of them briefly summarized in the sections above) also regulate the cellular 
components involved in migration and invasion, and their activation state influences the 
invasive plasticity of cells (Alexander & Friedl, 2012). Chemokine receptors of the GPCR 
family such as CXCR4 or CXCR2 (also called CCR7) play a central role in the migration 
and metastasis of breast cancer cells (Cabioglu et al., 2005, 2009; Ruffini et al., 2007). 
Moreover, Mdm2-dependent E-cadherin degradation (Yang et al., 2006) or of the action 
of Mdm2 as an enhancer of MMP9 expression can lead to increased extracellular matrix 
breakdown and tumour invasiveness (Chen et al., 2013b). Given the overlap between 
migration-inducing and pro-survival pathways, recent evidences point at an interconnection 
between cancer invasion and therapy resistance. Thus, acquiring a migratory state probably 
contributes to resistance induction and vice versa (Alexander & Friedl, 2012). 
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6. 
Regulatory molecular nodes as ancillary players to 
support malignant transformation and breast 
cancer progression. 
In addition to the oncogenic drivers described above, other cancer-associated factors that are not necessarily genetically altered can cooperate with oncogenic-signalling routes or act in normal signalling compensatory pathways to strength tumoural 
properties or to cope with intrinsic tumour-derived vulnerabilities. Regulatory molecular 
nodes can integrate multiple upstream inputs and elicit diverse downstream outputs, what 
makes them suitable as non-oncogenic contributors to malignant transformation and 
progression. In this context, the serine/threonine kinase GRK2 is emerging as a key node 
in oncogenic signal transduction networks. In agreement with this notion, GRK2 levels 
or functionality are found altered in granulose cell tumours, thyroid and prostate cancer 
(King et al., 2003; Métayé et al., 2002; Prowatke et al., 2007) and recently associated with 
the aberrant activation of the PI3K/AKT pathway in some mammary cell lines (Salcedo 
et al., 2006). 
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6.1. GRK2 as a key node in the modulation of cellular signalling networks
a.G-protein-coupled receptor kinases  (GRKs): Family, structure and canonical function
 G-protein-coupled receptor kinases (GRKs) are a family of serine-threonine kinases 
composed of seven members (GRK1 to GRK7) that share a global homology of 60-70% and 
are grouped in three subfamilies: visual GRKs, present in cones and rods, include GRK1 
(or rhodopsin kinase) and GRK7; the b-Adrenergic receptor kinase family (b-ARK), to 
which GRK2 and GRK3 belong, and a third subfamily, which includes GRK4, 5 and 6 
(Premont & Gainetdinov, 2007) (Fig.I.10). Non-visual kinases are ubiquitous, excepting 
GRK4, which is predominantly expressed in testes and, to a lower extent, in brain and 
kidney. 
 GRKs have a multidomain structure, with a preserved central catalytic domain (so 
called KD for Kinase Domain) of around 500-520aa. The N-terminal domain spans 183-
188 residues and, except in GRK1 and GRK7, includes a N-terminal RGS homology (RH) 
domain that , in the case of GRK2 and GRK3, has been shown to allow the interaction 
with Gαq/11 proteins (Carman et al., 1999). The GRK’s C-terminal domain, more 
variable in extension and function, determines the localization of these proteins at the 
Figure I.10. GRKs family. Main domains of the three subfamilies of GRKs and localization of 
modulatory phosphorylation sites and regions involved in interaction with other proteins or the membrane 
are indicated.
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plasma membrane. A pleckstrin homology domain (PH) in GRK2/3 proteins mediates 
their agonist-induced translocation from the cytosol to the plasma membrane through 
interactions with phospholipids and with G protein bγ (Gbγ) subunits at the membrane 
surface (Koch et al., 1993; DebBurman et al., 1996; Pitcher et al.,1992). On the contrary, 
GRK5 is predominantly associated to cellular membranes by means of basic sequences at 
the N-and C-terminus of the protein. GRK1/4/6 and GRK7 are constitutively anchored 
to the plasma membrane through short C-terminal prenylation sequences (GRK1 and 7) 
or through palmitoylation sites (GRK4 and GRK6) (Gurevich et al., 2012; Pitcher et al., 
1996; Ptasienski, 1996). Interestingly, and unlike many other kinases, activation of GRKs 
does not require a previous phosphorylation in their activation loop. Instead, docking to 
active GPCRs and allosteric interactions with lipids directly triggers their kinase activity 
(Gurevich et al., 2012) (Fig.I.10). 
 As we have mentioned before, GRKs are involved not only in GPCR desensitization 
but also in the GPCR-mediated G protein-independent signalling through the engagement 
of arrestins to the receptor complex, which in turn recruits diverse components of 
signalling cascades. The mechanism by which GRKs determine whether to promote 
GPCR desensitization or G protein-independent signalling remains unclear, but it has 
been suggested that selective activation of specific GRKs or differential phosphorylation 
by particular GRKs of ligand-bound GPCRs (also termed “phosphorylation barcoding”) 
might be implicated in recruiting arrestins with a conformation competent to scaffold 
specific signalling molecules. For instance, phosphorylation of the angiotensin receptor 
by GRK2 and GRK3 modulates beta-arrestin-mediated GPCR internalization, whereas 
phosphorylation by GRK5 or GRK6 triggers the beta-arrestin-dependent signalling to 
MAPK (Kim et al., 2005). However, GRKs are emerging as new signal transducers by 
themselves, performing b-arrestin-independent roles in GPCR signalling cascades and also 
arising as new players in non-GPCRs-dependent pathways, as a result of functional or 
scaffolding interactions with a wide variety of substrates (Penela et al., 2003; Ribas et al., 
2007) (Fig. I.11).   
b. The complex interactome of  GRK2: GRK2 contributes to pathways controlling the 
hallmarks of  cancer
 GRK2 is a ubiquitous, essential, and best- characterized member of the GRK 
family. Recent evidences point at this kinase as a key node in the control of the most 
relevant signalling networks required for the proper function, homeostasis and viability of 
the cell. The fact that global GRK2 knockout mice are embryonically lethal (Jaber et al., 
1996) further supports the notion that this protein plays a central role in such key cellular 
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processes. Non-GPCR proteins that interact and/or are phosphorylated with GRK2 include 
single transmembrane RTKs and a variety of cytosolic or nuclear signalling proteins, and 
the impact of this protein on cell functions can be mediated by either its catalytic activity 
or in a kinase-independent manner by acting as a scaffold (Penela et al., 2010a) (Fig.I.11). 
 GRK2 contributes to cell proliferation triggered by some tumour-related GPCRs, 
such as the lipid S1P1 receptor, the Smoothened receptor or the chemokine receptor 
CXCR7 by mediating MAPK activation (Lipfert et al., 2013; Meloni et al., 2006; Molnar 
et al., 2007).  The mitogenic effect of GRK2 is based on its ability to phosphorylate or 
dynamically interact (in a kinase activity-independent way) with important modulators/
efectors engaged along the MAPK pathway, such as GIT-1, Raf, RhoA, Epac, PDEγ, 
Figure I.11 The complex GRK2 interactome. In addition to its ‘classical’ role triggering GPCR 
phosphorylation and b-arrestin binding (A) , GRK2 can modulate cell signalling by interacting with and 
/ or phosphoryating diverse non-GPCR substrates (B) which  point at this kinase as a a central signalling 
node and key modulator of relevant biological processes such as cell proliferation, survival, migration and 
cell metabolism. Red circles denotes phosphorylation by GRK.
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RKIP or Pin1 (Deiss et al., 2012; Eijkelkamp et al., 2010; Penela et al., 2008, 2010b; 
Robinson & Pitcher, 2013; Wan et al., 2003). In addition, we and others have recently 
reported that GRK2 is necessary to ensure a proper and timely progression of cell cycle, 
particularly during G1/S and G2/M transitions in response to extrinsic and intrinsic 
cues, respectively (revised in Penela et al., 2010). GRK2 levels fluctuate along cell cycle, 
being down-regulated during the G2/M transition. This transient GRK2 degradation is 
required for normal cell cycle progression. Interestingly, the default GRK2 protein decay 
in G2 is prevented in the presence of DNA damaging agents that trigger cell cycle arrest 
such as doxorubicin. Moreover, such accumulation of GKR2 inversely correlated with 
the activation of p53 triggered by G2/M checkpoints mechanisms helping to restrict the 
apoptotic face of arrested cells (Penela et al., 2010). Accordingly, we hypothesized that 
GRK2 can allow cells to cope with genotoxic stress by means of potentiating cell cycle 
arrest protection and survival response. Moreover, a role for GRK2 in cell proliferation 
during early embryonic development has also been suggested (Jiang et al., 2009). The 
ability of GRK2 to interact with Patched and to relieve the Patched-induced cytosolic 
retention of cyclin B in response to Hedgehog ligand appears to underlie the stimulatory 
effect of GRK2 in cell division. 
GRK2 is also able to interact with some key players in the processes of cellular 
stress response and growth arrest such as p38, Smad2/3, PI3K, AKT or Hsp90 (reviewed 
in Penela et al., 2010a), what  might positively impact on cell survival and resisting cell 
death.  p38, a critical player in apoptosis or survival in a cell-type specific context and a 
mediator of p53 activation in response to different stresses (Bulavin & Fornace, 2004), 
is phosphorylated by GRK2,  what prevents binding of the upstream activator MKK6 
(Peregrin et al., 2006).  GRK2 also interacts with both PI3K and AKT proteins, although 
the functional outcome of such interactions is not straightforward, as positive and negative 
effects have been described in a cell type-specific context. GRK2 contributes to the GPCR-
induced AKT activation by means of its association with the catalytic subunit of PI3Kgamma 
, while a direct interaction with the regulatory subunit p85 facilitates AKT activation in 
the context of cell cycle of epithelial cells (Rivas V et al., unpublished results). On the 
contrary, in non-epithelial cells a GRK2-mediated inhibition of Akt phosphorylation and 
canonical activation has been shown. Similarly, the connexion of GRK2 with the TGFb 
signalling axis is also complex, as TGFbeta elicits paradoxical effects on cell proliferation 
and migration in a cellular context-dependent manner (Lebrun, 2012; Siegel & Massagué, 
2003).  In response to TGFb-bound ALK5, GRK2 can associate to and phosphorylate 
Smad2/3 in their regulatory linker domain, preventing activation and nuclear translocation 
of the Smad complex, thereby leading to the inhibition of pro-arresting and pro-apoptotic 
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TGF-beta effects (Ho et al., 2005, 2007). Such regulation might favour a potential TGFb 
switch from a tumour suppressor to a tumour promoter, akin to that induced by oncogenic 
HRas-dependent, JNK-mediated phosphorylation of Smad3 (Liu et al., 2009). 
Recently, GRK2 has been shown to be involved in the homeostasis of cellular 
metabolism via the regulation of insulin and insulin-like growth factor pathways and 
mitochondria functionality, suggesting a novel role of GRK2 in controlling the cellular 
use of glucose and the ability of the cell to control energy production and expenditure 
(Ciccarelli et al., 2012; Vila-Bedmar et al., 2012). GRK2 over-expression inhibits glucose 
uptake through kinase activity-independent quenching of Gαq subunits that are required 
for GLUT4 translocation upon insulin stimulation, and of IRS1 transducers needed for 
insulin receptor downstream signalling (Garcia-guerra et al., 2010; Usui et al., 2005). 
Therefore, GRK2 downregulation leads to increased insulin sensitivity both in cells and 
in animal models of insulin resistance (Garcia-guerra et al., 2010; Gurevich et al., 2012). 
Interestingly, epidemiologic data suggest that patients with insulin resistance have a higher 
risk of developing several types of cancer, including breast cancer, as hyperinsulinemia 
results in stimulated DNA synthesis, cell proliferation and genomic instability. In addition, 
GRK2 can localize to the mitochondrial outer membrane by means of the cellular stress–
induced MAPK-mediated modification of the protein and the interaction with Hsp90. 
The consequences of such mitochondrial translocation are controversial because both 
detrimental (increased cytochrome C release and apoptosis) and protective (increased 
biogenesis and ATP production) effects have been reported (Fusco et al., 2012; Huang et 
al., 2014).   
 Finally, compelling evidences indicate a relevant role of GRK2 in cellular motility 
(revised in (Penela et al., 2014a)).  GRK2 interacts with or phosphorylates some cytoskeletal 
substrates implicated in cell remodelling, movement and migration such as ezrin, radixin 
or tubulin (Cant & Pitcher, 2005a; Kahsai et al., 2010a; Pitcher et al., 1998) (Fig. I.11), 
all of them involved in the acquisition of invasive properties. GRK2 phosphorylates ezrin 
at a single Thr567 residue in a PIP2-and Gbγ- dependent manner, which is important for 
maintaining ezrin in an active conformation with both the plasma membrane and F-actin 
binding domains accessible (Cant & Pitcher, 2005b). Similarly, GRK2 phosphorylates 
radixin at the critical Thr564 residue (Kahsai et al., 2010b). The functionality of the 
phosphorylation of tubulin by GRK2 has not been already addressed. Furthermore, an 
important function of GRK2 in epithelial cell migration through the interaction of GRK2 
with GIT1 (Penela et al., 2008) and more recently of HDAC6 (Lafarga et al., 2012a) have 
been reported.
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Notably, HDAC6 is a cytosolic histone deacetylase type II protein that is over-
expressed in a high proportion of breast tumours and contributes to cell growth, cell motility 
and (interestingly) to the invadopodia formation and maturation, through the regulation 
of acteylation-deacetylation of a growing number of proteins including Hsp90, the DNA 
mismatch repair protein MSH2, b-catenin or Ras, among others (Duong et al., 2008; Lee 
et al., 2008; Zhang et al., 2014). Related to cell motility, tubulin and cortactin have been 
identified as a major HDAC6 substrates both in normal and in cancer cells (Boyault et al., 
2007; Gao et al., 2007; Zhang et al., 2003). In particular, the extent of tubulin deacetylation 
correlates with increased microtubule dynamicity and plasticity, which are both required 
for cell cycle division (mitotic spindle), regulation of intracellular protein trafficking, cell 
motility and focal adhesion turnover (Aldana-Masangkay & Sakamoto, 2011). EGF-
induced GRK2-mediated phosphorylation of HDAC6 in residues serine 1060/1062 and 
1068 is necessary for both its full tubulin-deacetylation activity and pro-migratory effects 
(Lafarga et al., 2012). 
In sum, it is reasonable to hypothesize that through this complex interactome, 
GRK2 may act as an onco-modifier and assist in tumoural transformation in a cell-specific 
manner. 
c. Regulation of  GRK2
 Due to the complexity of GRK2 and its interactome, this protein is subject to a 
tightly regulation of its expression levels, activity and subcellular location. In this sense, 
our group has focused over the past decade on the study of the different mechanisms of 
GRK2 modulation, particularly of those related to the control of GRK2 degradation. 
GRK2 protein interacts with different regulators such as calcium-binding proteins, 
alpha-actinin, Hsp90 or caveolin, and undergoes different types of postranslational 
modifications that can either regulate its catalytic activity, divert the kinase to different 
substrates or modulate its subcellular location or proteolysis rate (reviewed in (Ribas et al., 
2007)). Kinase activity towards GPCRs is inhibited by the S-nitrosylation of Cys residues 
within its catalytic domain (Whalen et al., 2007). Second messenger-modulated kinases PKC 
and PKA can phosphorylate GRK2, leading to positive modulation of kinase activity and 
membrane targeting, respectively.  In addition, non-receptor tyrosine kinases such as c-Src 
and Proline-directed kinases (MAPK and CDK2-cyclinA) target the GRK2 protein. The 
activity of tyrosine-phosphorylated GRK2 is increased toward both soluble and membrane 
bound substrates, suggesting a direct effect on its catalytic activity, while modification of 
S670 by ERK1-2 or CDK2 hampers the bγ-mediated recruitment of GRK2 to the plasma 
membrane (Elorza et al., 2000). Interestingly, this latter modification at the C-terminus of 
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GRK2 causes a switch in the repertoire of kinase substrates, as it promotes the acquisition of 
a distinctive competent conformation at the active site (and not in docking sites) that allow 
phosphorylation of HDAC6 (Lafarga et al., 2012b). Since allosteric communication has 
been suggested to take place between the C-tail PH domain and the RH domain of GRK2, 
it is possible that structural alterations caused by covalent modifications at the C-terminus 
could be transmitted to the catalytic domain, resulting in different conformations.
On the other hand, phosphorylation has also direct effects on GRK2 stability (Fig.I 
12A).  Upon GPCR activation GRK2 is rapidly degraded in a ubiquitin and proteasome-
dependent manner (Penela, 1998). Further studies revealed that both c-Src and MAPK-
dependent phosphorylation of GRK2 underpin GPCR-induced degradation (Carman et al., 
1999; Elorza et al., 2003; Penela et al., 2001). c-Src phosphorylation sites have been localized 
to Tyr13, 86, and 92, and the Y13/86/92F GRK2 mutant is resistant to degradation (Penela 
et al., 2001).  Although both c-Src- and ERK-mediated phosphorylation of GRK2 could 
target GRK2 for degradation independently, ERK preferentially phosphorylates GRK2 
previously phosphorylated on tyrosine residues by c-Src (Elorza et al., 2003). Interestingly, 
our group discovered Mdm2 as the main E3 ligase implicated in GRK2 turnover by the 
proteasome pathway (Salcedo et al., 2006). Recently, we further characterized the Mdm2-
dependent GRK2 degradation and found that, upon GPCR activation, the Mdm2 action 
on GRK2 is dependent on the previous phosphorylation of GRK2 at Ser670 by MAP 
kinases, while tyrosine phosphorylation was dispensable (Nogués et al., 2011).  
Figure I.12. Regulation of GRK2 degradation A) 
Upon GPCR stimulation, b-arrestins act as signalling 
adaptors for c-Src and MAPK/ERK, which in turn 
phosphorylate GRK2 at Tyrosines and/or Serine 
670, respectively. These activities facilitate Mdm2-
dependent and independent degradation of GRK2. 
B) In the absence of GPCR stimulation, cytosolic 
b-arrestins would interfere with GRK2/Mdm2 
binding by competing for the ligase whereas in 
response to acute or sustained GPCR activation, 
co-recruitment of b-arrestin-Mdm2 complexes will 
allow the local delivery of extra Mdm2 to GRK2 to 
reduce kinase levels.
A)
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b-arrestins are known to recruit c-Src, ERK and Mdm2 to the vicinity of activated 
GPCRs (Luttrell et al., 2001; Wang et al., 2003) and are the scaffolding molecules in 
charge of facilitating their interaction with GRK2 upon GPCR activation.  However, in the 
absence of GPCR activity, arrestins do not participate in the Mdm2-mediated regulation of 
the GRK2 basal turn-over, but instead compete with GRK2 for Mdm2 and suppress basal 
GRK2 degradation (Nogués et al., 2011). In basal conditions, c-Src is also able to mediate 
Mmd2-independent GRK2 degradation, although the E3 ligase implicated in this process 
remains to be elucidated. Thus, arrestins play a coordinating role recruiting kinases and/or 
ubiquitin ligases to GRK2 in the basal condition or upon activation of GPCRs, regulating 
GRK2 turnover via different pathways (Fig.I.12). 
As aforementioned, GRK2 expression levels are also tightly controlled during cell 
cycle progression. Phosphorylation of the GRK2 S670 residue by the cell-cycle kinase 
CDK2-Cyclin A and the subsequent binding of the prolyl-isomerase Pin1, are required for 
transient GRK2 degradation during the G2/M transition (Penela et al., 2010b). Mdm2 
was shown to be the main E3 ligase implicated in the CDK2-Pin1-dependent degradation 
of GRK2 (in a way independent of the beta-arrestin scaffolding function), although the 
contribution of other ligases to this process cannot be ruled out.  Finally, interaction of 
GRK2 with the heat shock protein Hsp90 is also involved in the maintenance of stable 
kinase levels in cells. GRK2 - Hsp90 interaction seems to play a role in the proper folding 
and maturation of the newly synthesized GRK2 (Luo & Benovic, 2003).  
In contrast to the well-known regulation of GRK2 by post-transcriptional 
modifications and the proteasome pathway, little is known about the regulation of GRK 
transcription or mRNA translation. The GRK2 promoter was considered to be typical of 
‘‘housekeeping’’ genes. Studies using the human GRK2 gene promoter in aortic smooth 
muscle cells have revealed that its transcriptional activity is increased by phorphol esters 
or activation of Gαq or alpha1-adrenergic signalling pathways. On the contrary, pro-
inflammatory cytokines promoted the opposite effect (Penela et al., 2003). 
 Despite the fact that GRK2 is very finely regulated by the different mechanisms, 
summarized above, the balance between them seems to be frequently altered in pathological 
conditions, leading to alterations in GRK2 levels or activity. Consistently, aberrant GRK2 
functionality is found in inflammatory pathologies, metabolic or cardiovascular diseases 
and certain tumours, such as in granulose cell tumours, thyroid and prostate cancer (Métayé 
et al., 2002; King et al., 2003; Prowatke et al., 2007; Penela et al., 2010),  what suggests a 
potential role for GRK2 in the triggering or development of such processes. 
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 Regarding cancer, we have reported the up-regulation of GRK2 in different 
malignant mammary cell lines with aberrant activation of the PI3K/AKT pathway (Salcedo 
et al., 2006)(Fig.I.13).  The activation of the PI3K/Akt pathway by agonists such as IGF-1 
alters Mdm2 phosphorylation and triggers its nuclear localization, thus hampering Mdm2-
mediated GRK2 degradation, leading to enhanced GRK2 protein levels. Since Mdm2 
over-expression or its functional amplification are frequent events in neoplastic diseases, 
it’s feasible that in some tumoural contexts the increase in GRK2 expression might 
correlate with a higher activity of the ligase. Such circumstance may reflect a functional 
cooperation between GRK2 and Mdm2 in order to confer resistance to growth arrest and 
to apoptosis, as suggested by the fact that GRK2 attenuates the DNA damage-induced 
increase of p53, acting either in parallel to or in line with Mdm2 (Penela et al., 2010). In 
agreement with these hypotheses, in this work we have intended to investigate the impact 
of GRK2 expression in the tumoural hallmarks of breast cancer cells, and to delineate the 
functional consequences of altered GRK2 levels on the Mdm2 regulatory properties, with 
emphasis in the p53/Mdm2 regulatory axis .
Figure I.13. Tumoural de-
regulation of GRK2 turnover. 
IGF-1 stimulation induces GRK2 
protein accumulation in a PI3K-
dependent manner, by relieving 
the Mdm2- dependent degradation 
of GRK2.
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Despite of its profuse connectivity to diverse signalling pathways that impact on cell transformation, and the high-level expression of GRK2 in some tumoural contexts, a comprehensive study of the role of this kinase in tumour formation 
and progression has not been addressed in detail.  Contradictory results on its effects on 
cell proliferation have been reported depending on the tumour type.  However, most 
of these studies relayed on the use of cellular models and focused on “in vitro” cell-
culture proliferation, and did not address whether GRK2 might influence in vivo tumour 
proliferation or other processes relevant to tumour biology, such as the anchorage-
independent growth or the cellular survival to the stressful tumoural milieu. Therefore, 
the purpose of this research work was to identify and analyze in deep the contribution of 
GRK2 to breast cancer tumorigenesis, paying special attention to the unexplored role of 
this protein in breast cancer proliferation and invasion and its connection with the main 
oncogenic pathways involved in this type of cancer. Moreover, the possible connection 
between GRK2 and Mdm2 or HDAC6 in a breast cancer context was specifically 
investigated. 
Specific objectives: 
1. Investigate the occurrence of altered GRK2 levels in breast cancer, their underlying 
causes and the functional interplay between the upregulation of the oncoprotein Mdm2 
and GRK2 levels.
2. Analyze the regulatory loop between Mdm2 and GRK2 and delineate the 
functional consequences of altered GRK2 levels in the Mdm2/p53 regulatory axis. 
3. Determine the implication of GRK2-dependent regulation of HDAC6 in cell 
transformation and its relevance in wild-type or mutated p53 backgrounds.
4. Identify the impact of altering GRK2 levels in the acquisition of hallmarks of 
breast cancer, with particular focus on cell proliferation, survival and invasion.
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1. 
Materials 
1.1. Buffers and solutions
Name Composition Comments 
Buffer C 20 mM HEPES pH 7,5 
0.45 M NaCl 
1 mM EDTA 
Add fresh a protease 
inhibitor cocktail 
 
Coomasie staining solution 0.1%(w/v) Coomassie R250 
10% (v/v) acetic acid 
50% (v/v) methanol  
40% (v/v) H2O 
 
Coomasie destaining solution 10% (v/v) acetic acid 
50% (v/v) methanol 
40% (v/v) H2O  
 
Hypotonic buffer 20 mM HEPES pH 7,5 
10 mM MgCl2 
1 mM NaF 
0,1 mM EDTA 
1mM DTT 
 
Kinase assay buffer  
 
27 mM Tris-HCl (pH 7.5) 
6 mM MgCl2 
7,5 mM NaF 
1 mM EGTA 
1,4 mM EDTA 
10 μM ATP 
[γ32P]-ATP (2-3 cpm/pmol) 
 
 
 
 
 
 
(Perkin Elmer) 
LB broth 1% (w/v) bacto-tryptone 
0.5% (w/v) bacto-yeast extract 
1% (w/v) NaCl (171 mM) 
autoclaved 
 
LB-agar LB broth + 1.5% (w/v) agar autoclaved 
Mdm2-p53 interaction buffer 25 mM Tris-HCl (pH 8) 
2.7 mM KCl 
137 mM NaCl 
10%(v/v) Triton-X100 
10% Glicerol 
Add fresh a protease 
inhibitor cocktail 
PBS (1x) 137 mM NaCl (0.8% w/v) 
2.7 mM KCl (0.02% w/v) 
10 mM Na2HPO4 (0.144% w/v) 
1.75 mM KH2PO4 (0.024% w/v) 
pH 7.4 
autoclaved 
Ponceau staining solution 0.2% Ponceau-S in 
3.0% TCA 
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Name Composition Comments 
Buffer C 20 mM HEPES pH 7,5 
0.45 M NaCl 
1 mM EDTA 
Add fresh a protease 
inhibitor cocktail 
 
Coomasie staining solution 0.1%(w/v) Coomassie R250 
10% (v/v) acetic acid 
50% (v/v) methanol  
40% (v/v) H2O 
 
Coomasie destaining solution 10% (v/v) acetic acid 
50% (v/v) methanol 
40% (v/v) H2O  
 
Hypotonic buffer 20 mM HEPES pH 7,5 
10 mM MgCl2 
1 mM NaF 
0,1 mM EDTA 
1mM DTT 
 
Kinase assay buffer  
 
27 mM Tris-HCl (pH 7.5) 
6 mM MgCl2 
7,5 mM NaF 
1 mM EGTA 
1,4 mM EDTA 
10 μM ATP 
[γ32P]-ATP (2-3 cpm/pmol) 
 
 
 
 
 
 
(Perkin Elmer) 
LB broth 1% (w/v) bacto-tryptone 
0.5% (w/v) bacto-yeast extract 
1% (w/v) NaCl (171 mM) 
autoclaved 
 
LB-agar LB broth + 1.5% (w/v) agar autoclaved 
Mdm2-p53 interaction buffer 25 mM Tris-HCl (pH 8) 
2.7 mM KCl 
137 mM NaCl 
10%(v/v) Triton-X100 
10% Glicerol 
Add fresh a protease 
inhibitor cocktail 
PBS (1x) 137 mM NaCl (0.8% w/v) 
2.7 mM KCl (0.02% w/v) 
10 mM Na2HPO4 (0.144% w/v) 
1.75 mM KH2PO4 (0.024% w/v) 
pH 7.4 
autoclaved 
Ponceau staining solution 0.2% Ponceau-S in 
3.0% TCA 
 
Protease/phosphatase 
Inhibitor Cocktail:  
 
0.1 µM PMSF 
0.5 µM Benzamidin  
1 µg/µl Aprotinin 
0.1 µM NaVO3 
10 µg/ml STI 
10 µg/ml Bacitracin 
 
Protein sample buffer 4x 200mM Tris pH=6.8  
40% (v/v) glycerol 
0.15% (w/v) bromophenol blue 
4% (w/v) SDS 
5% (v/v) b-Mercaptoethanol 
 
RIPA buffer (1x) Tris-HCl 20mM pH 7.5 
150mM NaCl 
1% Triton-X100 
0.1% SDS 
0.5% sodium deoxycholate  
store at 4°C for 
less than 3 months 
 
Add fresh a protease 
inhibitor cocktail 
Resolving Polyacrylamide gel 
(6-15%) 
Acrylamide/N,N'methylen-
bisacrylamide 30:0.8 (w/v) 
0.375 M Tris-HCl pH 8.9 
0.1% SDS 
 
Running buffer(10x) 
 
0.25 M Tris base 
2.0 M glycine 
1% SDS 
 
Stacking Polyacrylamide gel 
(4%) 
Acrylamide/N,N'methylen-
bisacrylamide 30:0.8 (w/v) 
0.25 M Tris-HCl pH 6.8 
0.1% SDS 
 
TAE buffer (1x) 40 mM Tris-acetate pH 7.6 
1 mM EDTA 
autoclaved 
TBS (10x) 0.1 M Tris base 
1.5 M NaCl 
pH 7.4 with HCl conc. 
 
TBS-Tween (10x) 0.1 M Tris base 
1.5 M NaCl 
0.2% Tween-20 
pH 8.0 with HCl conc. 
 
Transfer buffer (2l) 
 
0,64g Na2CO3 
1,68g NaHCO3 
20% methanol (v/v) 
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1. 2. Oligonucleotides
All oligonucleotides for mutations were purchased from Sigma-Aldrich Spain 
Protease/phosphatase 
Inhibitor Cocktail:  
 
0.1 µM PMSF 
0.5 µM Benzamidin  
1 µg/µl Aprotinin 
0.1 µM NaVO3 
10 µg/ml STI 
10 µg/ml Bacitracin 
 
Protein sample buffer 4x 200mM Tris pH=6.8  
40% (v/v) glycerol 
0.15% (w/v) bromophenol blue 
4% (w/v) SDS 
5% (v/v) b-Mercaptoethanol 
 
RIPA buffer (1x) Tris-HCl 20mM pH 7.5 
150mM NaCl 
1% Triton-X100 
0.1% SDS 
0.5% sodium deoxycholate  
store at 4°C for 
less than 3 months 
 
Add fresh a protease 
inhibitor cocktail 
Resolving Polyacrylamide gel 
(6-15%) 
Acrylamide/N,N'methylen-
bisacrylamide 30:0.8 (w/v) 
0.375 M Tris-HCl pH 8.9 
0.1% SDS 
 
Running buffer(10x) 
 
0.25 M Tris base 
2.0 M glycine 
1% SDS 
 
Stacking Polyacrylamide gel 
(4%) 
Acrylamide/N,N'methylen-
bisacrylamide 30:0.8 (w/v) 
0.25 M Tris-HCl pH 6.8 
0.1% SDS 
 
TAE buffer (1x) 40 mM Tris-acetate pH 7.6 
1 mM EDTA 
autoclaved 
TBS (10x) 0.1 M Tris base 
1.5 M NaCl 
pH 7.4 with HCl conc. 
 
TBS-Tween (10x) 0.1 M Tris base 
1.5 M NaCl 
0.2% Tween-20 
pH 8.0 with HCl conc. 
 
Transfer buffer (2l) 
 
0,64g Na2CO3 
1,68g NaHCO3 
20% methanol (v/v) 
 
	  
Primer name Oligonucleotide sequence 
Flag-Mdm2 S115/116A Fw 5´ - cagcaggaagcagcggactcaggtac - 3´ 
Flag-Mdm2 S115/116A Rev 5´ - gtacctgagtccgctgcttcctgctg - 3´ 
Flag-Mdm2 S172A Fw 5´ - cagaagaaaatgcagatgaattatctgg - 3´ 
Flag-Mdm2 S172A Rev 5' - ccagataattcatctgcattttcttctg - 3' 
Flag-Mdm2 S213/216/218A Fw 5' - gaagcagtagcgctgaatctgcaggggcgccatcgaatc - 3' 
Flag-Mdm2 S213/216/218A Rev 5' - gattcgatggcgcccctgcagattcagcgctactgcttc - 3' 
Flag-Mdm2 S254/256A Fw 5' - gaagttgaagctctcgacgcagaagattatagcc - 3' 
Flag-Mdm2 S254/256A Rev 5' - ggctataatcttctgcgtcgagagcttcaacttc - 3' 
Flag-Mdm2 S260/262A Fw 5' - cgactcagaagattatgcccttgctgaagaagg - 3' 
Flag-Mdm2 S260/262A Rev 5' - ccttcttcagcaagggcataatcttctgagtcg - 3' 
Flag-Mdm2 S284/286A Fw 5' - ggcaggggaggctgatacagattc - 3' 
Flag-Mdm2 S284/286A Rev 5' - gaatctgtatcagcctcccctgcc - 3' 
Flag-Mdm2 T350/351A Fw 5' - ctggaaaacgcagcacaagctgaagagg - 3' 
Flag-Mdm2 T350/351A Rev 5' - cctcttcagcttgtgctgcgttttccag - 3' 
Quickchange - pDest - Generation   
HDAC6 - Fw 5' - caccatgacctcaaccggcc - 3' 
GFP- Rev 5' - gggttacttgtacagctcgtccatgccgac - 3' 
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1. 3. DNA enzymes
1. 4. Primary antibodies
Primer name Oligonucleotide sequence 
Flag-Mdm2 S115/116A Fw 5´ - cagcaggaagcagcggactcaggtac - 3´ 
Flag-Mdm2 S115/116A Rev 5´ - gtacctgagtccgctgcttcctgctg - 3´ 
Flag-Mdm2 S172A Fw 5´ - cagaagaaaatgcagatgaattatctgg - 3´ 
Flag-Mdm2 S172A Rev 5' - ccagataattcatctgcattttcttctg - 3' 
Flag-Mdm2 S213/216/218A Fw 5' - gaagcagtagcgctgaatctgcaggggcgccatcgaatc - 3' 
Flag-Mdm2 S213/216/218A Rev 5' - gattcgatggcgcccctgcagattcagcgctactgcttc - 3' 
Flag-Mdm2 S254/256A Fw 5' - gaagttgaagctctcgacgcagaagattatagcc - 3' 
Flag-Mdm2 S254/256A Rev 5' - ggctataatcttctgcgtcgagagcttcaacttc - 3' 
Flag-Mdm2 S260/262A Fw 5' - cgactcagaagattatgcccttgctgaagaagg - 3' 
Flag-Mdm2 S260/262A Rev 5' - ccttcttcagcaagggcataatcttctgagtcg - 3' 
Flag-Mdm2 S284/286A Fw 5' - ggcaggggaggctgatacagattc - 3' 
Flag-Mdm2 S284/286A Rev 5' - gaatctgtatcagcctcccctgcc - 3' 
Flag-Mdm2 T350/351A Fw 5' - ctggaaaacgcagcacaagctgaagagg - 3' 
Flag-Mdm2 T350/351A Rev 5' - cctcttcagcttgtgctgcgttttccag - 3' 
Quickchange - pDest - Generation   
HDAC6 - Fw 5' - caccatgacctcaaccggcc - 3' 
GFP- Rev 5' - gggttacttgtacagctcgtccatgccgac - 3' 
	  
Enzyme Supplier 
BP Clonase Invitrogen 
DpnI New England Biolabs 
LR Clonase II  Invitrogen 
Pfu ultra Stratagene 
Platinum Taq Invitrogen 
Taq polymerase New England Biolabs 
	  
Antigen Reference Supplier Species Dilution 
Acetyl-a-tubulin Clone 6-11B-1 Sigma Mouse WB (1/2000) / IF (1/100) 
Actin I-19 (sc-1616) Santa Cruz Goat WB (1/1000)  
Akt 9272 Cell Signalling Rabbit WB (1/1000) 
Cleaved-caspase 3 Asp175 Cell Signalling Rabbit WB (1/1000) / IHC (1/200) 
Cortactin Clone 4F11 Millipore Mouse WB (1/1000) / IF (1/200) 
Cyclin D1 sc246 Santa Cruz Mouse WB (1/1000) 
E-Cadherin 4065 Cell Signalling Rabbit WB (1/1000) 
Erk1 (C-16): sc-93 Santa Cruz Rabbit WB (0.75 mg/ml) 
Erk2 (c-14): sc-154 Santa Cruz Rabbit WB (0.75 mg/ml) 
Falloidin-TRITC P-1951 Sigma - IF (1/100-1/500) 
FLAG M1  F3040 Sigma Mouse WB (1:1000) / IP (1-2 mg) 
GAPDH   ab8245 Abcam Mouse WB (1:2000 - 1/4000) 
GIT1 H-170 (sc-13961) Santa Cruz Rabbit WB (1/500) 
GRK2  C-15 (sc-562 Santa Cruz Rabbit WB (1/500) 
GRK2/3  clone C5/1.1 05-465 Millipore Mouse WB (1:2000) / IP (1-2 mg) 
GRK2 PF1   Our laboratory Rabbit WB (1:1000) / IP (1-2 mg) 
GRK2 PF2  Our laboratory Rabbit IHC (1/200-1/1000) 
GST (Z-5): sc-459 Santa Cruz Rabbit WB (1/500) 
HDAC6 H-300 Santa Cruz Rabbit WB (1/500) 
KI67 Clone SP6 Thermo Scientific Rabbit IHC (1/300) 
Mdm2 N-20 (sc-813) Santa Cruz Rabbit WB (1/500) / IP (1-2mg) 
Mdm2 Ab-5 (4B2C1.11) Calbiochem Mouse WB (2 mg/ml) 
Mdm2 SMP-14 (sc-965) Santa Cruz Mouse WB (1/500) 
Mdm2 SMP14 DAKO Mouse IHC (1/200) 
MT1-MMP  Dr. P.Chavrier Mouse WB (1/1000) 
Noxa 114C307 Abcam Mouse WB (1-2 mg/ml) 
Nucleolin CL3(H-250) (sc-13057) Santa Cruz Rabbit WB (1/1000) 
p21 C-19 (sc-397) Santa Cruz Rabbit WB (1/1000) 
p53 DO-1 (sc-126) Santa Cruz Mouse WB (1/1000) / IHC (1/400) 
p-Akt (Ser473) 9271 Cell Signalling Rabbit WB (1/1000) / IHC (1/200) 
p-Erk1-2 (Thr202/204)  9101 Cell Signalling Rabbit WB (1/1000) 
p-GRK2 (Ser670) 44202 Biosource Rabbit WB (1/500) 
p-Histone-3 (Ser10) 06-570 Millipore Rabbit WB (1/500) 
p-p53 (Ser15) 16G8 (9286) Cell Signalling Mouse WB (1/500) 
Pan-Ras Ab-3 Calbiochem Mouse WB (2.5 mg/ml) 
Pin1 C-20 (sc-7409) Santa Cruz Rabbit WB (1/1000) 
Pro-Caspase 3 9662 Cell Signalling Rabbit WB (1/1000) 
a -Tubulin DM1A Sigma Mouse WB (1/1000) 
Vimentin Clone V9 Dako Mouse WB (1/1000) 
	  
97
Materials & Methods
1. 5. Antibodies conjugated to agarose beads
1. 6. Secondary antibodies
Antigen Reference Supplier Species Dilution 
Acetyl-a-tubulin Clone 6-11B-1 Sigma Mouse WB (1/2000) / IF (1/100) 
Actin I-19 (sc-1616) Santa Cruz Goat WB (1/1000)  
Akt 9272 Cell Signalling Rabbit WB (1/1000) 
Cleaved-caspase 3 Asp175 Cell Signalling Rabbit WB (1/1000) / IHC (1/200) 
Cortactin Clone 4F11 Millipore Mouse WB (1/1000) / IF (1/200) 
Cyclin D1 sc246 Santa Cruz Mouse WB (1/1000) 
E-Cadherin 4065 Cell Signalling Rabbit WB (1/1000) 
Erk1 (C-16): sc-93 Santa Cruz Rabbit WB (0.75 mg/ml) 
Erk2 (c-14): sc-154 Santa Cruz Rabbit WB (0.75 mg/ml) 
Falloidin-TRITC P-1951 Sigma - IF (1/100-1/500) 
FLAG M1  F3040 Sigma Mouse WB (1:1000) / IP (1-2 mg) 
GAPDH   ab8245 Abcam Mouse WB (1:2000 - 1/4000) 
GIT1 H-170 (sc-13961) Santa Cruz Rabbit WB (1/500) 
GRK2  C-15 (sc-562 Santa Cruz Rabbit WB (1/500) 
GRK2/3  clone C5/1.1 05-465 Millipore Mouse WB (1:2000) / IP (1-2 mg) 
GRK2 PF1   Our laboratory Rabbit WB (1:1000) / IP (1-2 mg) 
GRK2 PF2  Our laboratory Rabbit IHC (1/200-1/1000) 
GST (Z-5): sc-459 Santa Cruz Rabbit WB (1/500) 
HDAC6 H-300 Santa Cruz Rabbit WB (1/500) 
KI67 Clone SP6 Thermo Scientific Rabbit IHC (1/300) 
Mdm2 N-20 (sc-813) Santa Cruz Rabbit WB (1/500) / IP (1-2mg) 
Mdm2 Ab-5 (4B2C1.11) Calbiochem Mouse WB (2 mg/ml) 
Mdm2 SMP-14 (sc-965) Santa Cruz Mouse WB (1/500) 
Mdm2 SMP14 DAKO Mouse IHC (1/200) 
MT1-MMP  Dr. P.Chavrier Mouse WB (1/1000) 
Noxa 114C307 Abcam Mouse WB (1-2 mg/ml) 
Nucleolin CL3(H-250) (sc-13057) Santa Cruz Rabbit WB (1/1000) 
p21 C-19 (sc-397) Santa Cruz Rabbit WB (1/1000) 
p53 DO-1 (sc-126) Santa Cruz Mouse WB (1/1000) / IHC (1/400) 
p-Akt (Ser473) 9271 Cell Signalling Rabbit WB (1/1000) / IHC (1/200) 
p-Erk1-2 (Thr202/204)  9101 Cell Signalling Rabbit WB (1/1000) 
p-GRK2 (Ser670) 44202 Biosource Rabbit WB (1/500) 
p-Histone-3 (Ser10) 06-570 Millipore Rabbit WB (1/500) 
p-p53 (Ser15) 16G8 (9286) Cell Signalling Mouse WB (1/500) 
Pan-Ras Ab-3 Calbiochem Mouse WB (2.5 mg/ml) 
Pin1 C-20 (sc-7409) Santa Cruz Rabbit WB (1/1000) 
Pro-Caspase 3 9662 Cell Signalling Rabbit WB (1/1000) 
a -Tubulin DM1A Sigma Mouse WB (1/1000) 
Vimentin Clone V9 Dako Mouse WB (1/1000) 
	  
Antigen Epitope/Reference Supplier Species Dilution 
P53-AC DO-1  Santa Cruz Mouse IP (2 mg/sample) 
Mdm2-AC SMP-14  Santa Cruz Mouse IP (1-2mg/sample) 
	  
Name, antigen Company  Dilution 
Alexa Fluor 680, goat anti-mouse IgG Molecular probes 1 mg/ml 
IRDyeTM 800 CW, donkey anti-mouse 
IgG  
Rockland 0.5 mg/ml 
Alexa Fluor 680, goat anti-rabbit IgG Molecular probes 1 mg/ml 
IRDyeTM 800 CW, goat anti-rabbit IgG Rockland 0.5 mg/ml 
Alexa Fluor 680, donkey anti-goat IgG Molecular probes 1 mg/ml 
IRDyeTM 800 CW, goat anti-goat IgG Rockland 0.5 mg/ml 
Soluble rabbit peroxidase-anti-mouse IgG Nordic immunology 1/50000 
Soluble mouse peroxidase-anti-rabbit IgG Nordic immunology 1/50000 
Soluble mouse peroxidase-anti-goat IgG Nordic immunology 1/50000 
Biotin-conjugated donkey anti-rabbit IgG Jackson Immnunoresearch 1/100 (IHC) 
Biotin-conjugated donkey anti-mouse IgG Jackson Immnunoresearch 1/100 (IHC) 
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1. 7. Plasmids
1. 8. Adenoviral constructs
cDNA vector Origin 
EGFR   
Flag-Mdm2 pCMV Dr. L Mayo (, USA) 
Flag-Mdm2 S115/116A pCMV Generated as part of this thesis 
Flag-Mdm2 S172A pCMV Generated as part of this thesis 
Flag-Mdm2 S213/216/218A pCMV Generated as part of this thesis 
Flag-Mdm2 S254/256A pCMV Generated as part of this thesis 
Flag-Mdm2 S260/262A pCMV Generated as part of this thesis 
Flag-Mdm2 S284/286A pCMV Generated as part of this thesis 
Flag-Mdm2 T350/351A pCMV Generated as part of this thesis 
GRK2 pcDNA3.1 
Dr J Benovic (The Kimmel Cancer Center, 
USA) 
GRK2 K220R pcDNA3.1 
Dr J Benovic (The Kimmel Cancer Center, 
USA) 
HDAC6-GFP pEGF 
Dr F Sanchez-Madrid (ISS La Princesa, 
Madrid, Spain) 
HDAC6 S1060/1062/1068A-GFP pEGF Generated in our laboratory 
Her/Neu (ERBB2) pORF InvivoGene 
Mdm2 pC/pCDNA3 Dr. Manuel Serrano (CNIO, Spain) 
p53 pLMV Clontech 
pDest-HDAC6-GFP pDEST-DH1 Generated as part of this thesis 
pDest- HDAC6 S1060/1062/1068A-
GFP pDEST-DH1 Generated as part of this thesis 
pMD2G  Dr F.Martin Belmonte (CBMSO, Spain) 
psPax2  Dr F.Martin Belmonte (CBMSO, Spain) 
Ras-V12  Dr. Manuel Serrano (CNIO, Spain) 
	  
Name Species Origin 
Cre-recombinase  
Gene Transfer Vector Core Facility, University 
of Iowa  
GRK2 human 
Provided by Dr. S. Ferguson (Robarts 
Research Institute, Ontario, Canada) 
Sh-GRK2 rat 
5’- GCAGAGACGTCTTTGATACC-3’ 
(Generated in our Laboratory) 
GRK2-K220R human 
Provided by Dr. S. Ferguson (Robarts 
Research Institute, Ontario, Canada) 
Lamin human Provided by Dr. J.Aldudo (CBMSO, Spain) 
Sh-GRK2 human 
5′- GCAAGAAAGCCAAGAACAAGC-3′ 
/Generated in our Laboratory) 
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1. 9. Human SiRNA constructs
1. 10. Fusion proteins
1. 11. Cell treatments
Name Origin /Company 
GRK2 #1 (Hs_ADRBK1_1) Qiagen 
GRK2 #2 (Hs_ADRBK1_2) Qiagen 
GRK2 #9 (Hs_ADRBK1_9) Qiagen 
GRK2 #10 (Hs_ADRBK1_10) Qiagen 
GRK2 (On target SmartPool) Dharmacon 
HDAC6 (On target SmartPool) Dharmacon  
MT1-MMP (On target SmartPool) Dharmacon  
Non-Targeting (On target SmartPool) Dharmacon  
	  
Name Origin 
GRK2 Generated in our laboratory 
GST Generated in our laboratory 
GST-Mdm2 Generated in our laboratory 
GST-Mdm2 Abnova 
GST-Mdm2 100-200 Generated in our laboratory 
GST-Mdm2 100-491 Generated in our laboratory 
GST-Mdm2 ring domain Generated in our laboratory 
His-Mdm2 Abcam 
	  
Name Description Company 
17-b-Estradiol Oestrogen Sigma 
4' OHT Tamoxifen Sigma 
AG1478 EGFR inhibitor Sigma 
CCL-21 Chemokine (signalling through the CCR7 receptor) Preprotech 
Cycloheximide Protein synthesis inhibitor Calbiochem 
Cisplatin Apoptosis Inductor Sigma 
Doxorubicin Inhibitor of macromolecular biosynthesis. Sigma 
EGF Agonist of EGFR. Acts as a survival factor Calbiochem 
Etoposide Cytotoxic agent (topoisomerase inhibitor) Sigma 
Heregulin Growth factor that binds with ERB3 and ERB4 
receptors. It also promotes motility and invasiveness of 
breast cancer cells.  
Preprotech 
HLI737 Inhibitor of Mdm2 ubiquitin ligase (E3) BostonBiochem 
Nutlin3a Inhibitor of Mdm2-p53 interaction Calbiochem 
Paclitaxel Drug that interferes with the normal breakdown of 
microtubules during cell division 
Sigma 
Saha (Vorinostat) Histone deacetylase inhibitor Cayman chemical company 
SDF1a Chemokine (signalling through the CXCR4 receptor) Preprotech 
Tubacin Selective HDAC6 inhibitor Enzo 
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1. 12. Reagents
1. 13. Cell lines 
Name Company 
Charcoal Medium Invitrogen 
Collagen type I (rat-tail) BD-Biosciences 
DMEM GIBCO 
DAB Vector Laboratories 
Doxycyclin Sigma 
Dynabeads Dynal 
Elite ABC kit Vector Laboratories 
F12-HAMs GIBCO 
Gelatin GFP-Conjugates Molecular Probes 
Hydrocortisone Sigma 
Hygromicin Sigma 
Hyperfilms Amersham 
Insulin GIBCO 
Lipofectamine Life-technologies 
Lullaby OZ-Biosciences 
Matrigel BD-Biosciences 
Nuclear extraction kit Panomics 
Nucleofection technology Lonza 
[γ32P]-ATP Perkin-Elmer 
Protein/DNA arrays Panomics 
Puromycin Invitrogen 
Ras activity assay Cytoskeleton 
35S-labeled methionine/cysteine New England Nuclear. 
Tetracyclin Sigma 
Transferrin Sigma 
	  
 Cell lines Origin 
184B5 ATCC 
293T Dr. Fernando Martin Belmonte (CBMSO) 
HEK293 ATCC 
Hs578T Dr. José M. Cuezva (CBMSO, Madrid, Spain) 
MCF7 Dr. Manuel Serrano (CNIO, Madrid, Spain) 
MCF10A Dr. Manuel Serrano (CNIO, Madrid, Spain) 
MDA-MB-157 ATCC 
MDA-MB-231 ATCC 
MDA-MB-361 ATTC 
MDA-MB-468 Dr. Manuel Serrano (CNIO, Madrid, Spain) 
T47D ATCC 
Stable cell lines   
184B5-GRK2-A Generated in our laboratory 
184B5-GRK2-R Generated in our laboratory 
MCF7-Tet-On-GRK2-wt16 Generated in our laboratory  
MCF7-Tet-On-GRK2-K220R Generated in our laboratory 
MDA-MB-231-H2B-GFP Dr. P.Chavrier (Institut Curie, Paris, France) 
MDA-MB-231-HDAC-GFP Generated as part of this thesis 
MDA-MB-231-HDAC6-S1060/1062/1068A-
GFP Generated as part of this thesis 
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 Cell lines Origin 
184B5 ATCC 
293T Dr. Fernando Martin Belmonte (CBMSO) 
HEK293 ATCC 
Hs578T Dr. José M. Cuezva (CBMSO, Madrid, Spain) 
MCF7 Dr. Manuel Serrano (CNIO, Madrid, Spain) 
MCF10A Dr. Manuel Serrano (CNIO, Madrid, Spain) 
MDA-MB-157 ATCC 
MDA-MB-231 ATCC 
MDA-MB-361 ATTC 
MDA-MB-468 Dr. Manuel Serrano (CNIO, Madrid, Spain) 
T47D ATCC 
Stable cell lines   
184B5-GRK2-A Generated in our laboratory 
184B5-GRK2-R Generated in our laboratory 
MCF7-Tet-On-GRK2-wt16 Generated in our laboratory  
MCF7-Tet-On-GRK2-K220R Generated in our laboratory 
MDA-MB-231-H2B-GFP Dr. P.Chavrier (Institut Curie, Paris, France) 
MDA-MB-231-HDAC-GFP Generated as part of this thesis 
MDA-MB-231-HDAC6-S1060/1062/1068A-
GFP Generated as part of this thesis 
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2.
Methods
2.1 DNA manipulations  
a) DNA mutagenesis
The possible specific sites of Mdm2 phosphorylation by GRK2 were mutated 
using the QuickChange® site-directed mutagenesis kit (Stratagene). The basic procedure 
utilizes a supercoiled double-stranded DNA (dsDNA) vector with an insert of interest 
(Flag-Mdm2) and two synthetic oligonucleotide primers, each complementary to opposite 
strands of the insert sequence containing the desired point mutations. The primers were 
designed according to the manufacturer’s guidelines and extended by PCR using the 
reagents provided in the kit under the following conditions:
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Step Cycles Temperature Time Purpose 
1 1 95ºC 30 sec  
2 18 95ºC 50 sec DNA 
denaturing 
  60ºC 50 sec Primers 
annealing 
  68ºC 7 min Template 
elongation 
3 1 68ºC 7 min  
4 1 4ºC ∞  
Following the PCR, products were treated with DpnI restriction enzyme for 1 hour 
at 37°C to digest the parental DNA template. To select for mutation-containing synthesized 
DNA, E.coli XL1-Blue supercompetent cells were transformed with the resulting nicked 
vectors according to manufacturer’s instructions and bacteria plated onto LB-ampicillin 
(50 µg/ml) agar plates. Resulting colonies were grown in LB broth-ampicillin (10 µg/ml) 
for plasmid preparation (Promega Spin Miniprep Kit, Promega). Plasmids were subjected 
to DNA sequencing to verify the mutation and the fidelity of the whole cDNA sequence. 
 Finally, Large-scale purification of plasmid DNA (maxi-prep) was performed using 
Endofree Plasmid purification kit® (Qiagen) according to the manufacturer’s instructions, 
and plasmids were transfected into 293 cells to check the proper expression of the mutants. 
(Fig. MM.1). 
b) Generation of  retroviral constructions
HDAC6-GFP and HDAC6-S1060/1062/1068A-GFP pDEST (lentivirus) 
constructs were generated using the Gateway® system of invitrogen.  The Gateway® 
Technology is a universal cloning method that uses the lambda recombination system to 
facilitate transfer of heterologous DNA sequences (flanked by modified att sites) between 
vectors (Hartley, 2000, Landy, 1989). The two recombination reactions that constitute the 
basis of the Gateway® Technology are briefly summarized in fig. MM.2.
Figure MM.1: Generation of possible 
GRK2-dependent phosphorylation defective 
mutants in Mdm2. Mutants were designed 
as described above and, once they had been 
sequenced and amplified, plasmids were 
transfected into 293 cells. A representative 
western blot of the different mutants generated 
is shown.
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Briefly, the basic procedure requires the cloning of a blunt-end PCR product into one 
of the pENTR™ TOPO® vectors to generate an entry clone.  Afterwards, performing an LR 
recombination reaction, an expression construct® destination vector of choice (lentivirus) 
was generated, and finally the expression construct is introduced into the appropriate host 
(293T cells) to generate the lentivirus and infect the desired cells to express the proteins. 
First of all, we used the pENTR™ Directional TOPO®Cloning Kits to directionally 
clone a blunt-end PCR product into a vector for entry into the Gateway® System. In this 
system, PCR products are directionally cloned by adding four bases to the forward primer 
(CACC) at the 5′ end of the primer. The overhang in the cloning vector (GTGG) invades 
the 5′ end of the PCR product, anneals to the added bases, and stabilizes the PCR product 
in the correct orientation. To ensure that our PCR product clones directionally with high 
efficiency, the reverse PCR primer must not be complementary to the overhang sequence 
GTGG at the 5′ end. 
 The primers HDAC6-Fw and GST-Rv were extended by PCR using dsDNA of 
HDAC6 constructs as template, the reagents provided in the kit and the Quick Change 
XL-Site-Directed PCR under the following conditions:
Figure MM.2: The basis of the Gateway System. A) BP Reaction: Facilitates recombination of an attB 
substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (donor vector) 
to create an attL-containing entry clone. This reaction is catalyzed by BP Clonase™ enzyme mix. B) LR 
Reaction: Facilitates recombination of an attL substrate (entry clone) with an attR substrate (destination 
vector) to create an attB-containing expression clone. This reaction is catalyzed by LR Clonase™ enzyme 
mix.
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Step Cycles Temperature Time Purpose 
1 1 95ºC 30 sec  
2 18 95ºC 50 sec DNA 
denaturing 
  60ºC 50 sec Primers 
annealing 
  68ºC 7 min Template 
elongation 
3 1 68ºC 7 min  
4 1 4ºC ∞  
Blunt-end PCR products were verified by using agarose gel electrophoresis (1%) and 
gel-purify by using the Qiagen gel extraction kit (Qiagen). Purified products were cloned 
into the pENTR™ TOPO® vector following the manufacturer’s indications. One Shot® 
competent E. coli cells were transformed with the resulting recombinant vectors and plated 
onto LB-kanamicin (50 µg/ml) agar plates. Upon plasmid preparation (Endofree Plasmid 
purification kit®, Qiagen), positive colonies were confirmed by an additional PCR using 
the primers HDAC6-Fw  and GST-Rv  under the following conditions.
After selection and sequencing of the pENTRYs, the positive plasmids were subjected 
to a LR recombination reaction (Gateway® LR Clonase® II enzyme mix) between an attL-
containing entry clone and an attR-containing destination vector to generate an expression 
clone (pDEST DH1= lentivirus) containing our proteins of interest. The LR recombination 
reaction was performed as indicated by the manufacturer.
Reactions were incubated overnight at room temperature and stopped by adding 
2 µl of the Proteinase K solution and incubating them for 10 minutes at 37°C. pDEST® 
constructs were then transformed into DH5α™competent E. coli and plated onto LB-
ampicilin (50 µg/ml) agar plates. Resulting colonies were grown in LB broth- ampicilin (50 
µg/ml) for plasmid preparation (Endofree Plasmid purification kit®, Qiagen). Plasmids 
were subjected to DNA sequencing to verify the fidelity of the whole cDNA sequence. 
c) Transformation of  electrocompetent bacteria 
50 µl of electrocompetent E. coli (XL1-Blue supercompetent cells, Stratagene, One 
Shot® TOP10 cells or electrocompetent DH5a cells) were transformed with 10 ng of 
plasmid following the well-established Heat-shock bacterial transformation protocol. 
d) Storage of  bacteria 
The long-term storage of bacteria containing transformed plasmids was at -80 °C in 
10% glycerol.
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e) DNA sequencing
Isolated plasmids were sequenced by the external sequencing facility (Parque 
Científico de Madrid) using specific primers to verify the mutation and the fidelity of the 
whole cDNA sequence. The chromatograms were analysed with the Chromas Lite 2.1 
software and fasta files were analysed with Sequence Viewer software to annotate the final 
sequence and to perform alignments of DNA sequences.
f) DNA agarose gel electrophoresis
Size determination and separation of DNA was achieved by means of TAE agarose 
gel electrophoresis. DNA samples were run in 0.8-1% (w/v) of electrophoresis grade 
agarose (Invitrogen) gels supplemented with0.6 µg/ml of ethidium bromide. As DNA size 
markers HindIII digestion fragments of λ and ø29 phages were used. Gels were run at 0.01 
Volts/mm2 and DNA was visualised using a UV transilluminator.
g) Quantification of  DNA
The concentration of DNA samples was measured with a Nanodrop 
spectrophotometer and software (Thermo Scientific). Quantification of the band obtained 
in the 1% (w/v) agarose gel was also used to measure DNA concentration. 
2. 2 Culture and manipulation of mammalian cell lines
a) Maintaining and subculturing the cells
184B5 and MCF10A cells were cultured in DMEM /F12-HAMS medium 
supplemented with glutamine 2mM and penicillin/streptomycin (0.01%/0.063%) 
and containing 5% (v/v) horse serum (HS), 10 µg/ml insulin, 20 ng/ml EGF, 100 µg/
ml transferrin, and 0.5 µg/ml hydrocortisone. MDA-MB-361, MDA-MB-468, MCF7 
and Hs578T cells were maintained in DMEM supplemented with 10% (v/v) fetal 
bovine serum (FBS), glutamine 2mM and penicillin/streptomycin (0.01%/0.063%) at 
37°C in a humidified 5% CO2 atmosphere. T47D cells were cultured in DMEM 10% 
FBS supplemented with 0.2 Units/ml bovine insulin, glutamine 2mM and penicillin/
streptomycin (0.01%/0.063%). MDA-MB-157 and MDA-MB-231 cells from ATTC were 
first cultured and amplified in L-15 medium supplemented with glutamine 2mM and 
penicillin/streptomycin (0.01%/0.063%) and containing 15% (v/v) FBS at 37% in an CO2 
null atmosphere and then adapted and maintained in DMEM medium supplemented with 
10% (v/v) FBS, glutamine 2mM and penicillin/streptomycin (0.01%/0.063%) at 37°C in 
a humidified 5% CO2 atmosphere. 
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In order to detach cells from the plate for subculturing, they were washed with PBS 
and incubated with trypsin for several minutes at 37ºC (0.5 ml of trypsin for 10 cm dish). 
Afterwards, cells were resuspended in 10 ml of fresh media. The appropriate passage of 
cells was performed, usually ranging between 1:4 and 1:12, depending on the cell type.
b) Freezing/thawing
Cells from a confluent 10 cm dish were collected and resuspended in 1 ml of ice-cold 
freezing medium (90:10 fetal bovine serum / DMSO or 90:10 normal medium / DMSO) 
and transferred to a 1.5 ml cryo-tube (Nunc). Cells were first stored at -20ºC 2hours, then 
at -80oC for 2-3 days and finally were transferred to liquid N2 for long-term storage. Cells 
were quickly thawed by warming them in a 37oC water-bath. Next, the suspension was 
transferred into a 10 cm dish with 15 ml of pre-warmed growth medium. The next day, the 
medium was replaced for a fresh one.
c) Generation of  stable cell lines
 GRK2-184B5 cells
Stably transfected 184B5 cells over-expressing GRK2-wild type were generated 
in 184B5 cells by using Fugene HD, selected with 200 ng/ml hygromycin and collected 
as pooled positive transfectants. A summary of the different positive clones generated is 
represented in fig. MM3. 
GRK2wt / GRK2K220R MCF7-TET-ON system
MCF7-TET-ON system over-expressing GRK2-wt or the mutant GRK2-K220R 
was generated in our lab following the instructions of T-RExtm System (Invitrogen). 
The T-RExtm System is a tetracycline-regulated mammalian expression system that is 
based on the binding of tetracycline to the Tet repressor and derepression of the promoter 
controlling expression of the gene of interest (Yao et al., 1998). The mechanism of Tet-
mediated repression is briefly summarized in fig. MM.4. 
Figure MM.3: Generation of stable GRK2-
over-expressing 184B5 cells. The pooled 
positive clones were lysed using RIPA 
buffer and immunoblotted with GRK2 to 
characterize the over-expression levels of 
GRK2. A representative western blot of the 
clones used in this thesis is represented. 
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To start the process, the GRK2 wt or the kinase death mutant (GRK2-K220R) were 
cloned into the inducible expression vector, and the resulting construct co-transfected with 
the regulatory plasmid, pcDNA™6/TR into MCF7 mammalian cells using lipofectamine/
plus reagent. After 48 hours of transfection, cells were selected with blasticidin and Zeocin 
to isolate a single stable cell line expressing both the Tet represor and our gen of interest. 
Cells are treated with tetracycline (1 mg/ml) for several hours to check the inducible 
transcription of GRK2 or K220R (Fig. MM.5). 
Figure MM.4: Tetracycline-controlled gen expression. A) Ligation of the desired 
gene into the inducible expression vector provided by Invitrogen. B) Cells were transfected according to 
the requirement of the chosen cell type. In the absence of tetracycline, the Tet repressor forms a homodimer 
that binds with extremely high affinity to each TetO2 sequence in the promoter of the inducible expression 
vector. Binding of the Tet repressor homodimers to the TetO2 sequences represses transcription of the 
gene of interest.  C)  Upon addition, tetracycline binds with high affinity to each Tet repressor homodimer 
and causes a conformational change in the repressor that renders it unable to bind to the Tet operator. 
The Tet repressor:tetracycline complex then dissociates from the Tet operator and allows induction of 
transcription from the gene of interest.
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HDAC6-GFP/ -HDAC6-S1060/62/68A-GFP MDA-MB-231 cells
MDA-MB-231 stable over-expressing HDAC6 and the GRK2-dependent triple 
phosphorylation defective mutant HDAC6-S1060/1062/1068A were generated using 
lentiviral constructs. First, the infectious lentivirus particles are generated using the Gateway 
system as described above and packed using the 293T cell line. We used lipofectamine2000 
to reverse co - transfect 293T cells with three plasmids: (1) the lentiviral vector pDEST-
DH1 that contains GFP-HDAC6 wild type, the triple mutant of phosphorylation sites 
(1 mg) or an empty pDest vector, (2) the pVSVG plasmid (1.5 mg)  and (3) the psPAX2 
plasmid (1.5 mg) with gag, pol, and rev genes, allowing virus to form the capside and 
to infect host cells. A suspension of 10^6 293T cells per condition was incubated for 
18h at 37ºC and 5% CO2 with the transfection mixture diluted in OPTIMEN following 
the manufacturer’s indications. Medium was replaced the next day by normal medium 
containing antibiotics and maintained for 24-48 hours. Virus-containing supernatants were 
collected and centrifuged at 5000 g for 2 minutes at room temperature to eliminate 293T 
remains. 
Upon supplementation with polybrene (which aggregates virus particles) to a final 
concentration of 8 µg/ml virus-containing supernatants were added to the MDA-MB-231 
cells (250000cells/M6 well).  After 24-48h, medium was replaced with culture medium 
containing puromycin (10 ng/ml) for selection, and surviving colonies were collected and 
analyzed for western blot to check the expression levels of our proteins as shown in the fig. 
MM6. 
Figure MM.5: Inducible expression of GRK2 
wild-type or K220R in MCF7 cells. The TET-On 
MCF7 cells with the repressed GRK2 wt or the 
kinase-dead mutant were treated with tetracycline 
(1 µg/ml) for the indicated times. Lysates of these 
cells were immunoblotted with GRK2 to check 
for protein expression induction.
Figure MM.6: Generation of stable HDAC6-wt or 
S1060/1062/1068A GFP-over-expressing MDA-
MB-231 cells. The pooled positive clones were lysed 
using RIPA buffer and immunoblotted with HDAC6 
to characterize the over-expression levels of HDAC6. 
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d) Transient transfection-infection
 Lipofectamine/Plus Method
Sub-confluent cells were transfected with the indicated combinations of cDNA or 
shRNA constructs by means of the Lipofectamine/Plus reagents (Invitrogen) diluted in 
OPTIMEN, following manufacturer’s instructions. When indicated, cells were transiently 
co-transfected with a cDNA encoding the CD8 antigen for subsequent cell selection by 
using polystyrene microbeads precoated with anti-CD8 antibody (Dynabeads M450, Dynal 
Biotech, Oslo, Norway). The transfection medium was replaced after 3h of incubation by 
growth medium to lower the cytotoxic effect of lipofectamine and cells were maintained 
24 or 48 hours.  
 “Nucleofector” Cell Electroporation
184B5, MCF10A and MDA-MB-231 cells were transiently transfected using the 
Cell Line Nucleofector System (Lonza), following manufacturer’s instructions. Cells 
cultured at 75-80% confluence were trypsinized and a pellet of 2*10^6 cells per condition 
was resuspended with a 100ml mixture of kit solution V plus 1-2mg of DNA or 20-400nM 
of siRNA. Quickly, this mixture was transferred into a certified cuvette provided by 
LONZA and electroporated using the program P-020 or X-013 for 184B5/MCF10A or 
MDA-MB-231 cells, respectively.
 Lullaby™ siRNA Reverse Transfection 
For transient siRNA transfections, cells were also reversely transfected with 
Lullaby™ (OZ-Biosciences), following manufacturer’s instructions. Briefly, boht Lullaby 
reagent (8 mL/100 mL) and siRNA (optimal concentration of 25 nM) was diluted in 
culture medium without serum (OPTIMEM) The siRNA mixture was added into the 
diluted Lullaby reagent and mixed immediately and carefully 4-5 times by pipetting up 
and down.  After 20 min. incubation at room temperature, the siRNA /Lullaby complexes 
were poured on cell culture dishes and a suspension of cells  (2*10^6 cells per condition in 
2 ml of culture medium containing serum) was added to  the preformed complexes. Cells 
were cultivated under standard conditions for 24-48 hours after transfection, but sometimes 
assays were monitored up to 96 hours post-transfection. 
 Adenoviral infection
Cells are infected with adenoviral constructs for GRK2 (GRK2-wild-type, GRK2-
K220R or shGRK2), with an adenovirus control or with a combination of shGRK2 and 
GRK2-K220R constructs (100MOIS) in OPTIMEM medium supplemented with 2% FBS 
for at least 6 hours. After 6-12 hours of infection, the infected medium was replaced with 
normal growth medium and cells were maintained for 24 or 48 hours.
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e) Cell treatments
MDA-MB-468 cells cultured at 80% confluence in DMEM 10% FBS were treated 
with EGFR inhibitor AG1478 (500nM). 
MCF7 and T47D cells cultured in phenol free DMEM-F12HAMS (GIBCO) at 
80% confluence were oestrogen-starved for 48-72 hours (using Charcoal Serum) and then 
treated with 17b-estradiol (20nM) or Tamoxifen (1 or 5 µM). 
To measure resistance to genotoxic agents, 184B5 or MCF7 cells were treated with 
doxorubicin (0,9nM), Paclitaxel (0.5µM), Etoposide (2µM) or cisplatin (0.5µM)  for 0.5, 1, 
2, 10 or 36 hours.  
To inhibit different aspects of Mdm2 action over p53, MCF7 cells were treated with 
nutlin3a, an inhibitor of Mdm2-p53 interaction (1, 5 or 10 mM) or with the ubiquitinase 
activity inhibitor HLI737 (3µM)
184B5 and/or MDA-MB231 cells were serum-starved (0.1-1% HS or FBS) for 4 
hours or ON and stimulated with Heregulin (20ng/ml), EGF (40 or 100ng/ml), SDF1a 
(50 or 100 ng/ml), CCL21 (60nM) or FBS (20%) . 
184B5 and MDA-MB-231 cells were treated with HDAC6 inhibitors SAHA (3µM) 
or tubacin (10µM). To determine the IC50 of SAHA effects in MDA-MB-231 cells, cells 
were treated with different dosages of SAHA (0, 12.3nM, 30nM, 76.8nM, 192nM, 0.48µM, 
1.2µM, 3 µM and 7,4 µM) and viability was analyzed by using xCellLigence System (Roche)
2.3 Animal models
MyrAKT transgenic mice were generated as described in (Blanco-Aparicio et al., 
2007).  Mammary glands from nine weeks old transgenic mice and wild type littermates 
were provided by Amancio Carnero’s group (IBiS, Universidad de Sevilla, Spain). Paired 
non-tumoural and tumoural mammary glands samples from transgenic FUB/N-tg 
(MMTVneu) mice (Jackson) were provided by Santos Mañes’s lab (CNB, Madrid).  Snap-
frozen mammary tissue was ground to a fine powder in liquid nitrogen using a mortar and 
was re-suspended in buffer A (50 mM TrisHCl pH 7.5, 150 mM NaCl, 0.1% SDS, 1% NP40 
and 5% sodium deoxycholate) supplemented with a protease inhibitor cocktail (Leupeptin, 
Aprotinin, Orthovanadate, NaF and PMSF). Homogenates were centrifuged at 10000g 
for 10 min at 4ºC twice, and fat was removed from the surface. Final supernatants were 
analyzed by western blot.  
6-8 weeks old athymic nude-FOXN1 nu/nu were provided form Harlan and kept 
in conditions of 22 ± 2 º C temperature, 45-55% humidity, rate of light / dark 12/12 hours 
and food and water “ad libitum”.
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2. 4 Preparation of cell lysates
a) Cell lysis
To prepare cellular lysates, collected cells were resuspended in 100-1000 µl of ice-
cold RIPA lysis buffer with protease/phosphatase inhibitors, transferred to a precooled 1.5 
ml reaction tube and incubated in a rocker (250rpm) for 1 hour. Afterwards, the lysates 
were centrifuged for 10-15 minutes at 4°C in a microfuge (14000 rpm). The cleared lysates 
were transferred to fresh pre-cooled 1.5 ml reaction tubes and stored at -80 °C.
b) Immunoprecipitation 
RIPA lysis buffer was utilised for immunoprecipitations with Mdm2 antibody. To 
detect MDM2-P53 co-immunoprecipitation, a low detergent lysis buffer was preferred 
(see p53-Mdm2 interaction buffer in materials section). 5 ml of anti-Mdm2-agarose beads 
monoclonal antibody (0.5 mg/ ml) or anti-p53-agarose beads (0.5 mg/ ml) monoclonal 
antibody were incubated with 1 mg of cell lysates in a rocker (250rpm) over-night at 4ºC. 
The beads were then washed 5-7 times in RIPA or p53-Mdm2 interaction buffer and 
analyzed by immunoblotting. 
c) Subcellular fractionation
Cells were washed with PBS and collected in hypotonic buffer (200 µl/10 cm dish), 
and incubated in ice for 10 min. After addition of 1% of NP40 cells were centrifuged at 
3.000 rpm for 5 min a 4 ºC. The supernatant was frozen and thawed in dry ice three times 
and cleared by centrifugation at 10000 rpm for 10-15 min at 4ºC. This fraction was taken 
as the cytosolic fraction and kept at -80ºC. In turn, the initial pellet was washed twice by 
centrifugation with hypotonic buffer supplemented with 1% NP-40 and lysed in 100 µl of 
buffer C for 20 min on ice.  Finally, buffer C lysates were centrifuged 10 min at 10000 rpm 
at 4ºC. The supernatant was taken as the nuclear fraction. For immnubloting, we usually 
used 10 µg of nuclear fraction and 30 µg of cytosolic fraction.
d) Nuclear extraction kit 
Nuclear extracts from adherent cells were prepared using the Nuclear Extraction 
Kit (Panomics) according to the manufacturer’s instructions. 
e) Determination of  protein concentration
Protein concentration in cellular lysates was determined using the DC Protein Assay 
Reagents A, B and S (Bio-Rad). 3 ml of cellular lysates were mixed with 25 ml of solution 
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obtained by the combination of 10 ml DC Protein Assay Reagents S and 500 ml of Reagent 
A. Afterwards, 200 µl of Reagent B was added and the solution was incubated 10 minutes 
at room temperature. Absorbance at 750 nm was measured on a Biorad iMark microplate 
Reader. Protein concentration was determined with respect to the absorbances of known 
concentrations of BSA protein. In general, 15-20 µg of total protein were used for western 
blotting.
2. 5 Immunoblotting
Cellular lysates/immunoprecipitations were separated by SDS-PAGE on a 6-15% 
Acrylamide/N,N’methylen-bisacrylamide gel. After electrophoresis, the proteins were 
transferred to nitrocellulose membranes (0.45 mm, BioRad) using a wet blotting apparatus 
(Bio-Rad). For metabolic labeling and pulse-chase experiments, proteins were transferred to 
previous methanol-activated-PVDF membranes (Millipore). The efficiency of transference 
was always evaluated by staining with Ponceau staining solution.  Ponceau was washed out 
with TBS-tween and the membranes were blocked for 1 hour in TBS-tween supplemented 
with 5% BSA at room temperature. Membranes were incubated with the primary 
antibodies primary antibodies in TBS-Tween supplemented with 3% BSA overnight at 
4°C (see Materials for antibodies dilution). Afterwards, the blots were washed three times 
for 10 minutes in TBS-Tween followed by incubation with the secondary antibodies 1 hour 
at room temperature (see Materials for antibodies dilution). After extensive washing with 
TBS-Tween, membrane-bound secondary antibodies were detected using ECL (Enhanced 
ChemiLuminiscence) from Amersham Pharmacia Biotech and Agfa films. Alternatively, 
in the case of fluorescent secondary antibodies, the Odyssey Infrared Imaging System was 
utilised. Bands were quantified by laser densitometry with a Biorad GS-700 scanner or by 
the software included in the Odyssey Infrared Imaging System. 
Staining gels with Coomassie Blue
In some cases, proteins were directly visualized with a coomasie staining solution 
(See materials). After SDS-PAGE electrophoresis, gels were stained for 20 min with 
coomasie and then destained with coomasie destaining solution until proteins became 
visible (1-2 h usually). Afterwards, gels were washed with distilled H2O for 20-30 min and 
dried in a gel dryer at 80°C for 45 min.
2.6 Protein/DNA arrays
The activity of transcription factors (TF) was examined by using a protein/DNA 
Arrays from Panomics. The procedure is simple and straightforward and involves three 
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steps: The first one requires a pre-incubation of biotin-labeled DNA binding oligonucleotides 
with a nuclear extract of interest (obtained following instructions of Nuclear Extraction 
Kit from Panomics) to allow the formation of protein/DNA complexes. In the second 
step, proteins/DNA complexes were separated from free probes, and the last step is the 
hybridation with the protein/DNA Array. Finally, the array was detected with a HRP-
based chemiluminiscence detection method. 
2.7 Protein Stability Assays
a) Cycloheximide treatment
Protein decay of doxorubicin-induced p53 was determined using translation shut-
off assays. 184B5 cells with (184B5-A) or without extra GRK2-wt were seeded at 80% 
confluence in a M12 well plate and incubated for 2h with the DNA-damaging agent 
doxorubicin (0.9µM) prior to the addition of 20µg/ml cycloheximide or vehicle, that was 
maintained during the chase periods to inhibit protein synthesis. 
b) Pulse-chase assay
Metabolic labeling and pulse-chase experiments were performed as described 
(Penela et al., 2001). HEK-293 cells transfected with Mdm2 in the presence or absence 
of wild-type GRK2 or GRK2-K220R were pulse-labeled for 15 min. Upon Mdm2 
immunoprecipitation, protein complexes were resolved by SDS-PAGE and transferred to 
PVDF membranes (previously treated with methanol for 5 min) to be developed using 
the Amersham hyperfilm from GE Healthcare Live Sciences. Band density of 35S-labeled 
Mdm2 was quantitated by laser densitometry analysis and data were corrected according 
to total Mdm2 protein detected by immunoblotting. 
2. 8 Determination of the phosphorylation sites of Mdm2 by GRK2
a) Protein kinase assay
Recombinant GRK2 protein (50nM) was incubated with or without the indicated 
purified GST-Mdm2 constructs (100nM) or GST in 50µl of kinase assay buffer. For 
the analysis of the GRK2-mediated phosphorylation of different Flag-Mdm2 mutants, 
recombinant GRK2-wt (100nM) were mixed in kinase assay buffer with immunoprecipitated 
tagged full-length or mutant constructs of Mdm2 expressed in cells.  After 30 minutes at 
30ºC, the reaction was stopped by the addition of SDS-sample buffer. Phosphorylated 
proteins were resolved by 6-10 % SDS-PAGE, stained with Coomassie and visualized by 
autoradiography for 4 to 24 h. 
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b) Proteomic approach for the identification of  phosphorylated peptides
GST-Mdm2 fusion protein was subjected to a protein kinase assay with recombinant 
GRK2 protein in the presence or absence of cold ATP (the procedure is the same as detailed 
in section above except for the absence of radioactive ATP) and then analyzed by mass 
spectrometry to identify possible phosphorylation sites in Mdm2 by GRK2. First, non-
phosphorylated Mdm2 was digested by tripsin and chymotrypsin to obtein the sequence 
coverage and then candidate peptides to be phosphorylated by GRK2 were analyzed by 
LC-MS/MS. The proteomic “Protein identification by LC-MS/MS (Ion Trap)” analysis 
was carried out in the ‘CBMSO PROTEIN CHEMISTRY FACILITY’, a member of 
ProteoRed network.
2.9 Ras activity assay
Cells were serum starved for 4 hours and treated wit EGF (100ng/ml for 2,5, or 20 
min). Cells were lysed in RIPA buffer and 25 µg of cell lysates were subjected to the G-lisa 
assay (Cytoskeleton) to measure Ras activation following manufacturer’s instructions. 
Absorbance was read at 490nm. Data are background subtracted.
2. 10 Cell proliferation Assays
a) MTT 
The measurement of cell viability in MCF7 and MDA-MB-468 cells was performed 
by tetrazolium salt-based colorimetric assays (MTT) that account for the number of active 
mitochondria in a cell population. 5000 cells were added to the wells of a 96-well plate in 
DMEM with 10%FBS. Each 24 hours, 20µl/well of CellTiter 96(R) AQueousOne Solution 
Reagent (Promega) was added. After 1 hour at 37ºC in a humidified, 5% CO2 atmosphere, 
the absorbance at 490nm was recorded using an ELISA plate reader. The background 
absorbance shown at zero cells/well was subtracted from the data.
b) Real-time monitoring of  cell adhesion, proliferation and cell viability using the 
xCELLigence System (Roche Applied Science).
The conceptual basis of this technology is that cells when attached to the plate act as 
mini-condensers and change the electrical impedance that is being continuously recorded 
by means of several electrodes located underneath the plate. (Fig. MM.7A) Cellular 
impedance was converted to a cell index (CI) that allows for the assessment of different 
cellular processes. As cells attach and proliferate over time, impedance rises as does the 
cell index recorded. Changes in their adherence, viability and morphology also change 
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the impedance and can thus be monitored. Thus, cell proliferation, cell surface coverage, 
cellular adhesion strength or cell viability can be measured in a real-time label-free cellular 
setting.  This technique has been previously shown to strongly correlate with classical 
methods for the detection of these cellular processes (Limame et al., 2012). 
For each experiment growth media baseline impedance was measured in each well 
before the addition of the cells to ensure all changes recorded were normalised to those initial 
values determined by the ionic composition of the media. Approximately 5000 cells were 
added per well onto a E-Plate 16 and monitoring started shortly afterwards. Continuous 
impedance measurements were monitored every 15 minutes for varying times (70-150hrs). 
In low-serum proliferation assays, an initial amount of 10000 cells were seeded per well. 
In order to define the specific parameters to be measured in each experiment a 
careful analysis of the global kinetics is necessary. The first 8-16 h after the cells were plated 
correspond to the adhesion phase (see fig. MM.7), that represents the necessary time to 
complete total spreading of the cell. Usually within 4-6h the cells were already attached, 
therefore cell index values were normalized at 4-6 hours to analyze proliferation events. 
Cell growth was calculated as the slope (hours-1) of the cell index curve using the RTCA 
software integrated in xCELLLigence system. 
Figure MM.7: Real-time monitoring of cell behavior using the XCellLigence System. Roche Applied 
Science has developed a system by which electrical impedance is continuously recorded by means of 
several electrodes located underneath the plate that is directly connected to a computer. Once cells start 
attaching to the plate, cell index increases its value. Cell adhesion (B) and morphological changes were 
assessed in the first 16-20 hours. After that, proliferative events were recorded with a detection of slope 
change. (C). To analyze the effects of cytotoxic agents, the toxin was usually added once cells have been 
attached to the plate. Negative slopes show cells detaching from the plate due to cell death. 
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Drugs treatment- real time monitoring and IC50 
Cell proliferation assays using several cancer cell lines were carry out to assess 
the efficacy and potency of different anti-cancer compounds. The xCELLigence system 
was used to quantitatively and dynamically monitor cell cytotoxicity. After addition of a 
cytotoxic agent, cells start to die changing their morphology and detaching from the plate, 
what results in a decrease in cell index value and in a negative growth slope (fig MM7.Bd). 
CELLigence system allows the assessment of important parameters such as rate and onset 
of cytotoxicity as well as calculation of time-dependent IC50s. 
To determine saha and tubacin effects, cell growth was sorted out in two different 
time frames. The first lapse ranges from 0 to 40 hours to analyze proliferative events, and 
the second lapse goes from 40 to 150 hours to determine the effects of treatment when 
non-treated control cells start to die. Cell index values were normalized at 4-6 or at 40 
hours respectively and growth slope was calculated as indicated before. To calculate IC50, 
different dosages of SAHA (from 0 to 7.4 mM) were added to MDA-MB-231 cells seeded 
by duplicate or triplicate and IC50 values were calculated as the area unser the curve using 
the software integrated in XCellLigence system (sigmoidal response-slope variable). In a 
similar way, the effects of  nutlin3a  (1, 5 and 10 mM) were also analyzed by XCellLigence 
in MCF7 cells. 
2. 11 Colony formation in Soft Agar - Anchorage independent growth assay
5000 Cells were re-suspended in DMEM containing 0.3% low-melting agarose and 
10% FBS (upper layer), and seeded onto a coating of 0.7% low-melting agarose in DMEM 
containing 10% FBS (Bottom layer). Once a week an extra upper layer was added to allow 
for  the formation of colonies and growth.  (Fig. MM.8) 
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Figure MM.8: Colony formation in Soft Agar scheme. The soft agar colony formation assay is a 
common method to monitor anchorage-independent growth, which measures proliferation in a semisolid 
culture media after 3-4 weeks. Agar plates were prepared in 35-mm petri dishes by first applying 1.5-ml 
bottom layer of 0.7% agar in growth medium. Over this basal layer, an additional ml layer of 0.3% agar 
in the same medium with the appropriate concentration of cells was added. Cells were incubated at 37ºC 
in a humidified atmosphere of 5% CO2 in air and refed after 7 days by addition of 1ml of 0.3%agar/
growth medium. Colonies were measured, fixed and stained with crystal violet. Agar growth assay could 
be scored at 1 and 3 weeks. 
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After 1 or 3 weeks of growth cells were fixed with methanol and stained with 0.005% 
Crystal Violet. Number and size of colonies were scored. Z-stacks were acquired using a 
a 10X objective of a Zeiss microscope with a Coolsnap FX color camera. The area of 100-
200 colonies per each condition was measured with Image J.  Colonies were distributed 
in three groups according to their size: Large, Medium and Small, which were defined 
by the ratio between the median area of each group and the median area of the whole 
colonies in each of two independent experiments performed in duplicate (Ratio for large 
colonies = 5; Ratio for medium colonies = 2; Ratio for small colonies < 1). The number 
of colonies in each group was expressed as the percentage over the total colonies. Average 
Size (area) of large colonies were also scored and expressed as the fold-increase over the 
control condition. 
2. 12 In vivo Tumour Implantation and immunohistochemical assays. 
MCF7cells (1 x 10^6), MDA-MB-231 cells (5-10 x 10^6) or MDA-MB-468 cells (10 
x 10^6) in 100µl of PBS supplemented with 0.1% glucose and containing Matrigel (3,3mg/
ml) were subcutaneously implanted on the back of 8-10-weeks-old male and female atymic 
nude mice (Atymic nude-Foxn1 nu/nu)(6-8 mice/group). Tumour growth was monitored 
once every three days with callipers. Tumour size was calculated as volume of tumour 
(mm^3) with the formula [length (mm)2 x width(mm)] x 0.5236.  When tumour volume 
exceeded the 10% of the total weight of the animal (between 1500-2,000 mm^3), mice were 
sacrificed for ethical reasons. Tumours were processed for histological analysis to analyze 
the expression of different proteins. MCF7 Tet-on inducible cells were injected in mice 
pre-treated for 24 with doxycicline (Clontech, 2 mg/ml supplemented with 5% sucrose in 
drinking water). Once a week, doxycicline was replaced in the drinking water. Vehicle-
treated MCF7-TET-ON cells were injected in non-treated mice as a control.  
After 8 or 30-35 days post-implantation, tumour mass was excised and fixed with 
3.7% paraformaldehyde (PFA)/PBS. Paraffin-embedded serial sections (3µm thickness) 
were de-waxed with xylene and rehydrated, followed by blocking of non-specific binding 
and endogenous peroxidase activity 30 minutes with 5% normal horse serum and 20 
min with 3% H2O2 solution, respectively. Slides were stained with specific antibodies 
α-rabbitGRK2 (1:1000), α-rabbitKi67 (1:300), α-mouse p-53 (1:400), α-rabbit-cleaved-
caspase3 (1:200) antibodies. Sections were then overlaid with secondary biotinylated goat 
anti-mouse or rabbit IgG, followed by incubation with streptavidin-peroxidase conjugate 
(ABC Elite Kit Vector) to amplify the signal. For chromogenic localization of antibodies, 
3,3’-diaminobenzidine (DAB) was used. After optimal colour development, sections were 
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counterstained with Gill 2hematoxylin (Thermo Scientific). Protein immunostaining was 
quantified in 15-40 fields covering the entire tumour and represented as the area of positive 
cells over the total area of cells. Data were obtained from 15-40 images taken from tumours 
of at least 2 different mice. 
2.13 Immunohistochemistry Analysis of Human Breast Tumours. 
For immunohistocheminal analysis of human breast samples, a tissue microarray of 
5-µm core sections from 49 metastatic infiltrating ductal carcinoma samples (US Biomax) 
was used. The sections were deparaffinised and rehydrated in water, after which antigen 
retrieval was carried out by incubation in EDTA solution, pH 8.2 at 50ºC for 45 minutes. 
Endogenous peroxidase and non-specific antibody reactivity was blocked with peroxidase 
blocking reagent (Dako) at room temperature for 15 minutes. The sections were then 
incubated for 60-90 minutes at 4ºC with the anti-GRK2 PF2polyclonal antibody and 
with phospho-S473-AKT polyclonal antibody. Detection was performed with Envision 
Plus Detection System (Dako). Negative controls were used with goat serum replacing 
the primary antibody. The slides were counterstained with haematoxylin and after drying 
were mounted with DPX mountant for microscopy (VWR Int). 
2.14 Immunofluorescence and confocal microscopy
Cells were rinsed in PBS, fixed in 4% paraformaldehyde (PFA) for 30 min and 
washed again with PBS. When indicated, cells were treated with 4% PFA plus 0.5% triton 
for 1-2minutes (before fixation with PFA alone) or with 0.5% triton in PBS for 10 minutes 
(After PFA fixation). Non-specific sites were blocked by incubation in PBS containing 
1% BSA and 0.5% Triton-X100 for 1 h at RT. Cells were then washed 4 times in PBS 
and incubated 1 h with  anti-cortactin monoclonal antibody (1:200). After four washes 
with PBS, cells were incubated 1 h with Falloidin-FITC and Alexa Fluor 650 secondary 
antibody (1:200, Molecular Probes), washed again with PBS and incubated for 5-10 min 
with DAPI (1:5000). Finaly, samples were mounted in mowiol or prolong dapi (with this 
mounting medium the previous incubation with DAPI is not necessary). Samples were 
examined by confocal microscopy (Zeiss, Germany) or a widefield microscope DM6000 
B/M (Leica Microsystems) equipped with a CCD CoolSnap HQ camera (Roper Scientific). 
The quantitative analysis of fluorescence intensities was performed using a confocal laser 
microscope and the Analysis of Image System (LSM 510, Zeiss, Germany), Image J 
(http://rsb.info.nih.gov/ij/) or Metamorph (Molecular Devices Corp., Sunnyvale, CA)
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2.15 Cell Migration assays
a) Conventional Transwell for detection of  cell migration
A Transwell setup consists of an upper chamber (insert) that is placed onto a lower 
chamber (well). The insert contains a microporous membrane (6.5-mm Transwell filters 
with 8-µm pores (Costar) allowing passage of tumour cells. After a period of serum starvation 
(1% FBS during 18h hours or 0% FBS during 4 hours) a serum-free cell suspension (40000 
cells) is seeded in the insert and exposed to medium containing potential chemoattractants. 
During 5 hours of incubation at 37ºC and 5% CO2, cells migrate toward the bottom side 
of the membrane. The experimental design to assess time-dependent migratory behavior 
of cultured cells is represented in fig. MM.9A. Both migration toward quemoattractant-
containing medium and baseline migration (toward starving medium, no chemoattraction) 
as a negative control were included. Fibronectin (20 µg/ml)-coated filters were used to 
potentiate adhesion of MDA-MB-231 cells. After 5 hours of incubation, cells were fixed 
with ice-cold methanol, stained with DAPI 5µg/ml and counted in five random fields of 
each filter. 
b) Real time Cell migration by using xCellLigence 
Cell migration experiments were performed using modified 16-well plates (CIM-
16 plate, Roche Diagnostics, Spain) with each well consisting of an upper and a lower 
chamber separated by a microporous membrane containing randomly distributed 8 mm-
pores. This setup corresponds to conventional Transwell plates with microelectrodes 
attached to the underside of the membrane for impedance-based detection of migrated 
cells (Fig. MM.9B). Prior to each experiment, cells were deprived of FBS ON. Initially, 
chemoattractants (140mL) or serum-free media (30mL) were added to the lower and upper 
chambers respectively. The CIM- 16 plate was locked in the RTCA DP device at 37ºC and 
5% CO2 and a measurement step was performed as a background signal generated by cell-
free media. To initiate an experiment, cells were detached, resuspended in serum-free (SF) 
medium, counted and seeded in the upper chamber applying 40000 cells in 100 mL. After 
cell addition, continuous impedance measurements were monitored every 15 minutes 
for 24 hours.  Both directed migration towards 10% FBS or chemoattractant compounds 
(Chemotaxis) and random migration supported by SF medium on either side of the 
membrane (Chemokinesis) have been considered.  All raw data obtained were normalized 
to the single maximal value (CI) to eliminate units of measurement. Subsequently, signals 
representing net chemoattraction were obtained by subtracting background (SF) values 
from the positive control (medium containing FBS) signals as described in (Limame et al., 
2012).
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c) Random cell migration in 2D onto a collagen type I layer 
To analyze the motility and invasion of H2B-EGFP MDA-MB-231 tumour cells in 
sparse culture conditions on two- (2D) collagen I matrix, H2B-EGFP expressing MDA-
MB-231 cells were reverse transfected with Lullaby reagent (OZ Bioscience, France) 
plus 25 nM MT1-MMP or GRK2 siRNAs ON-TARGET PLUS SMARTpool PLUS 
(Dharmacon). 24 hours after transfection, 2000 cells/well were seeded in a 96 well-plate 
coated with a thick bottom layer (≥100 mm) of acidic-extracted type I collagen. After 
polymerization, L15 medium containing 15% FCS and 2 mM l-glutamine was added to 
each well. H2B-EGFP time-lapse sequences were recorded at 15-min intervals for 48 h 
over random fields (see fig. MM9.C). For time-lapse microscopy, we used a Nikon TE2000 
microscope equipped with a 10× NA 0.75 objective controlled by the Metamorph software 
(Molecular devices). This microscope was equipped with a cooled CCD camera (HQ2, 
Photometrics). To quantify cell motility, we determined a “displacement index” (DI) by 
Figure MM.9: Schemes of commonly used 2D-migration and invasion assays. An overview of the 
technical setup is schematically drawn for each assay and a close-up view is given right to it (inside the big 
circles). Arrows indicate the direction of cell movement. A) Transwell migration assay. Migration of a cell 
through a pore in the membrane is depicted. B) Real time cell migration (xCellLigence). Migration of a cell 
through a pore in the membrane takes place in the same way as in section A, but this system incorporates gold 
microelectrodes that sense impedance upon contact of cells crossing the pore. C) Random cell migration. 
H2B-GFP Cells were seeded onto a collagen type I bottom layer and monitored each 15 minutes. Cells 
perform radial movement, the area of which can be measured by projecting all the movements of the same 
cell in 72 hours. (D) Gelatin degradation assay. Cells are seeded onto a thin fluorescently labeled gelatin layer. 
At sites of invadopodia mediated matrix degradation a loss of fluorescence occurs, which can be documented 
and quantified by microscopic imaging. 
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dividing the area over which the H2B-EGFP-positive nuclei moved in a 48-72 hours time 
lapse (as result of the time lapse projection of the frames recorded every 15 min) by the area 
occupied by cells in the first frame of the time sequence. 
2.16 Gelatin degradation assay.
MDA-MB-231 cells were transfected with 20nM of required siRNAs using the Cell 
Line Nucleofector System (Lonza). 48-72 h post-transfection, cells were trypsinized, counted 
and 30,000 cells/well were incubated for 5 h on FITC or Alexa Fluor 488-conjugated 
cross linked gelatin (Molecular Probes, Invitrogen) and then fixed and stained for F-actin 
and cortactin as described Rey et al, 2011 and Fig. MM9.D. Briefly, coverslips (18-mm 
diameter) were coated with 0.5 mg/ml poly-l-lysine (Sigma–Aldrich) for 20 min at room 
temperature, washed with PBS and fixed with 0.5% glutaraldehyde (Sigma–Aldrich) for 15 
min. After three washes, coverslips were inverted on an 80ml drop of 0.2% fluorescently-
labeled gelatin in 2% sucrose - PBS, and incubated for 10 min at room temperature. After 
washing with PBS, coverslips were incubated in 5mg/ml sodium borohydride (Sigma–
Aldrich) for 3min, washed three times in PBS and finally incubated in 2ml of complete L15 
medium before adding the cells. To measure gelatin fluorescence intensities, at least 100 
cells from two different coverslips were analyzed in each experiment and positioned using a 
63x immersion oil objective of a widefield microscope DM6000 B/M (Leica Microsystems) 
equipped with a CCD CoolSnap HQ camera (Roper Scientific) and steered by Metamorph 
(Molecular Devices Corp., Sunnyvale, CA). For quantification of degradation, two 
parameters of interest were addressed: The percentage of cells degrading gelatin over the 
total number of cells and the degradation index (DI), referred to the degradation intensity 
and calculated by the total area of degraded matrix in one field (black pixels) divided by the 
total number of phalloidin-labeled cells in the field. The degradation index of Mock-treated 
cells (i.e. transfected with non-targetin siRNA) was set to 100, and degradation indexes of 
all cell populations were normalized to this value and expressed as a percentage. 
2.17 3D Cell Invasion assays
a)  Matrigel-coated Transwell for detection of  cell invasion
A protocol identical to the above transwell migration experiments (section 2.16.a) 
was followed for invasion experiments except for the application of a layer of Matrigel 
on the upper side of the membranes and dynamic process follow-up during 24 hours. 
Aliquoted Matrigel (Basement Membrane Matrix, growth factor reduced, BD Biosciences, 
Erembodegem, Belgium) was thawed overnight on ice and then mixed with ice-cold SF 
medium to obtain a final concentration of 250 mg/mL. Afterwards, 100 ml were seeded 
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onto each upper chamber of the transwell and let them dry ON at room temperature under 
sterile conditions. The next day, the matrix was rehydrated with SF medium and cells 
(100000) was added into the upper chamber and incubated for 24 hours at 37ºC and 5% 
CO2 atmosphere. A scheme of the procedure was detailed in fig. MM.10A. To stop the 
experiments, cells were fixed with cells were fixed with ice-cold methanol and stained with 
DAPI 5µg/ml and counted in five random fields of each filter.
b ) Random 3D-collagen I invasive migration assays
To analyze the motility and invasion of H2B-EGFP MDA-MB-231 tumour cells in 
sparse culture conditions in three-dimensional (3D) collagen I matrix, H2B-EGFP expressing 
MDA-MB-231 cells were reverse transfected with Lullaby reagent (OZ Bioscience, France) 
as in section 2.16.c and 24hours after transfection, 2000 cells/well were seeded in a 96 well-
plate coated with a thick bottom layer (≥ 100mm) of acidic-extracted type I collagen. For 
assessing invasion in 3D collagen-I, after attachment, cells were overlaid with a 2.2 mg/
ml type I collagen. After polymerization, L15 medium containing 15% FCS and 2 mM 
l-glutamine was added to each well. H2B-EGFP time-lapse sequences were recorded at 
Figure MM.10: Schemes of commonly used 3D-invasion assays. An overview of the technical setup is 
schematically drawn for each assay and a close up view is given right to it (inside the circles). Red arrows 
indicate the direction of cell movement. Hatched areas symbolize ECM. A) Transwell invasion assay. B) 
Random 3D-collagen I invasion assay. H2B-GFP cells are tracked on their route through the ECM via 
automated fluorescent microscopy. Their routes through 3D space can be recorded and measured by following 
GFP nuclei. C) Oristm Collagen I invasion assay. Cells are seeded on top of a thin ECM coated surface and 
are overlaid by a second thicker layer of ECM. In the center, a silicone plug creates a cell-free exclusion zone. 
Therefore, invasive cells are embedded in ECM and migrate from an outer ring into the center. D) Spheroid 
3D-collagen I invasion assay. Multicellular spheroids are embedded into ECM gels, which are submerged in 
growth medium. Invasive cells emerge from the cell clusters and lead to astral outgrowing structures.
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15-min intervals for 48-72 h over random fields (fig MM.10B).  For time-lapse microscopy, 
we used a Nikon TE2000 microscope equipped with a 10× NA 0.75 objective controlled by 
the Metamorph software (Molecular devices). This microscope was equipped with a cooled 
CCD camera (HQ2, Photometrics). Cell movement was quantified using the displacement 
index factor (DI) of H2B-EGFP-positive nuclei over the time sequence.
c) Oristm collagen I invasion assay 
H2B-EGFPexpressing MDA-MB-231 cells were reverse transfected with Lullaby 
reagent (OZ Bioscience, France) with 25nM of required siRNAs. 24 h post-transfection, 
cells were trypsinized, counted and 40,000 cells/well were seeded in the presence of 
OrisTM Cell Seeding Stoppers to restrict seeding to the outer annular regions of the wells 
in a 96 well-plate coated with a type I collagen bottom layer (Fig. MM.10C).  Removal of 
the stoppers reveals a 2 mm diameter unseeded region in the centre of each well, i.e. the 
detection zone, into which the seeded cells may then invade for a 48-72 h time period, once 
a collagen I overlay has been applied. Type I collagen was prepared from acid extracts of 
rat tail tendon at a final concentration of 2.2 mg/ml (Elsdale & Bard, 1972). H2B-EGFP 
images were acquired from each well at the beginning (T0) and 48 h post-invasion (T2) 
using a Nikon TE2000 microscope equipped with an 4X objective CFI Plan Fluor NA 0.13 
WD 17.1 controlled by the Metamorph software (Molecular devices). This microscope was 
equipped with a cooled CCD camera (HQ2, Photometrics). Image analysis was performed 
using Metamorph software. The index of invasion was determined by thresholding the area 
occupied by H2B-EGFP nuclei in the detection zone of each well after 48 h of invasion. 
This index is defined by the total area occupied by H2B-GFP nuclei in unseeded area 
(detection zone), at the end of the assay (T2) by subtracting the area occupied by H2B-GFP 
nuclei at the beginning of the experiment (T0). This area of invasion was normalized and 
results were presented as the fold increase of invasion over the control condition. 
d) Spheroids formation and 3D collagen I invasion assay
Multicellular spheroids of MDA-MB-231 cells were prepared with the hanging 
droplet method (Kelm et al., 2003), using 3×103 cells in 20ml droplet in complete L15 or 
DMEM media. For siRNA treatment, cells were transfected by nucleofection with 200nM 
SMARTpool siRNAs specific for GRK2 or MT1-MMP. After nucleofection, cells were 
seeded in a Petri dish and spheroids were made for 72 hours. After 3 days, spheroids 
were embedded in type I collagen (prepared from acid extracts of rat tail tendon at a 
final concentration of 2.2 mg/ml (Elsdale & Bard, 1972)). Spheroids were fixed in 4% 
paraformaldehyde immediately after polymerization of the matrix (T0) or after 2 days of 
invasion (T2) (see fig MM.10D).  After fixation, cells in spheroids were permeabilized for 
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15 min in 0.1% Triton X-100/PBS and labeled with Alexa545-phalloidin and DAPI. For 
quantification of invasion in 3D type I collagen matrix, phalloidin-labeled spheroids were 
imaged with a confocal microscope using a dry 5X CFI Plan objective, collecting a stack 
of images along the z-axis with a 10-15mm interval between optical sections. Spheroid-
mean diameter was measured using ImageJ software macro language. The mean diameter 
was measured from azimuthal averaging of intensity profile along a line centered on the 
spheroid. This averaging consists in measuring intensity profiles along a rotating line by 
5º steps and calculating the mean value over all angles of each pixel of the line. The mean 
diameter was then taken as the width at 1/10 of the maximal value of these averaged 
intensity profiles. Mean area (pr2) was calculated from the mean diameter. To rule out a 
proliferative component, spheroids were also stained with KI67 and imaged using a 10X 
objective to analyze the percentage of KI67 nuclei in the invasive areas.   T2 data were 
normalized with their corresponding T0, and statistical analyses were performed between 
the different normalized-T2conditions.
2. 18 Statistics. 
Data in all figures are expressed as mean ± SEM or SD as indicated. All results were 
confirmed in at least 2 separate experiments. Data were analyzed using Student’s T-test. 
Two-tailed p< 0.05 was considered statistically significant.(*p< 0.05, **p< 0.01, ***p< 
0.001). Statistical correlations obtained from samples of patients were analyzed using 
Pearson Test. (*p< 0.05, **p< 0.01, ***p< 0.001) and statistical analysis from spheroids 
3D collagen I invasion assay was performed using Abnova two factor in GraphPad Prism 
5 software.
2. 19 Study approval. 
The different transgenic mouse models used in this study were housed and bred 
following all established regulatory standards, and all the experiments were performed in 
accordance with guidelines of the European Convention for the Protection of Vertebrate 
Animals used for Experimental and Other Scientific Purposes (Directive 86/609/EEC) 
and with the authorization of the Bioethical Committee of the Universidad Autónoma 
de Madrid. Breast cancer samples from patients recruited at the Hospital Universitario 
La Paz (Madrid, Spain) were used for immunochemistry studies after approval by the 
Ethics Committee for Clinical Research of this institution. At the time of surgical patients 
were informed and provided consent that the excess of the rejected sample could be used 
for research purposes after diagnosis completion. A specific written consent from patients 
to participate in this particular study was not necessary since no additional sample was 
collected.
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1. 
GRK2 protein levels are enhanced in human transformed 
breast cancer cells of luminal epithelial origin.  
Our group had previously described that sustained activation of the insulin-like growth factor-1 receptor (IGF-1R) promoted activation of AKT, which in turn phosphorylated Mdm2 and mediated its nuclear translocation (Salcedo et al., 
2006). These events resulted in the inhibition of Mdm2-mediated GRK2 degradation, 
leading to enhanced GRK2 stability and increased kinase levels in both normal and 
tumoural mammary cell lines. Moreover, a constitutively active mutant of Akt (Akt-myr) 
markedly protected GRK2 from degradation, while pharmacological inhibition of Akt 
downmodulated the expression of GRK2 in different tumour cells (Salcedo et al., 2006). 
Interestingly, a significant proportion of all subtypes of human breast tumours displays 
increased activity of the PI3K/AKT signalling axis by means of mutations in PIK3CA or 
AKT genes or increased activity of the PI3K/AKT pathway by means of non-mutational 
alterations in signal transduction (Cancer and Atlas, 2012). In this context, it was tempting 
to suggest that deregulated AKT activity, by relieving the Mdm2-dependent degradation 
of GRK2, could stabilize/enhance kinase levels in some tumoural situations. Therefore, 
132
Results
we decided to examine the expression of GRK2 in a panel of breast tumour cell lines that 
mirrors many of the genomic abnormalities and molecular signatures found among the 
different subtypes of primary breast tumors (revised in (Vargo-Gogola & Rosen, 2007)). A 
comparative analysis of GRK2 protein levels showed that MDA-MB361, T47D and MCF7 
cells, which derive from luminal breast cancers, expressed 3- to 10 fold higher kinase levels 
than non-transformed MCF10A and 184B5 cell lines (Fig.R1). Moreover, GRK2 protein 
levels were also up-regulated in MDA-MB-468 cells that, although usually classified in the 
“basal A” subgroup, share expression of some luminal epithelial markers and present a 
tumoural behaviour more similar to that observed in the luminal phenotype (Antoon et al., 
2012; MacDougall & Matrisian, 2000; Neve et al., 2006). Conversely, GRK2 protein levels 
displayed by basal B breast cancer-derived MDA-MB231, MDA-MB157 and Hs578T cells 
were no different from those detected in normal mammary cells (Fig. R1). These results 
suggested that GRK2 would be increased in “luminal-like” breast cancers.
We searched for potential correlations among such altered GRK2 levels and other 
features of these transformed breast cells. Mdm2 levels are known to be up-regulated in 
all oestrogen receptor-positive tumours, which represent two-thirds of all breast cancers, 
and in 40-80% of metastatic breast tumours in advanced-stage (Araki et al., 2010; Lacroix 
et al., 2006). Therefore, it is not surprising that all cell types analyzed in our panel display 
increased levels of MDM2 (Fig. R2A). Up-regulation of GRK2 concurs with aberrant 
activation of AKT as compared to non-tumoural cells (Fig. R.2B), consistent with either 
mutational activation of PiK3CA or inactivation of PTEN in these cell types (Table1), 
thereby suggesting a connexion between enhanced levels of GRK2 and the PI3K/AKT 
axis. Interestingly, these mutations are not displayed by any of the basal cells analysed in our 
panel except for MDA-MB468 cells, that shows increased GRK2 expression. Additionally, 
Figure R.1. GRK2 levels are increased in “luminal-like” human breast cancer cell lines. GRK2 
expression levels were determined in non-transformed (NT), “luminal-like” and “basal-like” transformed 
breast cancer cells by western blot with an anti-GRK2 specific antibody. A representative blot is shown 
and data (mean ± SEM; n = 3) of protein levels relative to the amount of GRK2 in the 184B5 cell line are 
graphically represented. (*p< 0.05; **p< 0.01)
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it seems that over-expression of GRK2 is irrespective of the p53 levels (Fig. R2C) or the 
p53 status, since luminal cells of our panel display all the p53 genetic situations present 
in breast cancer (wild-type p53, p53 null and mutated p53 in MCF7, MDA-MB-361, and 
MDA-MB-468 and T47D, respectively, see Table 1.
Table1. Molecular characterization of oncogenic pathways in the breast cancer cell lines used in this 
study. Signalling mutated genes and molecular features of normal and breast cancer cell lines used in 
Fig.R.1. [(+), presence; (-), absence; (null), homozygous deletion].
Figure R.2. GRK2 enhanced levels are independent of the Mdm2 or p53 status but correlate with 
aberrant AKT activation in luminal transformed breast cancer cells. Analysis of Mdm2 protein expression 
(A), the Ser473-phosphorylated AKT and pan-AKT levels (B), and p53 levels (C) in cell lysates of the 
indicated breast cancer cell lines by means of immunoblotting with specific antibodies. Representative 
blots from three independent experiments are shown and Mdm2 values (mean ± SEM) are graphically 
represented, relative to the amount of Mdm2 in the 184B5 cell line. (*p< 0.05; **p< 0.01; ***p< 0.001).
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2. 
Oncogenic signalling governing breast cancer 
tumorigenesis up-regulates GRK2 in cellular and 
animal models.
We sought for additional molecular changes responsible for the up-regulation of GRK2 expression levels.  We noted that GRK2 up-regulated cells displayed amplification of receptor growth factors EGFR and HER2 and/or were 
ER and PR positive (Table1). Notably, all these receptors are able to trigger downstream 
activation of the PI3K/Akt cascade (She et al., 2008; Sun et al., 2001) (Fig. I.3). Therefore, 
we decided to explore whether these pathways modulated GRK2 expression.
2.1 Tyrosine kinase receptors are key modulators of GRK2 expression levels.
 As shown in Figure R.3A, co-transfection of HER2 and the oncogenic Ras-V12 
mutant, known to cooperatively induce the cellular transformation of mammary cells, 
triggered increased GRK2 protein in non-malignant MCF10A and 184B5 cells in parallel 
to AKT activation, whereas pharmacological blocking of the EGFR signalling (using the 
EGFR inhibitor AG1478) markedly reduced the high levels of GRK2 expressed by the 
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EGFR-overexpressing MDA-MB468 cells in parallel to decreased AKT activation (Fig. 
R.3B). Moreover, and consistent with our previous data showing that AKT activation 
blocks Mdm2-dependent GRK2 degradation through the phosphorylation of Mdm2 at 
S166 / 186 (Salcedo et al., 2006), we found enhanced phosphorylation of Mdm2 at these 
residues in non-transformed breast cells transfected with the oncogenes Ras/neu (Fig. 
R.3C), whereas the opposite occurs upon EGFR inhibition in MDA-MB-468 cells (Fig. 
R.3D).
In addition, we found GRK2 expression specifically increased in those mammary 
glands of transgenic MMTV-HER2 mice that spontaneously develop tumours, lasting 
unaltered in the remaining healthy glands of the same mice (Fig. R.4A). Interestingly, 
tumoural mammary glands also display higher activation of AKT compared to normal 
ones, pointing at an in vivo correlation between GRK2 expression and AKT activity. Such 
correlation was confirmed (Fig. R.4B) in mammary glands of transgenic mice expressing 
myr-AKT, a construct that is constitutively bound to plasma membrane and resembles 
the pathological localization of cancer-associated AKT mutations (Blanco-Aparicio et al., 
2007). Notably, Mdm2 protein levels were also up-regulated in the mammary gland of 
these mice (Fig. R.4B). 
FigureR.3. GFR-dependent tumoural transformation alters the cellular content of GRK2. A) Non-
transformed breast cell lines (MCF10A and 184B5) co-transfected with the oncogene v-Ras and Her2 or 
with an empty vector (-)  were immunoblotted with specific antibodies to measure GRK2 protein levels and 
the degree of AKT activation. B) The activation extent of the epidermal growth factor receptor (EGFR) 
correlates with GRK2 expression levels in MDA-MB-468 cells. Cells were treated with the selective 
inhibitor of EGFR  AG1478 (500nM) for the indicated times. GRK2 protein levels and ERK1-2 or AKT 
activation were assessed in total cell extracts by western blot. C-D) Mdm2 phosphorylation at S166/186 
was measured as in section A (C) or B (D). A-D) Data (mean ± SEM of 3 independent experiment) were 
expressed as the fold induction over control condition. (*p< 0.05, **p< 0.01 and ***p< 0.001). 
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2.2 GRK2 as a target of the oestrogen pathway
 Oestrogen withdrawal for 48-72 hours promoted a notable decrease of GRK2 protein 
levels in both MCF7 and T47D oestrogen receptor-positive cells (Fig. R.5A). Conversely, 
chronic exposure of these cells to oestrogen caused an increase of circa 2-fold after 5 days 
of treatment (Fig. R.5B). Interestingly, the time course of GRK2 accumulation was similar 
to that of HDAC6 or Mdm2 (Fig. R.5C and D), known transcriptional responders of 
oestrogen action (Okoro et al., 2013; Saji et al., 2005a). 
 It is well established that ERα-positive breast tumours respond to tamoxifen 
treatment. Hence, we sought to determine whether tamoxifen could reverse the oestrogen-
promoted accumulation of GRK2 to confirm the oestrogen dependence. Surprisingly, we 
found that tamoxifen treatment of T47D or MCF7 cells for several days did not modify 
the levels of GRK2 (Fig. R.6A). However, tamoxifen did not decrease HDAC6 expression 
levels either (Fig. R6B), what led us hypothesize that our transformed breast cancer cells 
could have acquired tamoxifen resistance. In fact, GRK2 and HDAC6 protein levels were 
reduced upon 4 days of low (1uM) or high (5uM) doses of tamoxifen treatment in the 
oestrogen receptor-positive non-transformed 184B5 cells (Fig. R6B).  Collectively, our data 
indicate that oestrogens directly control GRK2 expression in breast cells. 
Figure R.4. Concurrent increases of GRK2 protein levels and AKT activation in 
the mammary glands of transgenic mice lines with enhanced spontaneous breast 
tumourigenesis or predisposition to develop tumours. Total protein extracts were 
obtained from tumour-bearing and normal counterparts mammary glands of Her2-
transgenic females (mice, n=4) (A) or from glands of MyrAKT1-transgenic and non-
transgenic littermate mice as a control (n=2 per group) (B).  Tissular proteins were 
analyzed by western blot to determine GRK2 and Mdm2 expression levels and AKT 
activation using specific antibodies. Fold-stimulation of GRK2 levels normalized by actin 
expression over non-tumoural mammary glands is shown.
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Figure R.5. Expression of GRK2 in luminal breast tumour cells is under control of oestrogens. 
Oestrogen-receptor positive MCF-7 and T47D cells were grown in serum-complete culture medium 
(control condition) or phenol-free medium supplemented with charcoal-treated serum for 48-72 hours 
(oestrogen-depleted condition) (A), or upon oestrogen withdrawal cells were treated with 20nM 
17-b-estradiol for the indicated times (B-D). Cell lysates were analyzed for expression of GRK2 (A and 
B), HDAC6 (C) and Mdm2 (D) by western blot using specific antibodies. A-D) Data (mean ± SEM of 
4 independent experiment) were expressed as the fold induction over control condition. (*p< 0.05; **p< 
0.01; ***p< 0.001).
Figure R.6. GRK2 protein levels decay 
with the anti-oestrogenic tamoxifen in non-
transformed sensitive mammary cells, but not 
in transformed tamoxifen-resistant cell lines. 
184B5, MCF7 and T47D cells were first grown 
in oestrogen-depleted medium for 48-72 h and 
then treated with the oestrogenic antagonist 
tamoxifen (1µM or 5 µM) for the indicated 
times. GRK2 protein levels were assessed by 
Western Blot using actin as loading control and 
HDAC6 as a positive read-out of the tamoxifen-
dependent modulation of protein expression. 
Representative western blots are shown.
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 3. 
GRK2 is key to control the p53/Mdm2 axis through 
the regulation of Mdm2 stability, localization and 
functionality. 
Overall, our results indicate that GRK2 can be upregulated in mammary tumoural models as a result of the activation of known key drivers of breast cancer transformation, including, growth factor receptors, oestrogens or genetic 
alterations in the PI3K/AKT axis. We suggest that the converging stimulation of Akt by all 
these pathways would disrupt the normal Mdm2-dependent GRK2 degradation, leading 
to increased kinase stability and levels. This outcome would occur even in the presence of 
higher Mdm2 levels in such situations, since growth factor signalling via tyrosine kinase 
receptors and Ras leads to the activation of AP-1 and Ets family members, which have 
been shown to transcriptionally up-regulate Mdm2 (Manfredi, 2010), and Mdm2 is a direct 
target for the oestrogen pathway, contributing to tumour growth and survival (Brekman 
et al., 2011; Okoro et al., 2013). In fact, concurrent higher Mdm2 and GRK2 levels are 
observed in the luminal cells of our panel (Fig. R2), in response to oestrogens (Fig. R5) or 
in the mammary glands of myr-AKT transgenic mice (Fig. R.4B). Since we have reported 
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that Mdm2 and GRK2 can directly interact (Nogues et al., 2011), we decided to explore 
whether a different type of   functional interaction could be taking place between these two 
proteins in tumoural contexts. 
The regulatory loop between Mdm2 and p53 has been determined crucial to maintain 
the required levels of p53 and ensure proper cell cycle progression and subsequently the 
maintenance of cell homeostasis. The Mdm2 gene is one of the targets activated by the 
transcription factor p53, whereas Mdm2 protein inhibits p53 activity by controlling p53 
stability, localization and translation, thus giving rise to a negative feedback loop (Vousden 
& Prives, 2009). Moreover, Mdm2 also defines regulatory loops with other substrates such 
as MdmX, in which MdmX interacts and stabilizes Mdm2, increasing its action towards 
p53, whereas Mdm2 mediates MdmX ubiquitination and turnover (Wade et al., 2010). 
We hypothesized that the co-existence of increased levels of Mdm2 and GRK2 in luminal-
like breast cancer cells could reflect a functional cooperation between these factors in 
order to confer resistance to growth arrest and to apoptosis, as suggested by the fact that 
GRK2 attenuates the DNA damage-induced increase of p53 in the context of cell cycle 
(Penela et al., 2010b). Therefore, we explored whether GRK2 and Mdm2 could define a 
new regulatory loop, with a possible impact on p53 responsiveness and perhaps on other 
signaling nodes. 
3.1 GRK2 increases Mdm2 stability in a kinase-independent manner
Post-transcriptional modifications in Mdm2 are key events in the regulation of Mdm2 
functionality (Coutts et al., 2009) and p53 responsiveness. Some of these modifications 
involve the direct binding of different partners with Mdm2, modifying E3 ligase auto-
ubiquitination and stability (Lee & Lozano, 2006).  Based on our previous results of a 
direct Mdm2 and GRK2 interaction, (Nogués et al., 2011), we analyzed the effect of 
increasing GRK2 protein or activity levels on the stability of Mdm2. To investigate the 
role of GRK2 in Mdm2 turnover, pulse-chase assays were performed in HEK-293 cells 
transiently transfected with Mdm2 in the presence of wild type GRK2 or the catalytically 
inactive GRK2-K220R mutant. In control conditions, the half-life of Mdm2 was estimated 
to be of circa 15 minutes in line with other reports (Finlay, 1993). However, in the presence 
of wild-type GRK2, the protein decay of Mdm2 was notably retarded (~4-fold increase in 
half-life). Interestingly, a similar trend was noted when the catalytically inactive mutant 
of GRK2 (GRK2-K220R) was present (Fig. R.7), pointing to a scaffold effect in Mdm2 
stabilization, either by favoring a ligase conformation that reduces auto-ubiquitination or 
altering the recruitment of factors required for Mdm2 degradation.  
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3.2 GRK2 increases the basal association of Mdm2 with p53, resulting in a 
reduction of p53 steady-state levels. 
 We next investigated whether such effects of GRK2 levels and activity on Mdm2 
levels had an impact on Mdm2-mediated regulation of p53. We initially utilized the HEK293 
cell line, which displays wild-type p53. GRK2 wild-type or the catalytically inactive mutant 
GRK2-K220R were co-transfected with Mdm2 and with or without extra p53 and total 
levels of Mdm2 and Mdm2/p53 complexes were measured. Interestingly, both GRK2 
constructs tended to increase the basal steady-state levels of Mdm2 (Fig. R.8A), in line 
with our data above, although the wild-type form of GKR2 was more efficient. Notably 
however, only GRK2 wild-type was able to significantly increase Mdm2-p53 association 
in either endogenous or over-expressed p53 conditions (Fig. R.8B). In line with this, only 
the presence of extra wild-type GRK2 significantly decreased p53 levels or potentiated the 
effect of over-expressed Mdm2 on this parameter in HEK-293 cells (Fig. R.8C).  
Taken together, these data indicate that, even though the inactive mutant of GRK2 
could increase Mmd2 expression levels, only the wild type form GRK2 could promote an 
effect on p53 protein expression.
Figure R.7. GRK2 increases Mdm2 stability in a kinase-independent manner. HEK-293 
cells were co-transfected with wild-type Mdm2 in the presence or absence of GRK2wt activity or the 
catalytically inactive mutant GRK2-K220R. Degradation of the Mdm2 protein was assessed by pulse-
chase experiments as described in Materials and Methods. 35S-labeled proteins immunoprecipitated 
with the anti-Mdm2 antibody were resolved by SDS–PAGE followed by fluorography and densitometry. 
35S-labeled Mdm2 band densities were then normalized to total Mdm2 present in the immunoprecipitates. 
Data are mean ± SEM of at least 4 independent experiments performed in duplicate. A representative blot 
is shown  (*p< 0.05; **p< 0.01; ***p< 0.001).
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3.3 GRK2 prevents p53 stabilization upon genotoxic treatment by increasing 
Mdm2 protein stability. 
Under normal circumstances, p53 is maintained at very low levels by continuous 
ubiquitination and degradation. Genotoxic stress triggers de-phosphorylation of 
several Ser/Thr residues in the acidic domain of Mdm2 in order to protect p53 from 
degradation (Zhang & Prives, 2001). Additionally, DNA damage induces ATM-
dependent phosphorylation of Mdm2 at S395 (Cheng et al., 2011; Maya et al., 2001). The 
consequence of these modifications is to prevent poly-ubiquitination of p53 and to promote 
its rapid stabilization. Therefore, we next sought to establish whether GRK2, through the 
modulation of Mdm2, could alter p53 accumulation upon DNA damage. Stable expression 
of extra levels of GRK2 in non-transformed mammary 184B5 cells prevented p53 protein 
accumulation upon doxorubicin treatment (Fig. R. 9A). Given that ubiquitination and 
protein degradation (mainly by the ubiquitin ligase Mdm2) is a pivotal process in down-
regulating p53 functions (Shi & Gu, 2012), we next analyzed whether GRK2 altered p53 
turnover under cellular stress. The stability of p53 was determined in cells expressing extra 
Figure R.8. GRK2 kinase activity potentiates Mdm2 functionability towards p53. HEK-293 cells 
were transiently transfected with different combinations of p53, Mdm2 and wild type or GRK2-K220R 
constructs. A) Whole cell lisates were analyzed by immunoblotting with anti-GRK2 and anti-Mdm2 specific 
antibodies and normalized to levels from control. Data (mean ± SEM of 3-10 independent experiments) 
and representative blots are shown. B) p53 and Mdm2 interaction was assessed immunoprecipitating 
p53 with anti-p53 (DO1) antibody coupled to agarose beads and analysed by western blot. To compare 
the association of Mdm2 to p53, blots were normalized taking the maximum Mdm2/p53 association 
as a 1.  Data  (mean +/- SEM of 2-6 independent experiments) and representative blots were shown. 
C) GRK2 potentiates p53 turnover in a kinase-dependent manner. Whole cell lisates were analyzed by 
immunoblotting with specific antibodies. The amount of p53 in each condition was normalized to control 
condition. Data ( mean ± SEM of three independent experiments) and representative blotts are shown. (* 
or T p< 0.05; **p< 0.01; *** or TTT p< 0.001).
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GRK2 (185B5-GRK2) or control cells (184B5) upon doxorubicin-promoted DNA damage 
using a cycloheximide chase assay. After doxorubicin challenge, cycloheximide was added 
to inhibit de novo p53 synthesis and the steady-state levels of p53 were detected. As shown 
in Figure R.9B, the levels of p53 protein decline slowly in control cells with a half-life of 
~4h, while in the presence of extra GRK2 the half-life was decreased ~2-fold. Conversely, 
Mdm2 decay was alleviated in GRK2 over-expressing 184B5 cells, consistent with the 
GRK2-mediated stability effect on Mdm2 in 293 and MCF7 (Fig R.9C and R.7-8). To rule 
out the possibility that prolonged doxorubicin treatment (up to six hours) could cause some 
changes in protein expression, 184B5 cells were treated for several hours with doxorubicin 
without adding cycloheximide. As shown in figure R.9D and B, p53 levels were induced at 
1 hour of doxorubicin treatment and maintained high all along the experiment in a similar 
way to GRK2 protein levels.  These also verify recent results from our group showing 
that doxorubicin treatment are able to trigger GRK2 stabilization, which correlated with 
the extent of induction of p53 and apoptosis in the G2 checkpoint response (Penela et 
al., 2010b). Moreover, Mdm2 protein levels were also up-regulated, likely as a combined 
result of the transcriptional action of p53 and the new role herein described for GRK2 (Fig 
R.9D). Overall, these data are consistent with a role for GRK2 in favoring the degradation 
of p53 under stress conditions.
Figure R.9. GRK2 prevents p53 stabilization upon genotoxic treatment by increasing Mdm2 protein 
stability. A) Parental and stable 184B5 cells that over-express GRK2 were exposed to doxorubicin (0.9nM) 
for the indicated times. p53 protein induction was measured by western blot. Data (mean ±SEM) from 3 
independent experiments are shown. B-C) Parental and stable 184B5 cells that over-express GRK2 were 
treated with doxorubicin (0.9nM) for two hours to induce upregulation of p53. Then, cycloheximide (20µg/
ml) was added to cells for the indicated periods. Cells were lysed and total p53 (A) and Mdm2 (B) levels were 
determined by immunoblotting. Protein levels were normalized and depicted as percentage of expression 
at 0 hours of cycloheximide treatment. Data (mean ± SEM.) from 4 independent experiments are shown 
(*p<0.05, **p<0.01). D) 184B5 cells were exposed to a doxorubicin treatment (0.9nM) for several hours. Cell 
lysates were analyzed then by western blott with specific antibodies. A representative western is shown.
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3.4 GRK2 promotes the nuclear shuttling of Mdm2 in a kinase dependent manner. 
 It was assumed that the cytoplasm is the exclusive site of p53 degradation, however 
it is now evident that the nucleus constitutes also a significant proteasomal compartment 
for MDM2-mediated degradation with relevant physiological implications (Shirangi et al., 
2002). Thus, nuclear shuttling of Mdm2 is needed for p53 to be down-regulated quickly 
when DNA damage is repaired in normal cells and cellular homeostasis must be resumed. 
Survival signals contribute to switch the p53 pathway off in this context by triggering the 
nuclear import of MDM2 via AKT activation and ligase phosphorylation. As in tumoural 
contexts Mdm2 displays altered subcellular localizations, we next explored the potential 
effect of GRK2 on Mdm2 nuclear-cytosolic shuttling, as another posttranscriptional-
modified variable relevant for Mdm2 function and the output of p53 responsiveness. 
(Jackson et al., 2006; Ogawara et al., 2002).
Figure R.10. GRK2 promotes nuclear shuttling of Mdm2 in a kinase-dependent manner. A) Lysates 
from MCF7 cells were subcellularly fractionated upon tetracyclin-inducuble expression of wild-type 
GRK2 or mutant GRK2-K220R for the indicated times. The protein levels of GRK2, Mdm2 and p53 
were analyzed in cytoplasmic and nuclear fractions with specifics antibodies. Nucleolin and Actin content 
was used to monitor the accuracy of cellular fractionation and as loading controls. B-C) Cytoplasmic (B) 
or nuclear (C) Mdm2 expression data (mean  ±SEM  from 3 independent experiments) were plotted. (* or 
T p< 0.05; **p< 0.01; ***p< 0.001)
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 In order to establish this, we generated MCF7 breast cancer cells engineered using 
the TET-on system to timely induce the expression of wild-type GRK2 or its catalytically 
inactive mutant GRK2-K220R in the presence of tetracycline. After 24 and 48 hours of 
tetracycline treatment, a sub-cellular fractionation was performed and endogenous Mdm2 
protein levels analyzed in both nuclear and cytoplasmic compartments.  Consistently with 
our previous results in 293 cells, GRK2 or K220R increased Mdm2 expression levels in the 
cytoplasmic fraction of MCF7 cells in a kinase activity-independent manner (Fig. R.10A 
and B). However, we cannot discard a kinase dependent component since Mdm2 levels are 
significant higher at 48 hours in the presence of wild-type GRK2.  Interestingly however, 
GRK2 promotes a marked nuclear re-localization of the ligase in a way enhanced by its 
kinase activity (3-fold increase for wt vs 1.5-fold in the presence of K220R) (Fig. R.10A 
and C).
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4. 
GRK2 confers resistance to diverse genotoxic insults.
Both intrinsic and acquired resistance to cell death is a common and important feature of cancer progression that relies on the attenuation of p53 functions. Growth factors, tyrosine kinase receptors, and certain oncogenes have been shown 
to be effective inhibitors of apoptosis, and in many cases, their anti-apoptotic effects are 
mediated by the PI3K-induced activation of Akt that promotes Mdm2 nuclear shuttling 
and Mdm2-mediated ubiquitination and degradation of p53 protein (Datta et al., 1999; 
Ogawara et al., 2002).  Since we shown herein that GRK2 expression is up-regulated in 
different luminal like breast cancer cells and that the levels of this kinase can alter Mdm2 
levels and Mdm2-mediated p53 turnover upon basal and stress-induced conditions, 
we explored the potential effect of GRK2 levels in the activation of p53 and apoptotic 
response upon cellular damage. Although the cellular dosage of p53 protein is the single 
most important determinant of its function, posttranslational modifications by distinct 
stress-activated kinases are also relevant for transcriptional activation of p53 target genes, 
namely ATM-mediated phosphorylation at the p53 transactivation domain (Ser15).  This 
key residue lays on a docking motif for p300 that is required to promote DNA-dependent 
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acetylation of p53 at promoters and to trigger specific apoptotic functions of p53 (Chao 
et al., 2003, 2006; Sluss et al., 2004). Stable over-expression of moderate levels of GRK2 
protein (184B5-GRK2) strongly attenuates levels of phospho Serine 15 (Fig. R.11A). 
Moreover, extra levels of GRK2 in non-transformed mammary 184B5 cells also conferred 
resistance to p53 activation upon cisplatin and doxorubicin treatment, another genotoxic 
compounds commonly used in chemotherapeutic treatments (Fig. R.11 B and C).  
 Consistent with the GRK2-dependent down-modulation of Ser15 phosphorylation, 
GRK2 levels correlate inversely with robustness of apoptotic responses. Transformed MCF7 
cells were shown to be resistant to apoptosis triggered by the commonly used cytotoxic 
compounds paclitaxel (a microtubule damage agent) or etoposide (a genotoxic drug), as 
indicated by the modest decrease in pro-caspase 3 levels, which decay reflects caspase-3 
activation (Fig. R.12A). Such response was however apparent upon adeno-shRNA-
mediated GRK2 downmodulation (circa 50-70% of procaspase-3 decrease), what suggest 
that silencing GRK2 expression can sensitize these cells to cellular stresses. A similar trend 
in pro-caspase7 protein decay is noted in MCF7 cells transfected with a shRNA-GRK2 
construct compared to kinase overexpression (Fig. R.12B). Moreover, depletion of GRK2 
results in a notable increase of PARP cleavage induced by both etoposide or paclitaxel 
treatment compared to cells with extra GRK2 levels (Fig. R.12C), which otherwise 
accumulate less cleaved PARP than parental cells (Fig. R.12D). 
Overall, these results suggest that GRK2 could limit the p53 responsiveness, 
increasing cell resistance to programmed cell death and contributing to cell survival, both 
relevant hallmarks for tumor progression and important chemotherapeutic-resistant factors.
Figure R.11. Over-expression of GRK2 downmodulates the activation of p53 in response 
to genotoxic damage in non-transformed mammary cells. Parental and stable 184B5 cells that over-
express GRK2 were exposed to  etoposide (2µM) (A) cisplatin (0.5µM) (B) or doxorubicin (0.9nM) (C)
for the indicated times. Phospho-Ser15 p53 levels were determined in cellular lysates by western blot and 
normalized by total p53 levels. Data (mean ± SEM) of p53 activation from three independent experiments 
are shown. (*p<0.05, **p<0.01, ***p<0.001 are p values compared to control cells).
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Figure R.12. GRK2 confers cell-death resistance to diverse cytotoxic agents in luminal tumoural 
breast cells. (A-D) GRK2 levels inversely correlate with pro-apoptotic mediators. MCF7 cells either 
transiently transfected with the indicated constructs (A,D) or co-transfected with a cDNA encoding for 
the CD8 antigen (B-C) for subsequent CD8-based selection were treated with paclitaxel or etoposide 
as detailed in Methods section. Levels of GRK2, pro-caspase-3 (A), pro-caspase-7 (B) or the PARP 
fragment (C-D) were determined by western blot. Data are mean ± SEM (n= 2-4, *p<0.05, **p<0.01) 
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5. 
GRK2 compromises reactivation of p53 responsiveness in 
response to Nutlin3a. 
Strategies to induce p53 activation in tumors that retain wild-type p53 are promising for cancer therapy. In this context, the ubiquitin system has emerged as the central node for the development of cancer therapeutics focused on p53 induction (Yang et 
al., 2009). Since E3 ligases play a major role in determining the specificity of ubiquitination, 
they are regarded as key targets for therapeutic intervention. 
 Different strategies have been employed to specifically inhibit Mdm2-mediated 
p53 ubiquitination. Based on the structure of the p53/Mdm2 complex, a number of small 
molecules, including Nutlins, RITA, MI-63 and SyI-155, have been developed to block the 
binding of p53 to Mdm2 (Yang et al., 2009). Particularly, Nutlin-3a is a small molecule that 
binds Mdm2 at the hydrophobic p53 binding pocket within its N-terminus, resulting not 
only in non-genotoxic stabilization of p53, but also in the stimulation of p53 transcriptional 
activity (see scheme in Fig R.13A). Hence, Nutlin 3a treatment promotes cell cycle arrest 
and apoptosis in wild type p53-harboring tumoural cells in culture and in mouse xenografts 
(Tovar et al., 2006; Vaseva et al., 2009). Moreover, it has been shown that those cell lines 
that overexpress MDM2 are the most sensitive to Nutlin-3a treatment (Tovar et al., 2006). 
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 Since enhanced GRK2 levels protect cells from apoptosis upon genotoxic insults 
and increase Mdm2-p53 interaction, we analyzed the effects of Nutlin3a on p53 activation 
in cells expressing different GRK2 cellular dosages. As shown in Fig R.13B, Nutlin3a 
treatment of control MCF7 cells caused up-regulation of the p53 target genes p21 and the 
pro-apoptotic factor Noxa, along with increased expression of p53 and Mdm2. Interestingly, 
such reactivation of p53 responsiveness was compromised by over- expression of wild type 
GRK2 (and not significantly by the K220R mutant). Of note, Mdm2 was upregulated in 
cells expressing either extra GRK2 or K220R, suggesting that the Mdm2- stabilizing effect 
of GRK2 occurs independently of p53-mediated transcription of Mdm2. In addition, these 
results suggest that Mdm2 could be less “drugable” by Nutlin3a in the presence of high 
GRK2, probably because GRK2 promotes a strong Mdm2/p53 association and reduces 
Nutlin3a binding. Again, the efficacy of GRK2 action on avoiding p53 induction upon 
Nutlin3a treatment is higher when the kinase domain of GRK2 remains active, which 
strongly argues for the existence of both kinase-dependent and independent mechanisms 
of Mdm2 control by GRK2. 
 An alternative approach to prevent Mdm2-mediated p53 ubiquitination is by 
inhibiting the ubiquitin ligase activity of Mdm2. Recently, HLI373 has been identified as a 
water-soluble inhibitor of Mdm2 ubiquitinase activity (Yang et al., 2009). This compound 
Figure R.13. GRK2 attenuates the Nutlin 3a-induced up-regulation of p53 response in a 
process that requires Mdm2 ligase activity. A) Cartoon depicting the mechanism of action of Mdm2 
inhibitors (specially highlighted Nutlin-3a and HLI373).  B-C) MCF7 were infected with adenoviral GRK2 
constructs (wild type and mutant GRK2-K220R) or with a control adenovirus. Cells were treated with 
vehicle, 10µM nutlin3a  (B) or 3µM HLI373 (C) for 24 hours, and lysates were analyzed for expression 
of p21, p53, Mdm2 and Noxa with specific antibodies. GRK2 levels were also examined to confirm 
equivalent transduction of the different constructs used. Data (mean ± SEM) of four (B) or two (C) 
experiments are shown. (*p<0.05)
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also increases p53 levels, induces apoptosis and preferentially kills transformed cells 
retaining wild-type p53. Thus, we assessed whether GRK2 would also alter the response 
to this factor.  As shown in Figure R.13C, 24 hours-treatment of HLI373 in MCF7 cells 
promoted an increase of p53 responsiveness, by means of increased levels of p53 and its 
downstream effector p21. However, this induction was not reverted by the presence of 
extra levels of either GRK2 wild type or GRK2 K220R, suggesting that GRK2 would 
require the ubiquitinase activity of Mdm2 to potentiate p53 downmodulation. 
 Taken together, these data strongly point to GRK2 as a key mediator of apoptosis 
resistance in wild type-p53 breast cancer cells, by inhibiting the induction of p53 response 
upon genotoxic and Nutlin3a treatments. The mechanism underlying these events seems 
to involve the GRK2 dependent modulation of Mdm2, since the E3 activity of the ligase 
is necessary to promote GRK2-mediated p53 turnover in such situations. Moreover, these 
results also put forward that the impact of GRK2 in DNA damage-dependent activation of 
p53 could be routed independently of the ATM-CHK2 module, since Nutlin3a stabilizes 
p53 without requiring its phosphorylation by ATM or related DNA damage activated 
kinases (Efeyan et al., 2007).
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6. 
GRK2 phosphorylates Mdm2 in its acidic domain and 
nearby its nuclear localization sequence. 
The data above indicated that this novel regulatory role of GRK2 in p53 responsiveness might rely on kinase activity-mediated effects on different mechanisms that control Mdm2 stability, localization and/or Mdm2-dependent degradation of p53. Since 
we had previously reported that Mdm2 and GRK2 proteins interact in a direct manner 
(Nogués et al., 2011), we explored the possibility that Mdm2 could be a GRK2 substrate. 
Preliminary experiments in our lab showed that GRK2 phosphorylated Mdm2 in a specific 
way and with high affinity in “in vitro” kinase assays using recombinant GRK2 and purified 
GST-Mdm2 fusion protein. To further identify the specific sites of Mdm2 phosphorylation 
by GRK2, we used GST-fusion proteins spanning different regions of Mdm2 as substrates 
of the kinase assay (see Methods section and Fig. R.14A). As shown in Figure R.14B, full-
length Mdm2 was efficiently phosphorylated, while control GST protein was not. Deletion 
of the N-terminal p53-binding domain (residues 1-100) did not prevent the phosphorylation 
of Mdm2 by GRK2, whereas the RING-finger domain of Mdm2 (aa 430-491) was unable 
to be phosphorylated by GRK2. In contrast, an Mdm2 construct bearing residues 100-200 
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was phosphorylated to some extent. These results could mean that the phospho-acceptor 
sites would reside mainly on the central region of the ligase (residues 200-430), which 
displays important determinants for the interaction with a plethora of Mdm2 partners, 
but did not rule out that the 100-200aa region would harbor specific phosphorylation sites 
targeted by GRK2, and that the poor phosphorylation observed was due to an inefficient 
docking of the kinase to the substrate, supported in the full-length Mm2 by adjacent or 
accessory regions not present in the Mdm2100-200 construct. 
Figure R.14. Identification of GRK2-mediated phosphorylation sites in Mdm2. A) Cartoon depicting 
the different domains of Mdm2 and the GST-Mdm2 constructs used for the kinase assay. B) GST-
Mdm2 constructs,the his-tagged Mdm2 full lenght or GST alone (100nM) were incubated in vitro in the 
presence of recombinant GRK2 (50nM) and [32P]- ATP, followed by SDS-PAGE and analysis for 32P 
incorporation by autoradiography. Recombinant GRK2 was also incubated alone as a positive control 
of autophosphorlylation. The same amounts of the different fusion proteins were analyzed by Western 
Blot to confirm equal protein loading. C) GST-Mdm2 fusion protein (250ng) was subjected to a protein 
kinase assay with recombinant GRK2 protein (100nM) in the presence or absence of ATP and then was 
digested by trypsin and chymotrypsin to obtein the sequence coverage. Candidate peptides were analyzed 
by LC-MS/MS. Positive peptides and phosphorylation peaks are shown. D) A battery of Flag-Mdm2 
constructs displaying single, double, or triple mutations to alanine were generated to target potential 
serine/threonine residues in Mdm2 phosphorylated by GRK2. Upon cell expression of the indicated 
constructs, Mdm2 immunoprecipitates were incubated with recombinant GRK2 in the presence of [32P]- 
ATP as in section B, followed by SDS-PAGE and analysis for 32P incorporation by autoradiography 
(left pannels) or the presence of comparable amounts of GRK2 by Comassie staining. The presence of 
comparable amounts of Mdm2 was dedected by immunoblotting with the anti-flag antibody. Data are 
mean ± SEM of three independent experiments. (***p<0.001).
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To further explore this issue we performed proteomic analysis. Mass spectrometry 
assays, pointed at S115 or S116 and S172 (nearby the nuclear localization and exportation 
sequence), T216 in the acidic domain and S351 as residues phosphorylated in the presence 
of GRK2 (Fig. R.14C).  In order to confirm these results, a mutagenesis strategy was 
designed (Fig. MM1 and Fig. R.14D), generating a battery of single, double or triple 
mutations to alanine in the aminoacids that had been identified in the mass spectrometry 
assay. Additionally, some alanine point mutations were also generated in several 
aminoacids within the acidic domain, such as S256 and S260 or S262, which are normally 
phosphorylated in the cells under non-stressed conditions (Meek & Knippschild, 2003) 
but appear to be de-phosphorylated under DNA damage conditions, to check a possible 
opposite effect caused by GRK2-dependent phosphorylation of the E3 ligase. In vitro 
phosphorylation assays in HEK-293 cells indicated that mutation of residues S115/116 
significantly reduced Mdm2 phosphorylation by GRK2, whereas a tendency to diminished 
phosphorylation was noted upon mutation of S260/262 or T350/351 (Fig. R.14D). These 
data are consistent with our previous results showing that GRK2 activity promoted nuclear 
translocation of Mdm2, Mdm2-p53 association and p53 destabilization. Surprisingly, 
mutations of Mdm2 at S172, S231/T216/T218 or at S254/256 that otherwise prevent 
phosphorylation by other kinases (CK1, CDK2 or GSK3) (Meek & Knippschild, 2003; Shi 
& Gu, 2012; Zhang & Prives, 2001) seem to cause enhanced phosphorylation by GRK2.
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 7. 
GRK2 promotes the acquisition of oncogenic properties
Once the effects of GRK2 expression on the Mdm2/p53 axis had been preliminarily characterized, we next explored whether the enhanced levels of GRK2 detected in luminal breast cancer cells would have additional impact in the process of 
breast tumour proliferation. Notably, the breast cancer cell lines showing enhanced GRK2 
levels also displayed increased expression of key markers of cell proliferation (Cyclin D1), 
mitotic regulation (Pin1) and mitosis entry (phospo-His3) compared to non-transformed 
cells (Fig. R.15). Thus, we investigated whether GRK2 was able to induce expression 
of these proteins involved in cell growth in a non-tumorigenic background. Remarkably, 
transient GRK2 overexpression in either 184B5 or MCF10A non-transformed breast cells 
promoted a significant increase in the protein levels of the proliferation marker Pin1, to an 
extent similar to that triggered by Ras/Neu transformation (Fig R.16A), and also led to 
marked upregulation of the pHis3 proliferation marker (Fig R.16B). Stable overexpression 
of GRK2 in two different 184B5 clones replicated the same effects (Fig. R.16C).  
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Figure R.16. GRK2 over-expression potentiates the activation of the mitogenic Ras-dependent module 
in non-transformed mammary cells. (A-B) Up-regulation of the Pin1 (A) and p-Ser10-Histone 3, (pH3,B) 
mitogenic markers levels in 184B5 and MCF10A cells transfected with the indicated constructs.  (C-D) Stable 
up-regulation of GRK2 at high (184B5-R cells) or moderate (184B5-A cells) levels triggers a sustained increase 
of Pin1 (C) and pH3 (D) markers. In A-D panels data are mean ± SEM of 3-6 independent immunoblot 
experiments (*p< 0.05, **p<0.01 and ***p< 0.001, when compared to empty vector-transfected conditions 
or parental cells).
Figure R.15. GRK2 over-
expression in luminal breast 
cancer cells positively correlates 
with cell-cycle regulators, mitotic 
markers and proliferation rates. 
A) Different non-transformed 
and transformed breast tumour 
cells were analyzed for the 
expression levels of proteins 
involved in growth and survival 
by Western Blot. A representative 
gel showing Cyclin D1, Pin1 and 
phosphoSer10-Histone3 (pHis3) 
levels is included. B) Protein 
quantification was expressed as 
the fold-change over values of non-
transformed cell line 184B5 and 
data (mean ± SEM) are plotted 
(*p< 0.05, **p<0.01 and ***p< 
0.001)
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 7.1 GRK2 up-regulation enhances Ras activity in response to EGF
 The role of Pin1 in breast tumorigenesis has been widely documented (see 
Introduction). It has previously shown that Pin1 is a downstream effector of the Ras 
oncogene (Ryo, 2003; Ryo et al., 2002; Wulf et al., 2001). In addition, stimulation of the 
Ras-MAPK pathway also leads to phosphorylation of histone H3 (Dunn & Davie, 2005). 
Thus, although changes in Ras protein levels were not observed in the non-transformed 
breast cancer cell lines that over-express GRK2 (Fig. R.16), we explored if GRK2 could 
alter Ras activity to trigger up-regulation of Pin1 and p-His3. Thus, we determined the 
effect of modified GRK2 levels or activity on the activation of Ras upon EGF treatment by 
using a Ras GTPase loading assay (see methods). In parental cells, the activation of Ras 
rapidly peaks at 2 minutes of EGF treatment and then decays (Fig. R.17A). Interestingly, 
adenovirus-mediated infection of 184B5 cells with a wild-type GRK2 construct increased 
Ras activation at early times in response to EGF stimulation and prolonged its activated 
time course, whereas a GRK2-K220R construct did not. The same tendency was also 
observed using the other model of non-transfomed breast cell line MCF10A (Fig. R.17B). 
Overall, we can conclude that GRK2 enhances Ras activation by EGF in a kinase-
dependent manner.
 7.2 GRK2 enhances the activation of both mitogenic and pro-survival signaling 
in response to potential oncogenic stimuli. 
 As GRK2 increased the activation of Ras upon EGF treatment, we tested whether 
GRK2 would increase the activation of signaling pathways controlled by key growth 
factors receptors in breast cancer. EGF and Heregulin are known agonists of ErbB family of 
Fig. R17:GRK2 up-regulation enhances Ras activity in response to EGF. Increased GRK2 
strengths Ras activation upon EGF challenge in a catalytic kinase-dependent manner.  184B5 cells (A) 
or MCF10A (B) were infected with adenoviral constructs of wild type GRK2, the kinase-dead mutant 
(GRK2-K220R) or with a control adenovirus. After 48 hours of infection, cells were serum-starved for 
4 hours and stimulated with EGF (100ng/ml) for the indicated times. Ras activity was assessed using 
the G-LISA Ras Activation Assay Biochem Kit (Cytoskeleton). A representative result is shown and 
data (mean +/- SEM of 2-3 independent experiments) were plotted as fold-induction over the maximum 
of the control condition. Statistic analysis are indicated, * or T p< 0.05 ; *** or TTT p< 0.001,when 
compared to control cells (*) or to wild-type GRK2 transduced cells (T).
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receptors, which trigger cell growth and survival through the activation of the ERK1/2 and 
AKT pathways (Citri, 2003; Hynes & Lane, 2005). Interestingly, GRK2 over-expression 
clearly and significantly facilitated the stimulation of both the mitogenic ERK1/2 and 
the pro-survival Akt pathways by either Heregulin (Fig. R.18A) or EGF (Fig. R.18B) 
treatments. 
Figure R.18. GRK2 levels positively regulate AKT and ERK1/2 signalling in response 
to ErbB receptor ligands. Stably GRK2 over-expressing 184B5-A an -R cells and parental 184B5 cells 
were serum-starved (0.1-1% HS) for 2 hours and stimulated with (A) Heregulin (20ng/ml) or (B) EGF 
(100ng/ml) for the indicated times. ERK1/2 and AKT activation were assessed in cell lysates with specific 
antibodies. Data are mean +/- SEM of 2-6 independent experiments.* denotes statistical significance 
between stimulated over-expressing GRK2 and parental 184B5 cells and T between treated and untreated 
parental 184B5 cells  (* or T p< 0.05, ** or TT p< 0.01 and *** or TTT p< 0.001).
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7.3. HDAC6 is involved in the GRK2-mediated activation of the EGF pathway.
During the development of this thesis a novel role of the cytoplasmic type II histone 
deacetylase 6 HDAC6 in sustaining EGFR activation has been published (Deribe et al., 
2009). Enhanced HDAC6 activity towards tubulin contributes to reduce the microtubule 
(MT)-guided intracellular trafficking and to maintain the EGFR at the plasma membrane, 
thus promoting sustained activation of downstream cascades, which results in enhanced cell 
proliferation and survival (Deribe et al., 2009; Gao et al., 2010). Since our group recently 
described a functional interaction between GRK2 and HDAC6 (Lafarga et al., 2012a), 
we sought to analyze if this new interplay could also contribute to the ability of GRK2 to 
enhance the activation of signalling cascades downstream growth factor receptors.  
 Interestingly, we have recently reported that GRK2 dynamically and directly 
associates with and phosphorylates HDAC6 to specifically stimulate its alpha-tubulin 
deacetylase activity at discrete cellular localizations in epithelial cells (Lafarga et al., 
2012a). Remarkably, phosphorylation of GRK2 itself at S670 by ERK1/2 was required 
Figure R.19. The GRK2-dependent enhancement of growth factor signalling in breast cells 
involves GRK2-mediated HDAC6 regulation. A-B) Luminal breast tumour cells display parallel 
increases pSer670-GRK2 and total HDAC6 protein levels.. Data (mean ± SEM) were expressed as the 
fold-change over the non-transformed 184B5 cells (n=2-4), with actin serving as loading control. (C-D) 
GRK2-mediated phosphorylation of HDAC6 underlies the positive effect of GRK2 on EFG-triggered 
MAPK stimulation. Stably GRK2 over-expressing 184B5 cells were co-transfected with tagged HA-ERK1 
and the indicated GFP-HDAC6 constructs. Levels of ERK1 activation (C) and Tubulin acetylation (D) 
were analyzed as indicated in Material and Methods. Data are mean ± SEM(n=3)  *p< 0.05, **p<0.01 
and ***p< 0.001 in all panels.
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for the ability of the kinase to phosphorylate and regulate HDAC6, and GRK2-S670 
phosphorylation was promoted by stimuli such as EGF. Notably, enhanced levels of 
both HDAC6 and S670-phosphorylated GRK2 were detected in all cells in our panel 
that displayed GRK2 up-regulation (Fig. R.19A and B). Moreover, the increased EGF-
mediated signaling to ERK1/2 observed in 184B5 cells stably over-expressing GRK2 was 
not observed upon transfection of an HDAC6 mutant (HDAC6-S1060/1062/1068A) 
unable to be phosphorylated by GRK2 and previously shown to block the GRK2-mediated 
HDAC6 effects on cell motility (Lafarga et al., 2012a) (Fig. R.19C). Consistently, enhanced 
levels of tubulin acetylation upon EGF treatment were also detected in the presence of 
the HDAC6 mutant (Fig. R.19D), in agreement with the expected decrease of HDAC6 
activity in such conditions. These data strongly suggest that a reinforced GRK2/HDAC6 
functional interaction was playing a role in enhancing EGF signalling upon GRK2 up-
regulation in breast cells and strongly point to GRK2 as a novel contributor of the cell 
transformation through the regulation of several substrates such as HDAC6 or Mdm2. 
7.4. GRK2 modifies the activation pattern of several transcription factors 
controlled by p53 upon EGF treatment. 
Growth factor dependent signaling is often accompanied by reprogramming of gene-
expression pathways that cooperate with the mitogenic networks primary harnessed by 
deregulated signals/factors in order to trigger aberrant proliferation. Therefore, we analyzed 
the effect of GRK2 dosage on the activation state of key transcription factors involved in a 
variety of biological processes, including cell proliferation, differentiation, transformation, 
and apoptosis by using a profiling assay from Panomics (see Methods) (Fig. R.20A). Upon 
chronic EGF stimulation, stable GRK2-overexpressing 184B5 cells displayed remarkable 
changes in the activity of transcription factors (33 of a total of 56 factors analyzed were 
less active, 5 more active and the remaining factors unaltered, compared to EGF-treated 
parental cells) (Table2). Interestingly, some over-activated transcription factors in our 
panel such as AP1 or NFY have been found upregulated in gene-expression meta-analysis 
of metastasizing breast tumors (Thomassen et al., 2008), and are directly controlled by 
tyrosine kinase receptors of the ErbB family (Mechta et al., 1997), which is consistent with 
the positive role of GRK2 in the activation of growth receptor signaling pathways. 
Moreover, GRK2 seems to contribute to the over-activation of transcription factors 
with predominant roles in breast cancer such as CBF, which has been found mutated in 
breast cancer and may also have a role in aberrant ER signalling in luminal tumours (Banerji 
et al., 2012);  STAT1, which enhances breast tumor growth and immune suppression 
(Zhang, 2013) or the NF1 family of transcription factors, which has been shown to interact 
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with hormone receptors, histones, and histone deacetylases (Ray et al., 2013).  In addition, 
transcriptional activity of the up-stimulated Ets-1 factor is known to be enhanced by 
ERK1/2 (Wasylyk et al., 1997), suggesting a role for GRK2-mediated MAPK stimulation 
in its over-activation. 
Figure. R.20. Stable over-expression of GRK2 promotes remarkable changes in the activity of 
several transcription factors upon chronic mitogenic stimulation of non-transformed breast 184B5 
cells. A) Parental and stable GRK2 over-expressing 184B5 cells were treated with EGF (100 ng/ml) 
for 18h and nuclear extracts obtained as indicated in Methods section were incubated with a probe mix 
containing biotin-labelled DNA binding-consensus sequences for 48 transcription factors included in the 
TranSignal™ Protein/DNA Array I (Panomics, Redwood City, CA), many of them related to biological 
processes such as cell proliferation, differentiation, transformation, and apoptosis Representative 
hybridized array membranes for each experimental condition are shown in panel B. Each spot on the 
array corresponds to a specific transcription factor. B) Extracts from EGF-stimulated 184B5 cells that 
stably over-express GRK2 or from parental cells were analysed for the expression of GRK2 and p53 
proteins by western blot using laminin B1 as a loading control. A representative gel shows stronger EGF-
mediated upregulation of GRK2 levels and down-modulation of p53 in cells with extra GRK2, consisting 
with the array data of p53 activity. C) Schematic representation of the transcription factors in the array 
modulated by p53 as determined by Pathway Studio analysis using the Ariadne Genomics database. 
p53 itself has positive or negative effects on several TFs, which activity is altered accordingly to a p53 
downmodulation in cells with extra GRK2.
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In contrast, both p53 activity and protein levels were clearly attenuated in GRK2-
overexpressing 184B5 cells (Fig.R20B and Table2), in agreement with our previous findings 
indicating a role for GRK2 in p53 down-modulation. Thus, GRK2 over-expression in 
184B5 cells promoted a nuclear decrease in p53 levels both in un-stimulated and EGF-
stimulated conditions, whereas EGF treatment promoted an increase in GRK2 protein 
levels in parental and GRK2-overexpressing 184B5 cells, which strongly supports our 
previous results in which EGFR-dependent signaling caused up-regulation of GRK2 
protein levels in transformed breast cancer cell lines. As a central tumor-suppressive 
transcription factor, p53 regulates the expression of many genes, including the induction 
of transcriptional regulators as ER or GATA, which loss is a negative prognostic factor 
in breast cancer (Troester et al., 2006; Wei et al., 2006). In this context, it is tempting to 
suggest that the prevailing down-modulation of other transcription factors observed in our 
panel could be directly or indirectly regulated by the GRK2-mediated control of p53 (Fig. 
R.20C).  
7.5. The increase of GRK2 levels in non-transformed breast cancer cell lines 
confers growth and survival advantages under stress conditions.
During tumorigenic progression, cancer cells continuously encounter various 
growth-constraining conditions, such as low oxygen pressure (i.e., hypoxia), lack of cell-
cell contact, insufficient support by the extracellular matrix (possibly leading to anoikis) 
Table R.2. Table summarizing changes in the activity of TFs expressed in stable GRK2 over-
expressing 184B5 cells compared to that of parental cells. Upon chemoluminescence detection, the signal 
intensity of spots were subjected to scanning densitometry and normalized to control positive probes. The 
transcription factors whose activities were increased or decreased more than 1.5 fold compared to parental 
cells were taken as over-activated (+; red colour) or down-activated (-; blue colour), whereas variations of 
less than 1.5 fold were defined as no changes (n.c.).
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or nutritional deprivation. Thus, the cellular adaptive response to environmental stresses 
is recognized as an important mechanism that facilitates tumorigenic progression. Under 
stress conditions, cancer cells may secrete many autocrine and/or paracrine factors that 
eventually induce a favorable environment for tumor growth. These signals usually 
converge on the PI3K-Akt pathway to support cell growth and survival (Bruno et al., 2007; 
Gao et al., 2014).
Based on our results indicating that GRK2 levels enhance signaling through the 
PI3K/Akt and Ras pathways and supports apoptosis resistance upon genotoxic treatment, 
we next investigated whether increased GRK2 levels could endow normal breast cells 
with proliferative advantages in adverse conditions. Serum starvation is a physiologically 
relevant growth-constraining condition that provides an experimental system to analyze 
how normal cells undergo apoptosis in response to nutrients deficiency, and how malignant 
cancer cells successfully adapt and can continue their malignant growth (Mahbub Hasan 
et al., 2012). We found that stable over-expression of GRK2 in 184B5 cells promoted a 
5-fold increase in proliferation rate in low-serum conditions compared to parental cells, 
as monitored in a real time, cellular impedance-based growth assay (see Methods) (Fig. 
R.21A). Consistent with a relevant role for GRK2 kinase activity in the control of cell 
proliferation, adenoviral-mediated overexpression of the catalytically inactive GRK2-
K220R mutant in 184B5 cells was unable to promote cell proliferation in these conditions 
as the wild-type kinase did (Fig. R.21B).
Figure R.21: (A-B) The kinase activity of GRK2 fosters cell proliferation of non-transformed cells 
under restrictive growth conditions. Growth in 0.1% FBS of parental,   stably GRK2 over-expressing (A) 
or transduced with the indicated GRK2 constructs (B) 184B5 cells was monitored with the xCELLigence 
technology as described in Materials and Methods. Growth slope data (mean ± SD) are from 2 (A) or 4 
(B) independent experiments performed in duplicate or triplicate. *p<0.05, **p<0.01, when compared to 
parental or control conditions.
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8. 
GRK2 levels and activity modulate cell growth of 
transformed breast cancer cell lines
 8.1. GRK2 activity modulates proliferation of luminal-like breast cancer cells 
independent of their p53 status.
 Overall, our data indicated that up-regulation of GRK2 levels in untransformed 
breast cells modulated, in a way dependent on its kinase activity, integrated cellular 
responses such as growth or survival. We next investigated whether altering GRK2 levels 
in transformed breast cancer cells that already displayed high kinase levels also regulated 
cell proliferation. In the luminal cancer cell line MCF7, which retains wild type p53, 
further increasing GRK2 dosage by means of an adenovirus construct strongly fostered the 
already high growth rate of these cells in normal serum conditions, whereas the presence of 
a catalytically inactive mutant of GRK2 (K220R) had no comparable effect (Fig. R.22A). 
Furthermore, as shown in figure R.22B, GRK2 also promotes an upward trend in cell 
proliferation in the p53-mutated (p53-R273H) MDA-MB-468 cells whereas silencing its 
expression had a strong negative effect. Such negative effect in cell proliferation was not 
rescued with the catalytically inactive GRK2 mutant, indicating again a kinase-dependent 
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mechanism. These results suggested that GRK2 plays a relevant role in the growth of cells 
harbouring p53 mutations. This finding raised the question of a possible role of GRK2 
in “canonical” basal breast cancer cells (in which 80% present mutations in p53), despite 
that fact that kinase levels were not increased, in contrast to transformed cells of luminal 
lineage. 
8.2. GRK2 controls cell proliferation of the basal-like transformed breast cancer 
MDA-MB-231 cell line through the modulation of HDAC6.
 Recent evidences indicate that the p53-R280K mutation, present in the triple-
negative breast cancer cell line MDA-MB-231, acts as a gain of function p53 mutant and 
has an important role in mediating the cell growth and survival of these cells (Bae et al., 
2013). Therefore, we choose this cell line in order to establish the effect of modulating 
Figure R.22: GRK2 modulates cell growth of luminal transformed breast cancer cell lines. A) Luminal 
MCF7 cells were infected with different adenoviral constructs of GRK2 (either wild type, the kinase-dead 
mutant K220R or with a control adenovirus as indicated). Cells growing in 10% FBS-supplemented culture 
medium were seeded either onto 96-well gold electrode sensor plates to monitor changes in cell index for 4-5 
days. Data (cell growth slope) are the mean ± SEM of 3 independent experiments performed in duplicate. 
p values were * or T p<0.05 and **p<0.01 when compared between conditions or to control infected cells. 
Representative cell index graph  and western blot of transduced GRK2 protein levels are shown . B). MDA-
MB-468 cells were infected with a control adenovirus or different adenoviral constructs of GRK2 (wild-
type, shGRK2, GRK2-K220R or a combination of shGRK2 and GRK2-K220R). 48 hours after infection, 
cells were seeded onto a 96-well plate and cell growth ws measured using a MTT proliferation assay. Data 
(mean +/- SEM of 3 independent experiments) are represented as the percentage of growth over the 24 
hours proliferation state. (*p< 0.05)
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GRK2 levels in cell growth of a “canonical” basal breast cancer cell. As shown in Figure 
R.23A, knockdown of GRK2 levels clearly inhibited MDA-MB-231 cell growth, whereas 
the induction of extra GRK2 by infection with adenovirus promoted a slight increase in 
cell proliferation. Moreover, the effect of GRK2 on cell proliferation of MDA-MB-231 cells 
would require the kinase activity of GRK2, since the over-expression of the catalytically 
inactive form of GRK2 cannot increase cell proliferation as efficiently as the wild-type 
form of GRK2 (Fig.R.23B). These data strongly suggested that GRK2 could also play a 
role in the tumorigenesis of basal breast tumours harbouring p53 mutations. 
To investigate whether the GRK2-dependent phosphorylation of HDAC6 was 
involved, we generated MDA-MB-231 breast cancer cells engineered using the Gateway 
system to stably over-express wild-type HDAC6 or the GRK2-phosphorylation defective 
mutant HDAC6-S1060/1062/1068A. Remarkably, expression of wt-HDAC6 strongly 
increased the proliferation slope of MDA-MB-231 cells, whereas expression of the 
HDAC6S1060/1062/1068A mutant enhanced tubulin acetylation status and did not 
mimic the effect of wt HDAC6 on cell proliferation (Fig. R.24A-B). 
Figure R.23:  GRK2 also modulates cell growth of “canonical” basal transformed breast 
cancer cell lines. A) MDA-MB-231 cells were infected with adenoviral construcs of GRK2 (wild type 
or ShGRK2) or with a control adenovirus and cell growth was assessed using the XCellLigence System. 
At indicated times, fold of the cell index ( ± SEM) from 3 independent experiments are shown. GRK2 
expression levels at the the beginning and at the end of the experiment were measured by western blot 
to ensure the proper functioning of the adenoviral infection. B) MDA-MB-231 cells were infected with 
adenoviral construcs of GRK2 (wild type or GRK2-K220R) or with a control adenovirus and cell growth 
was assessed using the XCellLigence System. Cell growth slope was calculated as in Fig. R.21. Data 
(mean  ± SEM of 3 independent experimental approaches) are represented.
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Figure R.24: GRK2-dependent phosphorylation of HDAC6 is essential for cell growth of MDA-
MB-231 cells. A) Stably transfected MDA-MB-231 cells over-expressing GFP-HDAC6-wild type or the 
phosphodefective HDAC6 mutant GFP-HDAC6 S1060/1062/1068A were seeded onto a 96-well gold 
electrode sensor plate in 10% FBS and cell growth was monitored with the xCELLigence technology. 
Slope data is expressed as mean  ± SD of 2 independent experiments and normalized over the maximum 
cell slope (*p<0.05). A representative experiment is shown. B) Cells were collected at the end of the 
experiment and lysed to analyzed the levels of HDAC6 expression and actetylated tubulin by western 
blot. Acetylation levels of tubulin were normalized by the total levels of Tubulin. A representative western 
blot and Data (mean  ± SD of 2 independent experiments performed by triplicated) are shown.
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9. 
Subcellular distribution of GRK2 is disturbed in p53-
mutated breast cancer cell lines
Since we could not detect any changes in total GRK2 expression in the basal lineage cells analyzed (Fig R.1), we searched for changes in normal kinase subcellular distribution that could support our new finding. Recent publications point that 
GRK2 is localized to centrosomes and plays a central role in mediating EGFR–promoted 
separation of duplicated centrosomes (So et al., 2013). These findings pose new questions 
regarding the potential role of GRK2 in the control of nuclear features. Thus, we investigated 
whether GRK2 changes its sub-cellular distribution in cell lines harbouring mutations in 
p53 such as MDA-MB468 (p53-R273H), T47D (p53-F194L), MDA-MB-231 (p53-R280K) 
and Hs578T (p53-V157F). As shown in Figure R.25A, all p53-mutated breast cancer cell 
lines displayed a notable increase of GRK2 in the nuclear fraction, compared to the wild-
type p53 and non-transformed breast cell lines MCF10A and 184B5. This effect seems to be 
independent of the breast cancer subtype, since MDA-MB-468 and T47D present a more 
luminal phenotype whereas MDA-MB-231 and Hs578T cells belong to the “canonical” 
basal group. Interestingly, a marked up-regulation of GRK2 phosphorylation at S670 was 
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specifically noted in parallel in the nuclear fraction of GRK2 (Fig. R.25B), suggesting that 
this post-transcriptional modification of GRK2 would confer a novel layer of regulation 
by switching the sub-cellular distribution of the kinase. Of note, as mentioned above, 
GRK2 is robustly phosphorylated at S670 in response to EGF (Penela et al., 2008), and 
such modification is instrumental in enhancing localized phosphorylation of HDAC6 in 
situ (Lafarga et al., 2012a). Thus, it is tempting to suggest that phosphorylation of GRK2 
at S670 acts as a signalling switch to potentiate cell proliferation and survival responses. 
However, the precise molecular mechanisms by which GRK2 is phosphorylated during 
breast cancer transformation and the possible nuclear function of GRK2 remain to be 
elucidated.  
Figure R.25: Sub-cellular distribution of GRK2 is disturbed in p53-mutated breast cancer cell 
lines. Non-transformed breast cell lines and different breast tumour cells expressing mutant p53 
were subcellularly fractionated. The protein levels of GRK2 (A) , and GRK2-phospho-Serine 670 
(B) were analyzed in cytoplasmic and nuclear fractions with specifics antibodies. Nucleolin and 
GAPDH content was used to monitor the accuracy of cellular fractionation and as loading controls. 
Data (mean  ± SEM) from 3 independent experiments are represented as the protein expression 
distribution between the nuclear and cytoplasmic fraction expressed as %. (*p< 0.05 and **p< 0.01).
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10. 
GRK2 promotes cellular resistance to chemotherapeutic 
drugs
Resistance to chemotherapy is another important feature of cancer progression. As shown in previous figures, enhanced GRK2 levels conferred resistance to apoptosis triggered by the commonly used genotoxic compounds paclitaxel, 
etoposide or doxorubicin in wild-type p53 harbouring cells. This effect seemed to rely on 
the GRK2-dependent control of the Mdm2/p53 regulatory axis. However, mutations of 
p53 protein occurs in more than 20% of breast human cancers, and mutant p53 display 
protein hyper-stabilization turning to ineffective those therapies based in the disruption of 
p53/Mdm2 interface. In this regard, it has been recently reported that the interaction of the 
chaperone Hsp90 with mutant p53 stabilizes its conformation and blocks its degradation 
by inhibiting Mdm2 activity (Li et al., 2011b, 2011a). In addition, the activity of HDAC6 
has been involved in the stabilization of mutant p53 in MDA-MB-231 cells by means of 
maintaining Hsp90 in an active state (Kovacs et al., 2005; Li et al., 2011b). Therefore, we 
sought to determine whether the interplay of GRK2 with HDAC6 and Mdm2 might have 
consequences in the response of wild type and mutant p53 to different chemotherapeutic 
drugs.
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10.1. GRK2 protects MCF7 breast cancer cells from Nutlin3a-induced death in a 
kinase dependent manner
 To assess the potential relevance of the GRK2/Mdm2 pathway in this context, we 
utilized the wild-type p53 transformed breast cancer cell line MCF7, where over-expression 
of GRK2 decreased the Nutlin3a-induced p53 response in a kinase dependent manner. We 
compared cell growth arrest by different dosages of Nutlin 3a in control, GRK2 and GRK2-
K220R populations (Fig. R.26). Nutlin-3a inhibited cell growth in all three populations in 
a dosage dependent manner. However, the presence of extra GRK2 markedly decreased 
growth arrest at low Nutlin3a doses. This effect seems to be kinase dependent since extra 
GRK2-K220R did not alter the Nutlin3a outcome.
Figure R.26: GRK2 protects from Nutlin3a-induced cell death of MCF7 cells in a kinase-
dependent manner. MCF7 cells transduced with different adenoviral constructs (control, GRK2 and 
GRK2-K220R) were pretreated for 2 hours with indicated concentrations of Nutlin3a and (10000 cells) and 
seeded into 96-well E-plates in the presence of 10% FBS. Cellular impedance was continuously recorded 
and converted to a cell index (CI) for cell proliferation determination. CI values were normalized after 
the adhesion stage. The slope of the resulting growing curves are plotted. Data are mean  ± SEM of 2-4 
independent experiments performed in duplicate. (*p< 0.05, **p< 0.01 and ***p< 0.001). Representative 
growth curves for increased Nutlin3a dosages are shown.
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10.2. GRK2 decreases SAHA and tubacin-induced death in non-transformed 
breast cancer cell lines (184B5 cell line) in a kinase dependent manner
 Emerging evidence indicate that HDAC6 inhibitors can also be used as anti-cancer 
agents. Pan-HDAC inhibitors such as suberoylanilide hydroxamic acid (SAHA), the first 
and currently only FDA-approved, or tubacin, a specific HDAC6 inhibitor that binds only 
to the tubulin deacetylation domain, are able to induce growth inhibition and apoptosis 
in different cancer cell types (Marks & Breslow, 2007; Marks & Jiang, 2005; Namdar et 
al., 2010). Since enhanced GRK2 levels would potentiate HDAC6 activity in the wild 
type p53, non-transformed breast cell line 184B5, we reasoned that the anti-proliferative 
and death-promoting effects of these HDAC6 blockers would be attenuated upon GRK2 
upregulation. Cell growth of 184B5 cells in serum-deprivation conditions usually occurs 
during the first 40-50 hours. Afterwards, cells show growth arrest that finally ends in 
cell death (Fig. R27A) We have monitored both events, defining the first period as “cell 
proliferation”, and the second one (from 40 to 100-150 hours) as  “cell death”, in order 
to determine if altering GRK2 levels modulates cell proliferation and/or or can revert 
cell death by increasing cell survival. Interestingly, incubation of 184B5 cells with SAHA 
or tubacin caused a strong inhibition of proliferation and induction of cell death in low 
serum conditions, and these effects were markedly counteracted upon adenovius-mediated 
overexpression of wild-type (but not the kinase-inactive K220R mutant) GRK2 (Fig. 
R.27B), further suggesting that high levels of this protein confers survival properties to 
breast cells in the presence of a variety of apoptosis inducers by mechanisms involving its 
kinase activity.
Figure. R.27: GRK2 kinase activity attenuates the pro-arresting and pro-death effects of HDAC 
inhibitors in non-transformed cells Pro-arresting and pro-death effects of the pan-HDAC inhibitor SAHA 
or tof he specific HDAC6 inhibitor tubacin were monitored using the xCellLigence System in 0.1% FBS-
growing 184B5 cells transduced with wt GRK2 or mutant GRK2-K220R as described in Methods. Data 
of cell index slopes represent mean ±SEM of n=2-4 experiments (*p<0.05).
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 10.3. GRK2 confers survival properties upon SAHA treatment in a p53-mutated 
context
Recent evidences reveal that SAHA shows preferential cytotoxicity in mutant 
p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-HSP90 
chaperone axis (Li et al., 2011a). We thus explored whether the positive regulation of 
HDAC6 by GRK2 could modulate the pharmacological responses of MDA-MB231 cells 
to HDAC6 inhibitors Therefore, we compared the effect of SAHA on the viability of 
MDA-MB231 cells that over-express wild type GRK2 to that on parental cells. Increased 
GRK2 levels enhanced normal growth of MDA-MB-231 cells (Fig. R.28A), clearly and 
significantly attenuated SAHA-induced cytotoxicity (Fig. R.28B) and markedly increased 
the IC50 of the drug (circa2-fold) (Fig. R.28C). 
Figure R.28: GRK2 lessens SAHA-induced death in breast cancer cells with mutant p53. A-B) Pro-
arresting and pro-death effects of the pan-HDAC inhibitor SAHA were monitored using the xCellLigence 
System in 10% FBS-growing MDA-MB-231 cells transduced with wt GRK2 or a control adenovirus. 
Data of cell index slopes at 3µM of Saha treatment represent mean ±SEM of n=4 (*p<0.05; **p<0.01; 
***p<0.001). C). MDA-MB-231 cells infected with GRK2 or adenovirus control were seeded onto a 
96well plate of XCellLigence. After 24 hours, SAHA compound was added at the indicated increasing 
concentrations. Cell index values were normalized after SAHA addition. Cell growth slopes are  represented 
and IC50 was calculated using the software of the XCellLigence as described in Materials and Methods 
section. Data are mean ± SD of 2 independent experiments performed by duplicate or triplicate.
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11. 
GRK2 favours the anchorage-independent growth of 
breast cancer cells in a kinase activity-dependent 
manner 
Resistance to cell-detachment-induced apoptosis (also termed anoikis) allowing anchorage-independent growth is one of the hallmarks of cell transformation (Eckert et al., 2004) and is related to increased aggressiveness (Guadamillas et 
al., 2011; Hanahan & Weinberg, 2011). In this process, malignant cells are able to survive 
and proliferate without cell adhesion and junctions–dependent signaling (Lee et al., 2008). 
Key molecular mechanisms underlying this tumoural hallmark involve PI3K/AKT and 
Ras-induced override of adhesion requirements for cell cycle progression (Thullberg et al., 
2007), and avoidance of anoikis by means of p53 down-modulation (Grossmann, 2002). 
Because both Ras and p53 functionality are influenced by GRK2 dosage, we investigated 
whether kinase levels and activity would modulate the capacity of cells to grow in soft 
agar in MCF7 breast cancer cells engineered to timely induce the expression of wild-type 
GRK2 or its catalytically inactive mutant GRK2-K220R in the presence of tetracycline 
(Fig. R.29A). Remarkably, induction of the expression of wt GRK2 strongly increased 
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(more than 10-fold after 3-weeks in culture) the ability of MCF7 cells to form colonies 
in soft agar conditions, whereas expression of the GRK2-K220R mutant did not mimic 
such effect (Fig. 29B-C). Moreover, the proportion of larger colonies (Fig. R.29D) and 
the overall size of these large colonies (Fig. R.29E) also increased in wild-type versus 
GRK2-K220R-expressing cells at both 1 week and 3 weeks of culture (Fig. R.29C), what 
might be ascribed to their own differences in proliferation rates (Fig. R.22). These results 
indicated that GRK2 kinase activity is a strong facilitator of the processes triggered to 
subvert adhesion control and to bypass anoikis. 
Figure R.29. GRK2 favours the anchorage-independent growth of luminal breast cancer cells in 
a kinase-dependent manner. (A) Time-course of GRK2 levels in Tet-on wt-GRK2 or mutant GRK2-
K220R MCF7 cells treated with tetracycline (TET). (B) Colony formation by stable Tet-on wt-GRK2 or 
mutant K220R-MCF7 cells in soft-agar medium in the presence or absence of tetracycline analysed as 
described in Methods section. (C-D) Extra levels of wt-GRK2, but not of inactive kinase, increase both 
the size and the proportion of large colonies grown in un-anchorage conditions. The area of colonies was 
measured using Image J and the size of colonies was scored as Large, Medium and Small as described 
in Methods. Bar-graphs showed the distribution (%) of the colonies according to their size (C) and the 
median size (D) of colonies. Data are mean ±SD of 2 independent experiments by duplicate. (* p<0.05, 
** p<0.01, *** p<0.001) .
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We carried out a similar experimental approach in a p53-mutated context, using the 
low GRK2-expressing basal MDA-MB-231 cells. As shown in figure R.30, adenovirus-
mediated infection of MDA-MB-231 cells with wild-type GRK2 potentiated the ability 
of these cells to form colonies in agar, and significantly increased the proportion of larger 
colonies. More important, downregulation of GRK2 expression by adenoviral delivery 
of a silencing construct (Ad-shGRK2) completely abrogated the anchorage-independent 
growth of these cells, suggesting that GRK2 is essential to efficiently escape anoikis and 
a key contributor to cell growth in these experimental conditions. Moreover, we can 
conclude that the role of GRK2 in this process is independent of the control of the wt-
p53 pathway, since GRK2 also potentiates the anchorage-independent growth in cells that 
harbour mutations on p53. 
Figure R.30: GRK2 favours the anchorage-independent growth of mutant p53 breast 
cancer cells in a kinase-dependent manner. Colony formation by MDA-MB-231 cells infected with 
different adenoviral construcs (Control, GRK2 wild-type and shGRK2) in soft-agar medium as described 
in Materials and Methods and Fig.R.29. Bar-graphs showed the distribution (%) of the colonies according 
to their size. Data are mean ±SD of 2 independent experiments performed by duplicate. (* p<0.05, *** 
p<0.001) . Lysates of MDA-MB-231 after 48 hours of infection were analyzed by immunoblotting with 
specific anti-GRK2 antibody to verify the efficiency of the infection.
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12. 
GRK2 is a relevant modulator of tumour growth in vivo
The different effects of GRK2 described in the sections above strongly supported an important role for GRK2 in promoting oncogenic phenotypes. In order to explore the impact of GRK2 levels in driving and/or maintaining tumor development in 
vivo, we investigated whether xenograft tumour growth in mice was influenced by the 
extent of GRK2 expression in human breast cancer cells displaying different molecular 
signatures in terms of GRK2 expression, p53 status and/or PI3K mutations. 
12.1 GRK2 influences in vivo tumour growth promoted by wt-p53 luminal breast 
cancer cells in a kinase-dependent manner by regulating proliferative and apoptotic 
pathways. 
 In a first approach, GRK2 or GRK2-K220R expression was induced by tetracycline 
in engineered MCF7-Tet-On cells prior to subcutaneous implantation in doxycycline-
treated nude mice, and subsequent evolution of tumours was compared. Non-induced 
MCF7 cells injected in non-doxycycline treated mice were used as controls. We observed 
that tumours formed by MCF7 cells over-expressing wild-type GRK2 developed earlier 
and reached significantly higher sizes (Fig. R.31A), whereas no apparent difference was 
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detected between tumours grown from control or GRK2-K220R-expressing cells (Fig 
R.31B). Staining of tumour sections demonstrated an increase in labelling of the proliferation 
marker Ki67 in MCF7-wtGRK2-induced tumours, along with a decrease in p53 and cleaved 
caspase 3 immunostaining compared to control cells, indicative of resistance to apoptosis, 
whereas no significant changes with respect to controls were observed in MCF7-K220R 
mutant-derived tumours (Fig. R31C and D), despite similar expression levels of GRK2 
protein were attained. Moreover, preliminary data showed a positive correlation between 
Mdm2 and GRK2 protein expression in all tumors (Fig. R.31E). Interestingly however, 
Mdm2 expression was higher in MCF7-wtGRK2-induced tumours than in MCF7-K220R 
mutant-derived tumours. Overall, these results are consistent with the idea that GRK2 , in 
a kinase dependent manner, is required for  modulation of cell proliferation and survival 
through the control of p53/Mdm2 axis. 
Figure 31. GRK2 modulates “in vivo” tumour growth in a kinase-dependent manner by regulating 
proliferative and apoptotic pathways. (A-B) Tumours formed by MCF7 cells over-expressing wtGRK2, 
but not the K220R mutant, developed earlier and reached significantly higher sizes. MCF7-TET-ON 
wt-GRK2 or GRK2-K220R-expressing cells pre-treated with tetracycline or vehicle (control) were 
subcutaneously implanted in doxycicline-treated or un-treated (control) nude mice. Tumour volume was 
measured each 2-3 days. Data are the mean ± SEM from tumour masses of 6-8 mice/group (* p<0.05, ** 
p<0.01 compared to untreated MCF7-Tet-on cells). C-D) Tumours were removed 30-35 days post-injection 
and sections analysed with specific antibodies for GRK2, Ki67, p53 and cleaved caspase-3  as described 
in Methods section. (Scale bar: 100 µm,  * p<0.05, p< 0.01,  *** p<0.001). E) Immunohistochemical 
detection of Mdm2 in tumours removed at 30-35 days. MDM2-positive immunoreactivity was found in 
doxycycline-treated mouse, specially in wtGRK2-derived tumours (Scale bar: 100 µm).
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These findings were confirmed using an alternative experimental setting, using 
adenoviral vectors to increase expression of wtGRK2 or GRK2-K220R in MCF7 cells 
prior to subcutaneous injection in mice. Again, enhanced wtGRK2 levels stimulated the 
rate and extent of tumour formation, while control and mutant GRK2 expressing cells 
behaved similarly (Fig. R.32A). More important, downregulation of GRK2 expression by 
adenoviral delivery of a silencing construct (Ad-shGRK2) completely abrogated tumour 
growth, in line with the effect of GRK2 downmodulation on cultured MCF7 cell proliferation 
and apoptosis induction (see Figs. R.10, R.22 and R.25). Opposite to the effect observed 
in tumours over-expressing wt GRK2, sections from the small shGRK2-MCF7- derived 
tumours at early time points indicated that along GRK2 downmodulation a substantial 
reduction in the proliferation marker Ki67 was taking place, as well as a marked increase 
in p53 levels, suggestive of enhanced apoptosis (Fig. R.32B). Interestingly, simultaneous 
expression in the silenced MCF7 cells of the catalytically inactive GRK2-K220R mutant 
did not rescue the blockade of tumour induction, once more indicating that kinase activity 
was required for the tumour-promoting effect of GRK2 in vivo (Fig. R32C). 
Figure. R. 32. GRK2 depletion abrogates “in vivo” tumour progression.  MCF7 cells were infected 
with the indicated adenoviral constructs, and GRK2 levels verified by western blot prior to subcutaneous 
injection in nude mice. Evolution of tumour volume (mm3) from 6-10 mice per condition was determined 
in panel A (*p<0.05, **p<0.01, ***p<0.001). B) Immunohistochemical analysis of the expression of 
GRK2, KI67, p53 and anexinV in tumour sections was performed 8-days post-injection. (Scale bar: 100 
µm). C) The effect of GRK2 downmodulation was not rescued by reintroduction of a kinase-inactive 
mutant . 
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 12.2. GRK2 modulates tumour growth promoted by transformed breast cancer 
cells harbouring p53 mutations.
 We next asked whether the in vivo ability of GRK2 to promote tumour growth 
and, conversely, the inhibitory effect on this process of GRK2 silencing was restricted to 
luminal cells with high levels of GRK2, wild-type p53, ER-positive and mutated PI3KCA 
such as MCF7 cells, or was also taking place in breast cancer cells with other molecular 
signatures. To address if such GRK2 effects were independent of the p53 status, we 
used MDA-MB-468 transformed cells (high GRK2 levels, ER negative, HER2 negative, 
mutated p53, mutated PTEN), in which we had previously observed that GRK2 up- or 
down- regulation alters proliferation in culture in opposite ways (Fig. R.23A). Interestingly, 
whereas tumours induced by MDA-MB-468 cells over-expressing wild-type GRK2 were 
slightly higher in size compared to those formed by control cells, kinase down-modulation 
using the adenoviral silencing construct markedly inhibited tumour formation in vivo (Fig. 
R.33A). Furthermore, GRK2 over-expression in the basal-like MDA-MB-231 cells (low 
GRK2 levels, ER negative, HER2 negative, mutated p53 and without mutations in the 
PI3K/AKT pathway) strongly induced higher tumour growth compared with tumours 
formed by MDA-MB-231 control cells (Fig. R.33B). 
 Taken together, these results showed that GRK2 is a key modulator of tumour 
growth promoted by either luminal or basal breast cancer cells, even when the extent 
of GRK2 expression in the two different lineages is different. Moreover, the ability of 
GRK2 to promote breast cancer development in vivo is independent of the p53 status, at 
least in some contexts, pointing at the existence of different GRK2-dependent regulatory 
mechanisms governing these processes. Overall, these data suggest a more general role for 
GRK2 in tumoural transformation. 
Figure. R. 33. GRK2 influences “in vivo” 
tumoural growth of transformed cells 
bearing mutant p53. MDA-MB-468 (A) or 
MDA-MB-231 (B) cells were infected with 
the indicated adenoviral constructs and 
implanted in 6 mice/group as in previous 
Figures.  Size of tumour masses raised 
from subcutaneously implanted cells were 
measured for 10 weeks after injection. 
Data are mean ± SEM of 6 mice per group 
(*p<0.05). Levels of GRK2 were monitored 
by western blot before injection in mice. 
(*p<0.05, **p<0.01, ***p<0.001). 
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13. 
GRK2: a new player in breast cancer invasive migration?
Cancer progression and outcome are conditioned by the acquisition of two key abilities by tumor cells: the growth and survival capability that trigger resistance to therapy and the invasion into host tissues resulting in local or systemic metastatic 
dissemination. Although both processes are often studied separately, the underlying 
mechanisms appear to be governed by similar signaling nodes. These overlapping 
pathways are usually controlled by growth factor and chemokine receptors, p53 mutations 
and components of the Ras/ MAPKs/ PI3K axis, among others (Alexander & Friedl, 
2012). Mdm2 also promotes cell migration and invasion through the ubiquitination and 
degradation of E-Cadherin (Yang et al., 2006) as well as by positively regulating Slug and 
MMP9  (Chen et al., 2013b; Jung et al., 2013a) and GRK2 has been shown to promote 
epithelial cell migration in both kinase-dependent and independent manners, by interacting 
with and/or phosphorylating relevant key drivers of cell motility such as ezrin, paxilin, 
tubulin, GIT1 or HDAC6 (reviewed in Penela et al., 2014). Based on these evidences, we 
set up to investigate a possible role for GRK2 in the invasive migration of breast cancer 
cells.
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13.1. GRK2 expression is enhanced in metastatic Infiltrating Ductal Carcinoma 
(IDC) samples from patients
 Previous data from our lab in collaboration with the Oncology and Pathological 
Anatomy Departments of the Hospital Universitario La Paz (Dr. David Hardisson) 
showed that GRK2 protein levels, as assessed by western blot analysis, were increased 
in an important proportion (41%) of a limited cohort (27) of infiltrating ductal carcinoma 
patients (Alicia Salcedo, Doctoral Thesis). Interestingly, an inmuno-histochemical analysis 
of paraffin-embedded sections of an independent cohort of 49 metastatic infiltrating ductal 
carcinomas showed that GRK2 up-regulation was present in circa 80% of the primary 
tumours from patients that underwent regional lymph node colonization (Fig. R.34.A), 
(i.e patient’s lymph nodes near the primary tumour tested positive for malignancy). 
Moreover, all of the AKT-positive metastatic samples displayed high levels of GRK2, 
which support the previously proposed AKT-dependent control of GRK2 expression in a 
human pathological context (Fig. R34B). 
Figure R.34: GRK2 expression is enhanced in metastatic infiltrating ductal carcinoma samples 
from patients. A) Increased pAKT in metastatic infiltrating ductal carcinomas correlates with increased 
GRK2 levels. Primary tumour samples of 49 patients were analyzed by immunohistochemistry to detect 
GRK2 and p-AKT with specific antibodies. Samples were scored as positive (moderate or strong staining, 
+) or negative (none or weak staining,-) for GRK2 and p-AKT levels. B). Samples were then stratified 
by pAKT levels and the distribution of GRK2 groups plotted in a pie chart (p = 4,24 E-05; Pearson test). 
Representative sections of GRK2 and pAKT staining of two patients are shown. C) Final metastasis of 
the 49 infiltrating ductal carcinomas was analyzed by immunohistochemistry to detect GRK2 levels with 
specific antibodies. Samples were scored in as positive (strong staining), medium (moderate or weak 
staining) and negative (none staining) for GRK2 levels.
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Localized spread to regional lymph nodes near the primary tumour is indicative 
of worse prognosis, being the initial step of the metastatic cascade (Cox et al., 2008). 
Interestingly, metastatic samples from these primary tumours either retained or acquired 
enhanced GRK2 levels, (Fig. R.34C) strongly arguing for an important role of GRK2 in 
the invasive process. 
13.2. GRK2 over-expression changes the molecular profiling of breast cells 
towards a mesenchymal-like phenotype. 
 We sought to determine whether moderate and stable over-expression of GRK2 in 
non-transformed breast cancer cells (184B5) could confer these cells migratory advantages 
by altering the molecular repertoire related to cell motility and invasion. As shown in 
figure R.35, GRK2 up-regulation increased the levels of GIT1, a relevant scaffolding 
protein involved in cell motility and cellular adhesion previously identified as a kinase-
activity- independent partner of GRK2 in epithelial cell migration (Penela et al., 2008). 
Moreover enhanced GRK2 levels also promoted the down-regulation of E-Cadherin, 
which is key for the progress of the epithelial-mesenchymal transition (EMT) process and 
a recently described Mdm2-regulated protein (Hazan et al., 2004; Sarrió et al., 2009; Yang 
et al., 2006).  Moreover, Vimentin, a mesenchymal marker up-regulated in many epithelial 
cancers (Markiewicz et al., 2012), was also enhanced upon  over-expression of GRK2 (Fig. 
R.35), in line with the notion that altered GRK2 expression levels might alter migratory 
responses and potentiate the invasion process. 
Figure R.35: Moderate and stable overexpression of GRK2 in non-transformed breast cells (184B5) 
regulates proteins implicated in tumour migration and EMT. A) Parental or GRK2-stable over-expressing 
184B5 cells were lysed and steady state levels of GRK2 and several factors that impel tumour migration 
and/or invasion such as  GIT1, E-Cadherin and Vimentin were quantified upon immunodetection with 
specific antibodies. The amount of each one protein in 184B5 cells was taken as 1. Data are mean ± SEM 
of 4 independent experiments. B) A representative gel is shown.
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13.3. GRK2 favors the chemotactic response of breast cells with different invasive 
potential
Chemotaxis integrates complex steps coordinated by transiently activated signaling 
networks: the detection of asymmetric extracellular cues (chemical gradients) by membrane 
receptors and the spatially controlled reorganization of intracellular signaling effectors and 
the cytoskeleton machinery, leading to cell polarization, membrane protrusion and the 
generation of dynamic adhesion and traction forces required to move the cell towards 
the signal source (Frame et al., 2002). As GRK2 is engaged in many of these processes 
that enable normal cell migration of epithelial cells (Penela et al., 2014b), we sought to 
analyze the effects of altering GRK2 expression in migration of breast cells with different 
invasive potential. Thus, stable over-expression of GRK2 to different extents in the non-
transformed breast cancer cell line 184B5 enhanced cell migration in response to EGF or 
Heregulin (Fig. R.36A). On the other hand, adenoviral infection of GRK2 in the highly 
metastatic MDA-MB-231 cells also potentiated their migratory capability upon Heregulin 
stimulation, whereas the knock down of the kinase strongly impeded the chemotactic 
response (Fig. R.36B). We next asked whether the ability of GRK2 to modulate migration 
was restricted to EGF and Heregulin treatments (acting through tyrosine kinase receptors) 
or was also taking place upon other chemotactic stimuli signaling through GPCR receptors. 
As shown in figure R.36C, GRK2 silencing clearly disrupted chemotactic migration of 
MDA-MB-231 cells induced in response to CCL21, a chemokine reported to mediates 
actin polymerization, pseudopodia formation, and invasive responses in this cell type 
(Müller et al., 2001). 
These data strongly suggested that GRK2 is a key player of epithelial cancer cell 
migration. Interestingly however, random (non-directed) cell migration of MDA-MB-231 
cells was inversely affected by the knockdown of GRK2 as assessed by two different 
experimental approaches (Fig. R.37A and B), suggesting that GRK2 levels would 
differentially effect directed and random migration processes (see Discussion) (Penela et 
al., 2014b).
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Figure R.36: GRK2 increases migration of different breast cell lines with different metastatic 
potential. A) 184B5 cells stably over-expressing different amounts of wt GRK2 (showed in the blot) were 
serum-starved and plated on Transwell filters. Cell migration towards Heregulin and EGF was assessed as 
detailed in Materials and Methods. Data are the mean ± SEM of 4–6 independent experiments performed 
in duplicate. (*p<0.05, **p<0.01, ***p<0.001). B) MDA-MB-231 cells were infected with the adenoviral 
constructs of  GRK2, shGRK2 or with a control adenovirus. Cell migration towards Heregulin was 
assessed using the xCellLigence system. Raw data were normalized to a (0–1) scale through division of all 
data by the maximum value obtained. Subsequently, random migration (SF) signals were subtracted from 
the positive (Heregulin) control counterparts per experiment to obtain a pure chemotactic signal. Graphs 
represent normalized data over migration of control cells. All results originate from three independent 
duplicate experiments and are represented as the mean +- SEM. (*p<0.05, **p<0.01, ***p<0.001). C) 
Cellular migration to CCL21 was significantly decreased upon reduction of GRK2 expression in MDA-
MB-231 cells. MDA-MB-231 cells infected with an adenoviral-GRK2 shRNA construct or a control 
adenovirus were serum starved and plated on Transwell filters with a bottom chamber covered with 
serum-free media with or without CCL21. Cell migration was assessed and data (mean ± SD of 2 
independent experiments performed in duplicate) normalized to the non-sitmulus condition. (*p<0.05, 
**p<0.01, ***p<0.001).
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13.4. GRK2 potentiates cell invasion through the basement membrane
 Breaching of the basement membrane, a highly cross-linked meshwork that separates 
epithelial cells from connective tissues, is the first physiological barrier to cancer-cell 
migration, because it does not contain pores large enough for passive invasion (Poincloux 
et al., 2009). Tumour cell invasion across tissue boundaries and metastasis requires the 
breaking of this membrane and extracellular matrix (ECM) remodeling.  These processes 
depend on the capacity of cancer cells to form invasive structures called invadopodia. 
However, the present knowledge of how invadopodia form and function is very limited. 
In order to start delineating the possible contribution of GRK2 to the cell invasion 
process, we utilized a transwell assay with the upper chamber covered with matrigel, whose 
composition mimics the basement membrane (mainly constituted by Type-IV collagen, 
laminin, entactin and heparan-sulphate proteoglycans). Either parental or 184B5 cells 
stably-over-expressing GRK2 were seeded on top of the matrigel upper chamber and their 
invasive ability was measured in response to the chemo-attractants EGF or Heregulin. 
As shown in Figure R.38A, GRK2 strongly potentiated the basally low directed invasive 
response to both stimuli. Conversely, knockdown of GRK2 in the highly invasive MDA-
MB-231 cell line profoundly decreased matrigel cell invasion (Figure 38.B and C) using 
fetal serum bovine as the chemo-attractant. Interestingly, the inhibitory effect of GRK2 
silencing is even stronger than the invasion blockade promoted by the down-modulation 
of MT1-MMP, a membrane-anchored metalloproteinase that is crucial for the breakdown 
of both BM and ECM (Poincloux et al., 2009). These data suggested a dual role of GRK2 
in the invasive migration of breast cancer cells, promoting both cell migration and the 
disruption of the basement membrane. 
Figure R.37: Random cell migration is negatively controlled by GRK2. A) MDA-MB-231 cells were 
infected with different adenoviral constructs (GRK2 wt, shGRK2 or a control) and random cell migration 
was measured by transwells assays (A) or using the X-CellLigence system  as described in Methods 
section. (B). Migrated cells were counted and normalized to the control condition. Data are mean ± SD 
of two independent experiments performed in duplicates. (*p<0.05, **p<0.01, ***p<0.001).
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Figure  R.38: GRK2 is necessary for the invasion through matrigel in both normal and transformed 
breast cells. A) Parental or GRK2-over-expressing 184B5 cells were seeded on Transwell filters precoated 
with 250 µg/mL matrigel and cell invasion was assessed in response to EGF and heregulin as detailed 
in Materials and Methods. Data are the mean ± SEM of 4–6 independent experiments performed in 
duplicate. (*p<0.05, **p<0.01). B) MDA-MB-231 cells were transfected with different siRNAs (non-
targeting, MT1-MMP or GRK2) using the Cell Line Nucleofector System (as described in Materials and 
Methods). After 24 hours, cells were serum-starved for 4 hours and seeded on Transwell filters precoated 
with 250 µg/mL matrigel and cell migration was assessed in response to 20% FBS. Data are the mean ± 
SD of 2 independent experiments performed in duplicate. (*p<0.05). Transfection efficiency was analyzed 
by western blot using specific antibodies towards MT1-MMP, GRK2 and Actin as the loading control. C) 
A representative experiment from B is shown. 
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13.5. GRK2 is also relevant for extracellular matrix remodeling and oriented cell 
invasion in 3D models.  
 After basement membrane crossing, cancer cells infiltrate local tissues by trafficking 
through a stromal extracellular matrix (ECM).  Therefore, we next assessed the contribution 
of GRK2 to such ECM invasion, using a highly metastatic cell line and conditions that 
mimic the 3D tumor environment. Thus, a OrisTM Collagen I Cell Invasion Assay was 
performed (see Materials and Methods section), using MDA-MB-231 cells that stably 
express the nuclear reporter protein Histone-2B(H2B)-EGFP (provided by Dr.P. Chavrier’s 
lab) and reconstituted acid-extracted type I collagen to mimic the architecture of native 
type I collagen fibrillar networks (ECM).  MDA-MB-231-H2B cells were then treated with 
siRNAs specific for GRK2, MT1-MMP or with non-targeting siRNA and their capacity to 
invade the collagen I-filled, cell-free central portion of the well over a 2-day culture period 
was measured (Fig. R.39A). As previously shown (Rey et al., 2011), knockdown of MT1-
MMP led to 40% reduction of the invasive capacity of MDA-MB-231 cells (Fig. R39A 
and B). Remarkably, silencing of GRK2 by 2 different siRNAs also resulted in a strong 
inhibition of ECM invasion of these cells. To rule out the possibility that the invasion 
defects observed in the GRK2-silenced transformed breast cancer cells were due to the 
GRK2-dependent contribution to cell proliferation, we analyzed the proliferation rate by 
measuring the total area of the well occupied upon 2 days of experiment. We could not 
detect any differences in cell growth of the different siRNA-treated cells in this type of 
experimental approach (Fig. R.39C), suggesting that the observed effect of GRK2 in the 
3D collagen type I invasion was independent of its role on breast cancer cell growth. To 
confirm this result, an independent experiment using a similar strategy was performed 
based on formation of multicellular spheroids by MDA-MB-231 cells (see Methods). We 
reconstituted a 3D in vivo-like environment for invasive breast cancer cells by embedding 
these multicellular spheroids of MDA-MB-231 cells within 3D gels of native acid-extracted 
type I collagen. As shown in figure R.40A, MDA-MB-231 cells invaded and disseminated 
in the surrounding matrix with a radial pattern over a 2-day culture period. Interestingly, 
GRK2 down-modulation significantly disrupted this ability, as potently as knockdown of 
the MT1-MMP matrix metalloproteinase (Fig. R.40A and B), which is a well-established 
essential factor for ECM remodeling and breast cancer invasion, in absence of significant 
effects on cell proliferation in such experimental conditions (Fig. R.40C).
 Taken together, our findings suggested that over-expression of GRK2 is able to 
promote invasive migration of breast cells whereas its presence appears to be critical to 
maintain the invasiveness of highly metastatic breast cancer cells through both the basal 
membrane and three-dimensional extracellular matrix. 
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Figure R.39: GRK2 is required for oriented Collagen type I invasion in 3D. A) H2B-EGFP/MDA-
MB-231 cells treated with the indicated siRNAs were tested using the Oris™ 3D-Collagen I invasion 
assay for 60 h. (see Methods section). Immunoblotting analysis of MT1-MMP and GRK2 levels in MDA-
MB-231 cells treated with the indicated siRNAs at the time of cell seeding (T0) and 48 h after seeding 
(T2) is shown. B) Invasion assay index was calculated by thresholding the area occupied by H2B-EGFP 
nuclei in the detection zone of each well after 48 h of invasion. This index is defined by the total area 
occupied by H2B-GFP nuclei in unseeded area (detection zone) at the end of the assay (T2) by subtracting 
the area occupied by H2B-GFP nuclei at the beginning of the experiment (T0). This area of invasion was 
normalized and results were presented as the fold increase of invasion over the control condition. Values 
represent mean invasion index ± SEM from 2 independent experiments. (*P<0.05 ;**P < 0.01). C) Cell 
proliferation is not modified by GRK2 in this experimental aproach. Cell proliferation was measured by 
calculating the total number of nuclei in the complete well (unseeded + seeded area) at the end of the assay 
(T2) normalizing by the nuclei number at the beginning of the experiment (T0). Data are mean ± SEM 
from two independent experiments.
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Figure R.40 GRK2 is required for 3D Collagen type I invasion upon spheroids formation. A) 
Multicellular spheroids of MDA-MB-231 cells (3 × 103 cells) were prepared in hanging droplets after 
nucleofection with MT1-MMP or GRK2 siRNAs and embedded in 3D type I collagen gels (2.2 mg/
ml, prepared from acid extracts of rat tail tendon). After 2 days, samples were fixed and stained with 
fluorescent phalloidin to label F-actin. Invasion was monitored by confocal microscopy at 0-day (T0) and 
after 2-days of culture (T2). A Western blot of the cell lysates at T0 and T2 was performed to analyze the 
levels of MT1-MMP and GRK2. B) Invasion area in 3D type I collagen gels was calculated by estimating 
the diameter of spheroids at T0 and T2. Spheroid diameters were averaged and used to calculate the mean 
invasion area (πr2). For each cell population, mean invasion area at T2 was normalized to mean invasion 
area at T0, and plotted with error bars representing ±SEM (N = 2 independent experiments for siRNA 
knockdown, analyzing a total of 15–35 spheroids for each cell population. (*P < 0.05; ***P < 0.001). 
C) The number of proliferative cells was calculated after immunoflorescence staining of the proliferative 
marker KI67. KI67 positive cells (%) in the invasive area was calculated as described in Methods section.
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13.6. GRK2 knockdown impairs the activity of ECM-degrading invadopodia.
 Migration and invasion are related processes that however relay on separated 
molecular programs responsible for their different outcome. Migration is defined as the 
movement of cells from one location to another on a particular substrate such as basal 
membranes, ECM fibers or plastic plates that proceeds without physical barriers. Therefore, 
migration is occurring on 2D surfaces or within 3D structures without any obstructive 
fiber network. Invasion is defined as cell movement through a 3D matrix or across basal 
membranes, which are accompanied by a restructuring of the environment. Thus, invasion 
processes requires adhesion, either proteolysis or squeezing strategies and migration 
through the ECM.  We thus explored whether the GRK2-dependent invasive effect could 
involve the modulation of the specific capability of breast cancer cells to degrade the matrix 
through the formation of invadopodia.
To discriminate the contribution of GRK2 to cell motility from that related to 
invasive migration of MDA-MB-231 cells, we set up a time-lapse video-microscopy assay 
using the stable MDA-MB-231-H2B-EGFP cell line seeded onto either a 2D collagen 
substrate or a 3D collagen-I matrix. Quantification of random cell motility was analyzed 
by calculating the displacement index of H2B-EGFP-labeled nuclei recorded over 48-60 
h.  As should be expected, silencing of the metalloproteinase MT1-MMP disrupted only 
the random invasive motility in 3D conditions (Fig. R.41A and B), but did not alter the 
2-D motility of these cells. Interestingly, down-modulation of GRK2 resulted in a similar 
pattern of effects (Fig. R.41A and B). 
 Overall, these data suggest that impaired invasion of GRK2-depleted MDA-MB-231 
cells in 3D collagen matrix is likely the consequence of a defect in the ECM-degradation 
ability of the cells, which finally result in the disruption of breast cancer cells movement. 
The fact that silencing of GRK2 was not altering random cell motility onto a collagen type 
I surface is consistent with previous results of our laboratory indicating that migration of 
different epithelial cells towards collagen fraction IV was unaltered by alterations in GRK2 
levels, which suggests that the pro-migratory effect of GRK2 is context specific and does 
not affect the overall cell motility (Penela et al., 2008). 
 When tumor cells are grown on a 2D matrix substratum in order to reconstitute 
tumor cell-Basal Membrane interactions in vitro, matrix proteolysis is restricted to ventral 
cell surface structures called invadopodia, which correspond to actin and cortactin-rich 
finger-like membrane protrusions enriched in MT1-MMP (Artym et al., 2006a; Poincloux 
et al., 2009). 
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To explore whether GRK2 might alter invadopodia activity, (Rey et al., 2011)we 
performed a localized degradation assay by culturing MDA-MB-231 cells on FITC-gelatin. 
As previously shown (Castro-Castro et al., 2012; Rey et al., 2011), knockdown of MT1-
MMP markedly reduced the proportion of “degradative” cells (from 25-30% to 5%) (Fig. 
R.42A-C) and invadopodia-dependent gelatin degradation to 10-20% of the capacity of cells 
treated with a non-targeting siRNA (Fig. R.42D). Remarkably, knockdown of GRK2 with 
Figure R.41: The absence of GRK2 does not affect migration in 2D Collagen type I matrix but 
disrupts invasive motility  of the cells in 3D conditions. A) H2B-GFP-expressing MDA-MB-231 cells 
treated with the indicated siRNAs (2000 cells/well), were seeded in 2D- type I collagen-coated wells and 
time-series of GFP signal were recorded at 15-min intervals for 48 h over 2 random fields. Representative 
images corresponding to the first frame and maximum projection of the time-series are shown for each cell 
population. Displacement Index (DI) of H2B-EGFP nuclei  are represented as the mean DI ± SEM from 
two independent experiments (in duplicate) with DI of mock-treated cells set to 1 (*P<0.05 **P < 0.01) 
B) H2B-EGFP-expressing MDA-MB-231 cells treated with indicated siRNAs (2000 cells/well), were 
embedded in a 3D-matrix of acid-extracted type I collagen, and time-series of GFP signal were recorded 
at 15-min intervals for 48 h over 2 random fields. Representative images corresponding to the first frame 
and maximum projection of the time-series are shown for each cell population and DI of H2B-GFP nuclei 
are represented the mean DI ± SEM from two independent experiments (in duplicate). 
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different siRNAs (Fig. R42.A), although it did not affect the morphology or spreading of 
MDA-MB-231cells on gelatin (Fig. R.42B), led to a significant inhibition (50-70%) of both 
invadopodial matrix degradation and the number of cells displaying degradation abilities. 
(Fig. R.42C-D). Overall, we can conclude that GRK2 is required for two-dimensional 
matrix proteolysis in the highly invasive human breast carcinoma cell line MDA-MB-231. 
Figure R.42: Depletion of GRK2 strongly decreases the capacity of MDA-MB-231 cells to degrade 
gelatin. MDA-MB-231 cell were transfected with different siRNA (non-targeting, MT1-MMP and 
different oligos for GRK2) by using the Cell Line Nucleofector®. Lysates were analysed by western 
blot to check the depletion of GRK2. A) MDA MB231 cells transfected with the indicated siRNAs were 
incubated on FITC-gelatin for 4 h, fixed and stained for F-actin and cortactin. Graphs depicting the 
percentage of degradative cells (B) and the degradation index (C) of MDA-MB-231 cells treated with 
indicated siRNA. Values represent means ± SEM from three independent experiments. *P<0.05; **P < 
0.01; **P<0.001 (compared to siRNA-non targeting transfected cells)
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197
Discussion
Numerous stress signals have been shown to cause p53 accumulation, mainly by means of the inhibition of Mdm2-dependent degradation of the protein. We report herein that GRK2, known to be a relevant modulator of diverse cellular 
functions by mechanisms involving either phosphorylation of different substrates or its 
ability to act as scaffold protein (Evron et al., 2012; Penela et al., 2010a; Ribas et al., 
2007), can weaken the efficacy of cellular stress responses by reinforcing the activity of 
Mdm2 and safeguarding it from inhibitory mechanisms. We find that increased GRK2 
levels in breast cancer cells have a relevant impact on cell proliferation, survival and 
anchorage-independent growth and on tumour growth promotion in vivo. Interestingly, 
such outcomes are clearly dependent on its kinase activity, since expression of GRK2-
K220R, a point mutant that lacks catalytic activity, is not able to mimic the effects of the 
wild-type protein, In this context, we put forward HDAC6, a recently described novel 
GRK2 substrate (Lafarga et al., 2012a), and Mdm2, new substrate identified thorough 
this thesis, as relevant direct targets underlying the effects of GRK2 on luminal breast 
cancer cells through the control of p53.
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1. 
Concurrent up-regulation of GRK2, Mdm2 and HDAC6 
emerges as a functional module characteristic of 
luminal breast cancer cells. 
Besides oncogenic drivers, alteration of relevant signalling nodes can critically modulate cancer progression-related cellular networks to strength key tumoural hallmarks (Hanahan & Weinberg, 2011). In this sense, GRK2 is emerging as a 
central signalling hub, not only through its canonical role in the desensitization of many 
G protein-coupled receptors (GPCR), but also by phosphorylating and/or dynamically 
interacting with important modulators/ effectors that are potentially relevant in cell 
transformation, migration or survival (Penela et al., 2010a). 
The present work uncovers that GRK2 protein levels are increased in the abundant 
group of infiltrating ductal breast carcinomas of luminal type, mainly in those ER-receptor 
positive (which represent two-thirds of all breast cancers) and in 80% of metastaticIDC. 
Interestingly, the stimulation of different transduction pathways (oestrogens or EGFR 
receptors, HER2/ras and PI3K/Akt cascades) known to be hyper-activated in luminal 
breast cancer cell lines as a result of mutation and/or amplification/over-expression of key 
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signalling proteins (Eroles et al., 2012), not only correlates with increased GRK2 levels but 
appears to converge in promoting enhanced GRK2 expression in transformed and non-
transformed breast epithelial cells (Fig.D1). Thus, the presence of estrogens up-regulates 
GRK2 levels in ER+ MCF7 and T47 cells, whilst the opposite occurs upon oestrogen 
withdrawal from the culture medium. On the other hand, blocking EGFR signalling in 
MDA-MB-468 cells down-modulates GRK2 levels, whereas activation of the Her2/Ras 
cascade triggers enhanced kinase expression in non-transformed MCF10A (basal-like) or 
184B5 (luminal-like) cells and in spontaneous tumours formed in MMTV-Her2 transgenic 
mice, suggesting that up-regulated GRK2 could also be a feature of certain non-luminal 
types of breast cancer such as the HER2E subtype (The Cancer Genome Atlas Network, 
2012).
 Our results are consistent with a relevant role for the activation of the Akt pathway 
in promoting GRK2 up-regulation.  The altered molecular signature of the cancer cells 
where GRK2 is enhanced share genetic alterations in this pathway (PI3KCA, PTEN) or 
hyper-stimulation of receptors (EGFR, Her2, ER) able to trigger Akt stimulation (Renoir, 
2013; Roskoski, 2014). Notably, the MDA-MB-468 cell line, frequently classified as basal 
A type (Gordon et al., 2003; Neve et al., 2006), displays mutations in this pathway, contrary 
to other basal breast cancer cell lines that show normal GRK2 expression. Moreover, 
enhanced Akt cascade activation positively correlates with GRK2 up-regulation in MMTV-
Her2 mammary gland tumours, in the mammary gland of Myr-Akt transgenic mice and in 
100% of metastatic infiltrating ductal carcinoma samples from patients.  We propose that 
mitogenic activation of AKT triggers phosphorylation of the E3 ligase MDM2 at serine 
166 and serine 186 and its subsequent recruitment to the nucleus, thus hampering Mdm2-
dependent proteolysis of cytoplasmatic substrates such as GRK2, increasing GRK2 protein 
levels as previously suggested for some breast cancer and melanoma cell types by (Salcedo 
et al., 2006). In fact, we observed a clear correlation between modification of GRK2 levels 
and phosphorylation of Mdm2 at these residues in normal breast cells transfected with 
the oncogenes Ras/Her2 and in transformed breast cancer cells upon EGFR inhibition. 
Such post-transcriptional mechanism for GRK2 up-regulation would be consistent with 
the fact that increased mRNA expression of the ADRBK1 gene has not been reported to 
our knowledge as a common feature in the context of breast cancer. It should be noted 
however that canonical transcriptional modulators as estrogens promoted GRK2 up-
regulation in ER+ MCF7 and T47D cells with a time course and pattern similar to that of 
a well-known ER transcriptional target such as Mdm2 or HDAC6 (Azuma et al., 2009; 
Brekman et al., 2011; Okoro et al., 2013). Therefore, the occurrence of mechanisms acting 
at this level cannot be ruled out, although ER-alpha activation in breast cancer cells also 
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triggers stimulation of the PI3K/Akt cascade, by either direct stimulation of the GPCR-30 
receptor or plasma membrane nucleation of Er-α/ kinase complexes (Lee et al., 2005). 
Interestingly, Mdm2 is also regulated by the Ras-driven Raf/MEK/MAP kinase 
pathway (Ries et al., 2000). Therefore, both Mdm2 and GRK2 could be found over-
expressed in similar tumoural contexts, since Mdm2 has been also found clearly up-
regulated in transformed breast cancer cells of luminal ER positive phenotype and in 
40%–80% of late-stage metastatic breast tumours, being associated with worse prognosis, 
increased metastasis and cancer progression (Araki et al., 2010; Lacroix et al., 2006). 
 Besides Mdm2, we also have found a clear correlation between up-regulated GRK2 
levels and over-expression of HDAC6 in luminal breast cancer cells (Fig.D2). HDAC6 
has been associated with malignant transformation and invasive motility in breast cancer 
(Duong et al., 2008; Lee et al., 2008). Interestingly, we have recently reported that GRK2 
directly associates with and phosphorylates HDAC6 to specifically stimulate its alpha-
tubulin deacetylase activity at discrete cellular localizations in epithelial cells (Lafarga et 
Figure D.1. Oncogenic pathways up-regulate GRK2 in luminal breast cancer cells. Growth 
factor receptors and/or downstream signalling effectors PI3K (1) and Ras (2), usually mutated or 
overactivated in luminal breast cancer as well as oestrogen receptors (3) enhance GRK2 expression. * 
means most commonly mutated proteins in this type of tumours.
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al., 2012a). Remarkably, phosphorylation of GRK2 itself at S670 by ERK1/2 in response 
to stimuli such as EGF was required for the ability of the kinase to phosphorylate and 
regulate HDAC6 (Lafarga et al., 2012a). Enhanced levels of S670-phosphorylated GRK2 
were detected in all cells in our panel that displayed GRK2 up-regulation, what would 
make more likely a functional interaction between both proteins. As observed for GRK2, 
HDAC6 levels can be induced by Ras oncogenic signalling in several cell types (Lee et al., 
2008) and are transcriptionally upregulated by estrogens in MCF7 cells (Saji et al., 2005b). 
 Taken together, our data suggest that enhanced activity of different tumour-
promoting cascades (PI3K/Akt, estrogens, EGFR, Ras/Neu) in specific breast cancer cells 
would potentiate the GRK2-HDAC6 signalling module and/or the co-existence of over-
expressed Mdm2 and GRK2 proteins, which could be beneficial for tumour development 
(Fig.D.2). Interestingly, over-activation of growth factor receptor pathways also converges 
in enhanced GRK2 protein expression in other tumoural cell types such as melanoma cells, 
where Mdm2 is also up-regulated (Polsky et al., 2001; Salcedo et al., 2006), suggesting 
that the presence of these new interactomes could be extrapolated to other pathological 
situations. In this regard, GRK2 has been found up-regulated in thyroid carcinoma, and 
granulose cell tumours (King et al., 2003; Métayé et al., 2008), where Mdm2 or HDAC6 
protein or activities are also enhanced and play a role in the onset of these pathologies 
(Ding et al., 2013; Haakenson and Zhang, 2013; Kanno et al., 2012; Rayburn et al., 2005; 
Giaginis et al., 2014). Our data and results from other groups suggest that GRK2 might 
contribute to the growth of these tumours by positively co-operating with the mitogenic 
effects of the smoothened receptor, IGF-1, EGF and HER2 receptors or by hampering the 
TGFb-triggered anti-proliferative signalling reported in many other cell types (Bliziotes et 
al., 2000; Dorsam & Gutkind, 2007; Freedman et al., 2002; Gao et al., 2005; Meloni et al., 
2006; Penela et al., 2010a; Wan et al., 2003). It is worth noting, however, that the impact 
of GRK2 expression on specific tumours might differ. Thus, up-regulated GRK2 reduced 
serum-(or PDGF)-induced cell proliferation in thyroid tumours instead of stimulating it 
as occurs in breast tumours (Métayé et al., 2008), while a potential role in motility was 
suggested in line with the pro-migratory effects on mammary tumour cells reported herein. 
In contrast, down-modulation of GRK2 has been reported in prostate cancers with higher 
grades of malignancy (Prowatke et al., 2007) and hepatocarcinoma cell lines, in which 
increased GRK2 levels attenuate IGF-1-dependent signalling and cell growth (Fu et al., 
2013; Wei et al., 2013; Zheng et al., 2012). Overall, the physiological outcome of altered 
GRK2 expression would depend on the cell-type-specific multi-molecular signalling 
complexes assembled by growth factors and on the pro-transducer vs pro-desensitizing 
effect of GRK2 on such complexes (Penela et al., 2010a). 
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Figure D.2. Luminal breast tumours could benefit from the up-regulation of GRK2,Mdm2 and 
HDAC6 proteins.  Oncogenic pathways responsibles for the up-regulation of GRK2 in luminal breast 
cancer also promote transcriptional expression and activation of Mdm2 or HDAC6.
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2. 
GRK2 is a novel kinase activity-dependent activator of 
Mmd2 that negatively regulates p53 
We find that GRK2 levels in transformed luminal mammary cells and in breast 
cancer cell-derived xenograft tumours inversely correlates with p53 content and activity. 
Notably, decreased p53 expression is only triggered by a catalytically active form of GRK2 in 
HEK293 cells and in MCF7-derived xenograft tumours. Moreover in non-tumoural 184B5 
cells chronically challenged with EGF, enhanced GRK2 levels reduced the transcriptional 
activity of p53 and other p53-controlled transcription factors, These data are consistent 
with previous results from our group showing also a negative correlation between GRK2 
levels and p53 expression and induction of apoptosis in the context of cell cycle (Penela et 
al., 2010b), strongly arguing for a relevant role of GRK2 in the modulation of p53 response 
in different cellular settings.  
 p53 protein expression is mainly regulated by the E3 ligase Mdm2, which mediates 
not only the ubiquitination and degradation of p53, but also controls its transcriptional 
activity and cell location. Interestingly, whereas Mdm2 regulates proteasome-dependent 
GRK2 turnover in normal cells, it appears that in a tumoural context over-activation of 
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growth factor receptor pathways triggers AKT-mediated Mdm2 phosphorylation and 
its recruitment to the nucleus, hampering this regulatory axis. We propose that in this 
scenario, GRK2 would interact with and phosphorylate MDM2, establishing a new 
regulatory feedback loop by which GRK2 potentiates Mdm2 activity towards p53 (Fig.D. 
3). Interestingly, enhanced GRK2 protects MCF7 cells from the p53 induction promoted 
upon treatment with Nutlin3a, a specific inhibitor of the Mdm2-p53 interface, whereas 
it does not modify p53 levels upon treatment with the E3 ubiquitinase Mdm2 inhibitor 
HLI373, confirming that the negative effect of GRK2 on p53 depends on Mdm2 ubiquitin 
ligase activity. Notably, GRK2 not only potentiates MDM2-p53 interaction, but also 
increases the basal-steady state of Mdm2 and Mdm2 stabilization in HEK 293 cells both 
in a kinase catalytic-dependent and independent ways. We suggest that the catalytic effects 
of GRK2 would be triggered by the direct multi-site phosphorylation of Mdm2 at residues 
S115/116, S260/262 and S351, which are situated within or close to relevant Mdm2 
domains such as the p53 binding site (aa1-108), the nuclear location or export sequences 
(NLS, NES, aa 179-185,190-202 respectively), the central acidic domain (CAD) (aa 243-
300) or in between Zn- and RING-fingers (aa 301-335, aa 432-491). These regions are 
usually selected for post-transductional modifications that affect the functional integrity of 
the ligase, thereby strongly arguing for a direct role of GRK2 in the regulation of Mdm2 
functionality. 
It has been proposed that Mdm2 differentially catalyze mono-ubiquitination and 
poly-ubiquitination of p53 in a dosage-dependent manner (Li et al., 2003), with higher 
doses of MDM2 favouring poly-ubiquitination and nuclear degradation of p53 (Christopher 
L. Brooks and Wei Gu, 2006; Li et al., 2003). Conversely, lower doses would trigger 
p53 multi-mono-ubiquitination that blocks the binding of p53 to DNA and promotes its 
nuclear exportation to the cytosol, where p53 can stimulate some apoptotic pathways 
(Marchenko & Moll, 2007; Marchenko et al., 2007). Therefore, by means of Mdm2 
stabilization and accumulation, GRK2 could favour p53 poly-ubiquitination versus mono-
ubiquitination, resulting in the observed increase of p53 turnover in GRK2 over-expressing 
breast cells. Interestingly, phosphorylation of Mdm2 residues S115/116 could also affect 
poly-ubiquitination of p53. These residues are in proximity to domains critical for nuclear 
shuttling of Mdm2, which inactivation abrogates Mdm2-dependent p53 degradation 
(Roth et al., 1998; Tao & Levine, 1999). Thus, it is tempting to hypothesize that their 
phosphorylation by GRK2 could result in alterations of Mdm2 sub-cellular distribution 
that would impact on the p53 turnover. This is in line with our observation that GRK2 
promotes increased nuclear translocation of Mdm2 and destabilization of p53 in a kinase-
dependent manner. In addition, S115/116 residues are near the p53 binding site of Mdm2, 
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suggesting that their modification could increase/stabilize the interaction of both proteins. 
Further studies with the Mdm2 defective mutants S115/116A will be necessary to unveil 
the role of GRK2 in this process. 
On the other hand, the central acidic domain (CAD) of Mdm2 is also critical for 
p53 binding and degradation [Martin et al, 2006, Cheng 2014]. This region undergoes 
constitutive phosphorylation on multiple serine residues (S229, S232, S240, S242, S246, 
S253, S256, S260, S262 and S269) in cultured cells (Kulikov et al., 2006). Glycogen 
synthase kinase 3 (GSK3), casein kinase II (CK2) and casein kinase I (CK1) have been 
shown to modify some of these sites (Fig I.5).  In this context we find that GRK2 is an 
additional kinase that targets serine 260 or 262 (or both) within the CAD domain. While 
S260 seems to be targeted preferentially by CK2 (Hjerrild et al., 2001), no kinase had been 
clearly identified for S262. Interestingly, phosphorylation of S260/S262 by GRK2 might 
Figure D.3. GRK2/Mdm2 feed-back loop.  In some tumoural contexts, GFR, GPCRs and ER would 
activate the PI3K/AKT pathway, which would result in the AKT-mediated phosphorylation of Mdm2 
and the blockade of the Mdm2-dependent cytosolic degradation of GRK2. In such situations, GRK2 
would in turn phosphorylate Mdm2 at S115/116 and S260/262 reinforcing Mdm2 stability, the nuclear 
shutling of the ligase and its E3 ligase activity towards p53.
206
Discussion
improve targeting of p53 to proteasome, as this modification lies close to the 257EDV259 
motif that is engaged in an intra-molecular interaction with the RING domain, which 
conceals the C-terminal interface of Mdm2 required for binding to 19S regulatory subunits 
(Kulikov et al., 2010) However, the multi-serine cluster mentioned above becomes hypo-
phosphorylated in response to DNA damage mainly due to the DNA damage-induced 
downmodulation of GSK3 (Kulikov R et al., 2005). Interestingly, phosphorylation of S242 
and S256 by GSK3 is dependent on prior phosphorylation of S246 and S260.  It is tempting 
to speculate that, GRK2 could cooperate with GSK3b in maintaining p53 levels low, 
priming the Mdm2 modification by this latter kinase in some cellular contexts such as in 
response to endoplasmic reticulum stress (that promotes p53 degradation) or under nutrient 
and energy load inducing protein synthesis and growth. On the other hand, GRK2 may 
functionally replace GSK3b in response to genotoxic stress in order to keep at bay p53 levels 
and restrict the apoptotic fate of cells in a Mmd2-dependent manner. Thus, while GSK3 is 
inhibited by an AKT2 and DNA-PK dependent mechanism as part of the genotoxic-driven 
p53 induction (Boehme et al., 2008), GRK2 is up-regulated under doxorubicin treatment, 
being feasible it might counterbalance CAD hypo-phosphorylation and p53 stabilization. 
Moreover, DNA damage and also cell cycle-derived signals contribute to stabilize p53 by 
promoting multi-site phosphorylation of Mdm2 by CK1, mainly at the CAD by targeting 
S240, S242, S246, S256 and S260 residues and also the N- and C-terminal of Mdm2 within 
suboptimal degron sequences that mediate the ligase recognition and destruction by the 
SCF-bTRCP pathway (Inuzuka et al., 2010). CK1δ phosphorylation of the MDM2 acidic 
domain also stimulates binding to the p53 core. It is possible that Mdm2 modification 
by GRK2 might interfere with phosphorylation of CK1, or vice versa, in the CAD and 
other regions of Mdm2. According to this, we observed that a phospho-defective mutant 
of Mdm2 at S172, which is a confidently assigned CK1 site in vitro, displayed enhanced 
phosphorylation by GRK2. Therefore, we hypothesize that under over-activation of 
oncogenic pathways GRK2-mediated modification of Mdm2 might alter the interaction 
of the ligase with phosphatases, kinases or partners that target the CAD domain or inhibit 
the p53/Mdm2 interaction. This notion might be extensive to other regions of Mdm2 
modified by GRK2. In particular, the T351 residue phosphorylated by GRK2 lies close 
to the main sites modified by ATM (S395) or cABL (Y394) after DNA damage. Another 
potential interplay of interest in the context of cell cycle and checkpoint activation could 
involve the mutually excluding modification of Mdm2 by CDK2 and GRK2, as suggested 
by the enhanced GRK2-mediated phosphorylation of a CDK2-phosphodefective mutant 
of Mdm2 (S213/T216/T218). MDM2 becomes phosphorylated by cyclinA-CDK2 during 
S-phase progression, and its activity towards p53 is reduced as result of the lower ligase 
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binding to p53 but higher to ARF protein. It is possible that this regulatory event favors that 
critical phases of the cell cycle can be on-check by means of the maintenance of a ready-to 
use pool of p53. In parallel, GRK2 is also phosphorylated by cyclinA-CDK2 during G2 
progression, which leads to GRK2 degradation in a Mdm2-dependent manner (previous 
data of our group). Therefore, it is feasible that CDK2 can switch the repertoire of Mdm2 
substrates, by facilitating a complex with GRK2 that could be competent to promote its 
ubiquitinatation. On the contrary, upon DNA damage, CDK2 activity is inhibited and 
GRK2 could be engaged in complexes with Mdm2 that would be non-productive in terms 
of GRK2 degradation but still productive in ligase phosphorylation by GRK2, thereby 
restricting the extent of Mdm2 inhibition and the p53 responsiveness. In this scenario, 
up-regulation of GRK2 can interfere in the genotoxic-induced activation of cell cycle 
checkpoints, contributing to increase genomic instability and cellular transformation. 
 Overall, high levels of GRK2 could endow the Mdm2 ligase with an intrinsic 
refractoriness to both DNA damage- and non-genotoxic-triggered inhibition (as inferred 
from the less sensitivity to Nutlin3a), due to the direct interaction with and phosphorylation 
by GRK2, and/or the influence of GRK2 on other phosphorylation events that tilt the 
functional balance of Mdm2 towards a p53 degradation. The impact of GRK2-dependent 
phosphorylation of Mdm2 on luminal breast cancer might be multifaceted as besides the 
potential direct effects on allosteric Mdm2 activation and protein sub-cellular localization, 
it can regulate the binding of other proteins to the CAD domain (regulatory proteins that 
control Mdm2 targeting to p53) or other regions. As consequence, this model of regulation 
might adjust the threshold for p53 activation depending on the proliferative or metabolic 
status of the cell. In addition it might weaken the accuracy of cell-cycle checkpoints and 
might foster the development of chemoresistance by attenuating the p53 response. How 
phosphorylation by GRK2 and other kinases is integrated at the same or close sites of 
Mdm2 in different cellular contexts (basal growing conditions, DNA damage, non-
genotoxic stresses as nucleolar, ER, metabolic etc) to reset the outcome of the p53/Mdm2 
feedback loop, is a relevant question that remains to be elucidated. 
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3. 
GRK2 mediates breast tumour progression in both wild 
type and mutant p53 contexts
We find that GRK2 down-modulation similarly inhibited tumour growth of either MCF7 (p53 wild-type) or MDA-MB-468 (mutant p53)-derived xenografts whereas the up-regulation of the kinase increases anchorage-
independent growth and tumour growth in vivo induced by MCF7 or MDA-MB-231 
(mutant p53) cells. These data may suggest that the ability of GRK2 to modulate breast 
tumour development in vivo is independent of the p53 status or, alternatively, that it has a 
double-edged sword role, attenuating p53’s tumour-suppressor functions in cells retaining 
the wild-type factor, but otherwise promoting p53’s oncogenic roles in contexts of mutant 
p53 expression (Fig.D.4). This notion is supported by the fact that Mdm2 and HDAC6 
control both wild-type and mutant p53 responsiveness
 In wild-type p53 contexts (which account for circa 80% of breast cancers) both the 
GRK2/Mdm2 axis and the interplay between GRK2/HDAC6 could cooperate to attenuate 
p53 responsiveness by means of the increase in p53 ubiquitination and degradation and the 
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decrease in its acetylation and functionality (Fig. D.4). In this regard, it has recently been 
noted that despite being considered a cytosolic protein, HDAC6 can be found in the nucleus 
and associated to actively transcribed chromatin (Liu et al., 2012). Interestingly, HDAC6 
could interact with wild-type p53 promoting its degradation in a Mdm2-dependent manner, 
due to removal of acetylation in particular sites that counterbalance protein ubiquitination 
(Ding et al., 2013). Transcriptional activity of p53 is also reduced by HDAC6 as its binding 
to p53 displaces the acetylase p300 (Ding et al., 2013), thereby reducing acetylation at 
the core protein and C-terminal sites. Such modifications are pivotal for proper sequence-
specific DNA-binding and important in protein stabilization (Brooks & Gu, 2011). On top 
of that, the ability of GRK2 to neutralize p53 activity might involve also other functional 
interactors. We show that enhanced GRK2 expression increases AKT activation upon 
growth factor stimulation, increases nuclear location of Mdm2 and decreases p53 levels. 
This could be consistent with an indirect effect of GRK2 on p53 response by potentiating 
the PI3K/Mdm2/p53 regulatory axis.
In marked contrast, mutant p53 is aberrantly stabilized in tumoural contexts by 
its uncoupling from Mdm2. In these situations, and opposite to wild-type p53, GRK2 
could contribute to protect mutant p53. It has been recently reported that HDAC6 activity 
promotes the stabilization of mutant p53 in MDA-MB-231 cells through the de-acetylation 
of Hsp90, which in turn inhibits p53 degradation by blocking Mdm2 (Kovacs et al., 
2005; Li et al., 2011b, 2011a). While Hsp90 associates with wild-type p53 only in rare 
occasions and transiently, many mutant p53 proteins display an abnormal folding in their 
core domain and form stable complexes with Hsp90, which chaperone activity stabilizes 
protein folding and prevents protein aggregation. It has been proposed that Mdm2 is non-
functionally trapped in ternary complexes with mutant p53 (Hsp90-Mdm2-p53) as presence 
of Hsp90 might simulate the inhibitory binding of ARF. Given that GRK2 may directly 
interact with Hsp90 (Chen et al., 2013; Luo & Benovic, 2003) and also phosphorylate and 
activate HDAC6 (Lafarga et al., 2012), it is tempting to suggest that GRK2 could stabilize 
mutant p53 by rendering active Hsp90, which could exert a dominant effect on Mdm2 
irrespective of its phosphorylation by GRK2. Furthermore, we can not rule out that GRK2 
would be unable to phosphorylate Mdm2 in the p53 ternary complex as the region that 
Hsp90 conceals (S258-S260) spans CAD phospho-sites of GRK2. In coherence  with these 
notions our results show that GRK2 over-expressing MDA-MB-231 cells (mutant p53) are 
less sensitive to death induced by SAHA, a pan-HDAC inhibitor that preferentially triggers 
destabilization of mutant p53 by disruption of the HDAC6/Hsp90 regulatory axis (Li et 
al., 2011a).(Fig.D.4) 
210
Discussion
Consistent with a role of GRK2/HDAC6 interaction in the control of mutant p53, we 
have demonstrated that different breast cancer cells harboring mutations of p53 accumulate 
higher levels of nuclear GRK2, which was phosphorylated at S670. This modification is 
not only instrumental for HDAC6 regulation and activation, but could be also relevant in 
the nuclear shuttling of the kinase, thus facilitating the formation of local specific GRK2 
interactions for mutant p53 stabilization. However, the effect of GRK2 on the regulation 
of different mutants of p53 might be different according to the specific mutations and 
the subsequent conformational changes of the protein. In this sense, p53280R-K mutant 
(expressed in MDA-MB-231 cells) has been shown to be strongly dependent on Hsp90 
regulation, whereas p53273R-H, a mutant p53 isoform present in MDA-MB468 cells, 
display lower ability to bind Hsp90 (Peng et al., 2001). Alternatively, those mutant p53 
Figure D.4.  Proposed model of GRK2 influence in tumour progression through the control of 
wild-type or mutated p53.  In wild type p53 tumours, GRK2 would act as a negative modulator of 
p53 response through the phosphorylation and activation of Mdm2, main E3 ligase responsible of p53 
degradation, and of HDAC6, which would promote the de-acetylation of p53, usually associated with 
tumour progression. On the other hand, GRK2 would contribute to mutant p53 stabilization through the 
regulation of HDAC6-Hsp90 axis and Pin1 expression.  GRK2 would also potentiate p53-independent 
functions of Mdm2 in both wild-type and mutated p53 conditions.
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proteins intrinsically resistant to MDM2-mediated degradation could be also insensitive 
to GRK2. It has been reported that the interaction of Mdm2 with some mutant p53s 
differs from that of wild-type p53 as they bind to the RING-finger of the ligase through 
the DNA-binding domain instead of using their respective classical N-terminal domains 
(Lukashchuk & Vousden, 2007). This interaction prevents mutant p53 ubiquitination 
and degradation by Mdm2 since key structural determinants within the RING domain 
involved in p53 targeting to the proteaosome are blocked (Kulikov et al., 2010).  Thus, 
stabilization of both Mdm2 and mutant p53 are not mutually exclusive (Cordon-cardo 
et al., 1994) and Mdm2 can provide pro-survival, proliferative and invasive properties 
in a p53-independent way (Manfredi, 2010).
In the search for additional players that might be involved in the GRK2 mediated 
modulation of the p53 response, it is worth noting the prolyl-isomerase Pin1. Notably, 
we find enhanced Pin1 expression upon GRK2 up-regulation in non-transformed cells 
and a positive correlation between both proteins in luminal breast cancer cells. Pin1 
over-expression has been previously reported in human breast cancer tissues and its 
transcription is enhanced by oncogenic Neu or Ras (which signalling pathways are also 
potentiated by GRK2 expression) via E2F activation, otherwise stimulated by Mdm2 
(Ryo et al., 2002; Wulf et al., 2001). Furthermore, Pin1 enhances the transformed 
phenotypes of Neu/Ras-transfected mammary epithelial cells (Ryo et al., 2002), and 
amplifies EGF signalling in breast cancer cells through its interaction with MEK1, 
leading to enhance HER-2 expression (Khanal et al., 2010). Moreover, Pin1 binds to 
different cell cycle and mitotic regulators, including GRK2 during G2/M transition 
(Penela et al., 2010b), acting as a central coordinator of cell cycle progression (Lu KP. 
2000). The key functional feature of Pin1 is to tune different signalling cascades engaged 
in cellular proliferation and survival by selectively altering their signal duration and 
intensity. Such additional layer of regulation defines Pin1 as a relevant component of 
tumourigenic pathways. However, Pin1 also positively regulates numerous mediators 
of apoptosis. This means that Pin1 potentiates signal transduction irrespective of the 
particular cellular context, thereby reinforcing the alteration of cellular networks but not 
triggering them. For instance, Pin1 is required for full activity of wild-type p53, allowing 
its stabilization by preventing Mdm2 binding in response to DNA damage as well as 
by its ability to transactivate p21 and trigger cell cycle arrest an apoptosis (Penela et al., 
2010b; Wulf et al., 2002). On the other hand, Pin1 can also stabilize p53 mutants with 
the same efficacy as the wild-type protein  and promote the gain-of-function of mutant 
p53 by causing a profound qualitative change in its transcriptional program (Girardini et 
al., 2011). While in normal cellular settings Mdm2-mediated degradation of GRK2 and 
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Mdm2-dependent stabilization of p53 are coordinated by Pin1 in parallel, thus reinforcing 
the efficacy of cellular checkpoints, our data suggest that in luminal breast tumour cell 
lines the over-expression of GRK2 and Pin1 would tilt the balance between proliferative 
signalling and cell cycle checkpoint control towards uncontrolled proliferation irrespective 
of p53 status. Such co-up-regulation of GRK2 and Pin1 also points out that tumoural 
signalling switch the normal outcome of GRK2-Pin1 interaction (that is degradation) by 
mechanisms to be determined, but probably related to different modifications in Mdm2 
(by AKT or Cdk2) or in Pin1 itself. Similarly, oncogenic signaling pathways override Pin1-
mediated p53 stabilization in tumour cells that retain wild-type protein. In contrast, cells 
harbouring mutant p53 are addict to such functional aspect of Pin1, and in this context the 
cooperation between GRK2 and Pin1 might be more relevant. However, further studies 
are required to define the physiological and pathological roles of Pin1/GRK2-mediated 
p53 regulation. 
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4. 
GRK2 is a central signalling node in cancer biology
In this work, we demonstrate that GRK2 plays a driver function in the development of central oncogenic features in breast cancer.  As such, GRK2 should be considered as a transducing hub shared by different pathways actively sending and receiving signals. 
It has been noted that cancer-associated genes often constitute this type of nodes and are 
frequently involved in both positive and negative regulatory loops, which alteration drives 
prolonged activation of downstream effectors (for instance ERK or transcription factors) 
and the transition from a normal cellular sate into a long-term deregulated tumoural-prone 
state. Most of these cancer genes are interconnected and three hot areas have emerged in 
the cancer signalling network around RAS, p53 and TGFb-signalling-dependent events 
(Cui et al., 2007). Interestingly, in such cancer-signalling map the more mutated genes a 
particular protein links to, the more probability of being a relevant cancer-associated onco-
modulator one. GRK2 not only has numerous functional links to cancer-mutated genes 
but also interconnects and potentially modulate the hot areas mentioned above by means 
of the regulation of Mdm2 and HDAC6, thereby allowing the alteration of proliferation, 
survival and motility. 
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4.1. GRK2 levels and activity modulate breast tumour proliferation through 
HDAC6 and Mdm2-dependent mechanisms.
 We show that increased GRK2 levels in untransformed MCF10A or 184B5 breast 
cells lead to an enhanced Ras loading and stimulation of ERK1/2 and Akt pathways in 
response to relevant growth factors such as heregulin or EGF, and to increased expression 
of Pin1 and phospho-His3 proliferation markers (both Ras-downstream effectors) in a 
way similar to the Ras/Neu induced transformation of breast cells. The over-activation 
of growth factor receptor signalling by extra GRK2 results in sustained proliferation. 
Moreover, up-regulation of GRK2 in transformed MCF7 orMDA-MB-231 cells enhances 
cell proliferation, markedly favours anchorage-independent growth and increases tumour 
growth in xenograft models in vivo. Moreover, this pro-mitogenic action of GRK2 requires 
its kinase activity, since the over-expression of a catalytically inactive mutant is not able 
to mimic such effects. Conversely, decreasing GRK2 levels hampers proliferation and 
anchorage-independent growth. Moreover, GRK2 down-regulation in MCF7 or MDA-
MB-468 cells strikingly abrogates their ability to form tumours in vivo, indicative of a 
critical role for GRK2 in this process.  
 Notably, HDAC6 has been shown to be required for oncogenic Ras- and HER2-
dependent fibroblast transformation (Lee et al., 2008) and for anchorage-independent 
growth of different cancer cells, including MCF7 (Lee et al., 2008; Mak et al., 2012). 
Moreover, HDAC6 knockout mice display reduced phosphorylation of ERK1/2 and Akt 
and lower levels of activated Ras (Aldana-Masangkay and Sakamoto, 2011). The influence 
of HDAC6 in these processes and signaling activities relies on deacetylation of several 
proteins (receptors, switchers, structural proteins, molecular chaperones, etc). It has been 
shown that enhanced HDAC6 activity reduces acetylation of Ras, an event required 
for efficient nucleotide exchange and for Ras-associated transforming activity (Yang et 
al., 2013). On the other hand, tubulin deacetylation contributes to the maintenance of 
EGFR at the plasma membrane by inhibiting MT-dependent receptor endocytosis, thus 
promoting sustained activation of downstream cascades and enhanced cell proliferation 
(Deribe et al., 2009; Gao et al., 2010). Our results point out GRK2 might affect the 
“mitogenic activity” of HDAC6 substrates by potentiating their deacetylation state in a 
HDAC6 phosphorylation-dependent manner. We show herein that an HDAC6 mutant 
unable to be phosphorylated by GRK2 (Lafarga et al., 2012a) inhibits the reinforcement of 
EGFR signalling to ERK1/2 observed in the presence of GRK2 up-regulation and leads to 
higher acetylated tubulin levels upon EGF challenge. Since both HDAC6 and GRK2 have 
been reported to interact with the EGFR (Chen et al., 2008; Deribe et al., 2009; Gao et 
al., 2005) we hypothesize that EGFR stimulation would promote a functional interaction 
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between GRK2 and HDAC6, leading to enhanced local deacytylase turnover, and more 
sustained EGFR downstream signalling (Fig.D.5). Such effect would be favoured by the 
higher GRK2 and HDAC6 levels present in luminal breast cancer cells (Fig.D.2). Notably, 
although less well characterized, it seems likely that the functional interaction between 
HDAC6 and GRK2 could be facilitated by relevant receptors other than the EGFR, since 
HDAC6 also interacts with other ErbB family receptors (Deribe et al., 2009), and with ER 
alpha estrogen receptors at or near the plasma membrane (Azuma et al., 2009), and ER 
stimulation can cause HDAC6-mediated tubulin deacetylation (Azuma et al., 2009), as 
well as GRK2-S670 phosphorylation (Dominguez et al., 2009).
On the other hand, novel functional aspects of Mdm2 have been described in relation 
to cellular proliferation and growth that involve the regulation of non-p53 key proteins such 
as Akt, E2F1, etc. in a ligase activity-independent manner. Thus, upregulation of Mdm2 
promotes AKT phosphorylation irrespective of p53 status by repressing transcription of 
the PI3K regulatory subunit p85 (Singh et al., 2013). Down-modulation of p85 relies on 
the interaction of Mdm2 with the transcriptional activator REST and prevention of its 
loading on the p85 promoter. Interestingly, the central region of Mdm2 (aa 121-275) is 
required for AKT phosphorylation and several sites of GRK2-mediated  phosphorylation 
have been identified in this region. In addition, the complex interplay between Mdm2 and 
E2F1 may allow GRK2 regulation of Mdm2 controlled S-phase entry and proliferation 
Figure D.5. Possible mechanism 
by which GRK2 enhances 
mitogenic pathways through the 
regulation of HDAC6. 
Oncogenic up-regulation of the 
GRK2-HDAC6 interface favours 
the phosphorylation of HDAC6 
by GRK2, which enhaces the 
deacetylase activity of HDAC6 
towards tubulin. Enhanced activity 
of HDAC6 would block the 
EGFR (and probably other RTKs) 
internalization and degradation, 
resulting in increased plasma 
membrane residence of active 
RTKs, able to promote maintained 
mitogenic and survival signalling 
pathways.
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in cancer cells. The N-terminal domain of Mdm2 contacts with E2F1 and stimulates 
its transcriptional ability to modulate genes required for S-phase progression (Gu et al., 
2003; Martin et al.,1995). Mdm2 can also activate E2F1 indirectly by promoting the 
ubiquitination and degradation of RB (retinoblastoma protein), an E2F1 inhibitor (Xiao 
et al., 1995), while E2F1 stability is also enhanced by the Mdm2-mediated displacement 
of the ligase complex SCF-Skp2 from the transcriptional factor (Zhang et al., 2005). By 
increasing Mdm2 stability, GRK2 expression levels could positively influence these novel 
functional outcomes of Mdm2. Interestingly, a similar up-regulation of Mdm2 caused 
by the T309G polymorphism in the Mdm2 promoter has been correlated with tumour 
susceptibility and worse prognosis in some tumours, particularly in breast cancer (Bond 
et al., 2004).  On top of that, Mdm2 is found to be one of the transcriptional targets of 
Ras/MAPK/ERK (Manfredi, 2010). Since GRK2 potentiates Ras activation in a kinase 
dependent manner, we hypothesize that a catalytically active GRK2 would be necessary 
to mediate Ras-dependent Mdm2 transcription, whereas the kinase independent impact 
of GRK2 on Mdm2 turnover could be controlled either by a scaffolding role of GRK2 or 
indirectly by the modulation of other proteins involved in the proteaosomal degradation 
of Mdm2. In sum, GRK2 is engaged in several positive feedback loops with HDAC6 and 
Mdm2, leading to activation of Ras and its downstream components AKT, ERK and 
PIN1, which are responsible for continuous activation of mitogenic pathways. 
4.2. GRK2 confers resistance to diverse cellular insults and influences therapeutic 
responses in vitro.  
 In response to cellular insults, post-translational modifications occurring on MDM2 
directly inhibit its E3 ligase function or restrain this protein in certain sub-cellular locations 
such as the nucleolus to relieve p53 from degradation (Bernardi et al., 2004; Shi & Gu, 2012). 
As a consequence, p53 is strongly accumulated, increasing cell cycle arrest and apoptotic 
responses. We put forward that the regulatory role of GRK2 on Mdm2 and HDAC6-
dependent tumoural competences would endow cells with an improved ability to resist 
p53-mediated cell death induced by different stresses (Hanahan & Weinberg, 2011). First, 
by decreasing p53 stability and activation, increased GRK2 expression in non-transformed 
cells enhances growth potential under nutrient starvation stress as well as resistance to cell 
death induced by common chemotherapeutic agents such as etoposide, cisplatin, paclitaxel 
or doxorubicin. Conversely, down-regulation of GRK2 sensitizes transformed breast 
cancer cells (MCF7) to these apoptotic stimuli. Second, extra levels of GRK2 in different 
breast cancer cells with different molecular signatures lessen both proliferation arrest and 
cytotoxic effectiveness of either Nutlin3-a (in MCF7 cells: wt p53, high levels of GRK2) 
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or HDAC6 inhibitors such as tubacin (in non transformed 184B5 cells: wt p53, normal 
levels of GRK2) or SAHA (in both 184B5 and MDA-MB-231 cells: mutant p53, normal 
levels of GRK2). It is tempting to speculate that phosphorylation of Mdm2 by GRK2 
could potentiate Mdm2/p53 interaction or promote allosteric alterations in the ligase that 
reduce affinity or conceal the binding site for Nutlin3a. In addition, modification of the 
central region and CAD domain by GRK2 could also affect the interaction of Mdm2 with 
other pro-arresting and pro-apoptotic proteins, either positively such as p21, Nsb1, Rb, 
p300  (which are targeted for degradation or inhibition), or negatively, such as ARF , thus 
resulting in different cellular responses that converge in fostering cell survival.  Parallel 
to such GRK2-mediated p53-dependent and -independent effects of Mdm2 in survival, 
phosphorylation of HDAC6 by GRK2 could also strength p53 deacetylation, what would 
promote the attenuation of p53 transcriptional activity and its degradation (Ding et al., 
2013; Ozaki et al., 2013), thereby resulting in increased cancer cell survival (Namdar et 
al., 2010). Interestingly, HDAC inhibitors markedly increase the acetylation state of p53, 
which is essential for p53-mediated cell growth arrest and apoptosis (Tang et al., 2008). 
Therefore, it is tempting to suggest that GRK2-mediated phosphorylation and 
activation of either Mdm2 or HDAC6 makes these molecules less sensitive to their 
inhibitors, thereby debilitating their therapeutic function. Such notion would be consistent 
with ineffective or partial responses shown by Nutlin3-a or by pan-HDAC6 inhibitors in 
GRK2-overexpressing ER-positive luminal cells (MCF7, MDA-MB361) (Tate et al., 2012,). 
Moreover, pan-HDAC inhibitors also display different efficacies among breast tumour 
cells with p53 mutant status. Notably, panobinostat (Novartis) elicits effective responses in 
triple-negative breast tumour cells (MDA-MB231, MDA-MB157), which do not display 
enhanced GRK2 levels but not in cells with high kinase levels such as MDA-MB468 (Tate 
et al., 2012). Finally, it must be taken into account that the positive action of GRK2 in 
the regulation of Mdm2-p53 axis may not synergize with its role as enhancer of HDAC6 
activity in some tumoural situations, such as those involving mutant p53 tumours. In this 
context, stable over-expression of MDM2 enhances SAHA- induced degradation of mutant 
p53 whereas the specific MDM2 inhibitor Nutlin-3a partially prevents SAHA-induced 
destabilization of mutp53 (Li et al., 2011b). These evidences suggest that GRK2 expression 
might be a relevant factor in the heterogeneous response to chemotherapeutic drugs noted 
in tumour cells with variable p53 status, Mdm2 functionality or HDAC6 content. Thus, 
a better understanding of the functional relationships between these proteins will help to 
delineate future therapeutic strategies of interest aimed to either manipulate the catalytic 
activity of GRK2 or the GRK2 -Mdm2/GRK2-HDAC6 interfaces. Notably, besides the 
Mmd2 and HDAC6 connections, the ability of GRK2 to interact with other molecules 
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such as Akt, p38, Smad2/3 or RKIP would also contribute to the anti-apoptotic effects 
observed in transformed breast cancer cells upon treatment with chemotherapeutic agents. 
Overall, our observations may have profound implications from a therapeutic 
perspective, as the extent of GRK2 expression could modify the clinical outcome of breast 
cancer treatments in patients. To date, strategies to induce p53 activation in tumours that 
retain wild-type p53, which represent 80% of all breast cancers, are promising cancer 
therapies. However, for the remaining 20% of tumours with mutant p53, which are mainly 
classified as triple-negative cases, there are not molecular-targeted therapeutic strategies 
so far. Moreover, this group of tumours is particularly refractory to chemotherapy and 
at risk to progress to metastatic breast cancer. On top of that, even in the more treatable 
groups of breast cancer patients the success of therapies is limited by the development 
of drug resistances. In fact, although ER-positive tumours are suitable for endocrine 
therapies, most develop resistance to treatment, which is also common in Her2-targeting 
therapies. Multiple lines of evidence suggest that these phenomena can be explained by the 
presence of complex bidirectional cross-talks between the ER and HER2pathways (Nahta 
& O’Regan, 2012; Tokuda et al., 2012). Thus, treatment strategies targeting either pathway 
are associated with up-regulation of the other one. In addition, antagonists of the “classic” 
nuclear ER (tamoxifen, raloxifene and ICI182,780), are also agonists of GPR30, what 
may induce unexpected proliferative responses. As a result, the efficacy of the tamoxifen 
therapy on luminal estrogen receptor-positive breast tumours is hampered in one-third of 
the women treated by mechanisms depending on increased growth factor receptors and 
PI3K signaling. Since GRK2 is emerging as a central onco-modulator of key tumoural 
processes such as cell proliferation and survival through its role in the control of global p53 
responsiveness or its strong connection with a wide variety of oncogenic pathways, it is 
feasible that GRK2 could be involved in the development of these resistances. Therefore, 
we can hypothesize that breast cancer treatments would benefit from the combination 
of well known molecular-targeted treatments and chemotherapies with the inhibition of 
GRK2 or specific GRK2-mediated molecular interactions.
4.3. GRK2 promotes cancer cell invasion and stromal remodelling
Also relevant to our understanding of cancer progression is the ability of tumour 
cells to migrate and disseminate to distant organs, a main cause of death in breast cancer 
patients. Interestingly, while GRK2 is up-regulated in circa 40% of patients of a general 
cohort with infiltrating ductal carcinoma, this figure raises up to 80% in patients that have 
experienced metastasis to lymph nodes. A similar trend is noted in Mdm2, which is up-
regulated more frequently in metastatic tumours than in primary ones (Datta et al., 2001). 
Therefore, both GRK2 and Mdm2 might play a relevant role in tumour cell migration 
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and invasion. In support of this, over-expression of GRK2 in the highly metastatic MDA-
MB-231 cells or in non-transformed breast cancer cells, potentiates either Heregulin or 
EGF-induced chemotaxis. However, GRK2 down-modulation in MDA-MB-231 cells 
does not affect cell migration in a collagen type I surface, suggesting that the overall impact 
of GRK2 on cell migration is not straightforward and varies depending on the stimuli 
considered. This is consistent with previous findings showing that GRK2 promotes cell 
motility towards fibronectin in fibroblast or epithelial cells, whereas migration of these cells 
towards collagen type IV was unaltered (Penela et al., 2008). The final outcome of GRK2 
in cell migration would depend on how its activity is engaged and integrated into signalling 
pathways that control different steps of the chemotactic process (receptor sensing, cell 
polarization, membrane protrusion, adhesion/de-adhesion cycles) in a cell type-specific 
and stimuli-dependent context, as both positive and negative effects or no effect of GRK2 
in motility have been reported (Penela et al., 2014a).   GRK2 could facilitate leading edge 
formation and cellular displacement of polarized mammary epithelial cells in a multifaceted 
way. First, it might amplify the intensity and duration of pro-migratory signalling 
downstream chemotactic receptors (EGF or S1P receptors) and integrins; second, GRK2 
can controls microtubule dynamics through the activation of HDAC6; third, it promotes 
reorganization of the actin cytoskeleton by stimulating ERM proteins and fourth, GRK2 
increases focal adhesion turnover via induction of GIT1-scaffolding functions (Fig.D.6A)
(Penela et al., 2014 and references therein).Consistently, extra levels of GRK2 potentiate 
GIT-1 expression levels and activation of MAPK and Ras in mammary 184B5 cells as well 
as HDAC6 activity and tubulin deacetylation, all together contributing to build up a robust 
chemotactic response. 
Striking features of the movement of mammary metastatic cells in vivo are their high 
speed during locomotion on ECM fibers  (due to weak adhesion contacts) and their high 
degree of persistent lineal motion (related to a higher polarization ability) compared to the 
random migration of less-efficient metastatic cells  (Condeelis & Segall, 2003). Therefore, 
reduced expression of GRK2 could lessen the efficacy of metastatic movement in vivo by 
limiting polarization and favouring tight adhesion. Consistently, our results indicate that 
upon GRK2 down-regulation random walking of MDA-MB-231 cells is increased (perhaps 
indicative of a desensitizing role of GRK2 on some autocrine- activated receptors in the 
absence of guiding cues), while cell migration towards Heregulin or CCL21 is impaired 
(Fig.D.6B).  Interestingly, expression of extra GRK2 levels in non-transformed 184B5 
breast cells strongly decreases E-cadherin expression levels, while those of vimentin are 
clearly up-regulated. These findings suggest the occurrence of an epithelial-mesenchymal 
transition-like process that could rely on GRK2 interplay with known factors leading to 
EMT, such as Mdm2 or components of the TGFb1 transducing pathway. Mdm2 promotes 
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cell migration and invasion through the ubiquitination and degradation of E-Cadherin (Yang 
et al., 2006), by neutralizing the MDM2 binding protein (MTBP)-mediated suppression 
of tumourigenesis and metastasis, as well as by positively regulating the mRNA of Slug, 
VEGF and MMP9  proteins (Chen et al., 2013b; Jung et al., 2013b). 
Figure D.6. Role of GRK2 in cell migration. A) By dynamically interacting with diverse substrates 
and effectors in different cellular locations, GRK2 may modulate several facets of the cell migration 
machinery in a stimuli and cellular context-dependent manner. FA, focal adhesions; FC, focal contacts. 
B) Proposed model for the role of GRK2 in the induction of cell polarization. Local fraction of receptor 
occupancy by chemoattractants would trigger stimulatory signals for the generation of internal signalling 
asymmetry, whereas global levels of occupied receptors would inhibit this parameter. In the presence of 
lower GRK2 levels/activity, stimulated GPCR would remain longer/more functional in the membrane, 
thus eliciting robust directional sensing responses and the specification of stable pseudopodia as if the 
gradient was steeper. Conversely, excessive GRK2 activity would diminish the global level of occupied 
receptors, resulting in the inability to differentiate the cell front from the back, as occurs in the absence of 
gradients, resulting in cessation of movement.
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During in vivo-monitored invasion into the surrounding tissue (Condeelis & Segall, 
2003), mammary tumour cells traverse long distance walking on ECM fibers that result 
from both tumoural- and stromal- (fibroblasts, immune cells) dependent microenvironment 
remodelling and by following EGF gradients. Cells often converge in the proximity of 
vessels, also endowed with a basement membrane and a dense coating of ECM that 
must be degraded or “squeezed” for intravasation. We have demonstrated that GRK2 is 
necessary for the breakdown of both basement membrane and extracellular matrix (ECM), 
since silencing of GRK2 in MDA-MB-231 cells hampers cell invasion to matrigel (similar 
to basement membrane) and to collagen type I (mimicking ECM) in 2D and 3D models of 
invasion. Moreover, GRK2 abrogation blocks the capability of tumoural cells to degrade 
gelatin, a process that it strictly dependent on MT1-MMP metaloproteinase activity and on 
formation of protrusive structures called invadopodia (Artym et al., 2006b) (Fig.D.7). This 
result suggests a role for GRK2 in the control of MT1-MMP expression or trafficking and/
or in the structural formation/maturation of invadopodia themselves. Underpinning these 
processes might be the functional interplay of GRK2 with p53, Mdm2 and/or HDAC6. It 
has been described that functional p53 inhibits the invasive capacity of tumoural cells by 
repressing several metaloproteinases such as MMP1, MMP2 or MMP13 (Ala-aho et al., 
2002; Kim et al., 2010b), whereas mutated p53 has the opposite effect (Adorno et al., 2009), 
suggesting that GRK2-dependent modulation of the p53/Mdm2 axis could contribute to cell 
invasion. The involvement of this regulatory axis in these cellular processes is strengthened 
by the anti-invasive effect of inhibitors of the of Mdm2-p53 interface as nutlin-3 (Polanski 
et al., 2010). Interestingly, on the basis that (mono)-ubiquitination is a key modification in 
protein internalization and vesicular trafficking, that Mdm2 mediates mono-ubiquitination 
of several substrates and mediates the internalization of membrane proteins (GPCRs or 
E-Cadherin), and the novel finding showing that ubiquitination of MT1-MMP impacts 
on metalloproteinase trafficking (Eisenach et al., 2012), it is tempting to suggest a role for 
Mdm2/ GRK2  by means of the ubiquitination of MT1-MMP (Eisenach et al., 2012), or 
of other proteins related with its intracellular trafficking.
Besides its potential role in the endowment of invadopodia with proteolytic activity, 
GRK2 might be also required for their structural assembly by means of the modulation of 
HDAC6 and/or GIT-1. HDAC6 is a key player of invadopodia formation through the 
regulation of tubulin and cortactin. Deacetylation of cortactin is essential for generation 
of a dendritic actin network to form the core of the nascent and elongating invadopodia, 
while microtubule dynamics linked to tubulin deacetylation is needed for MT1-MMP 
re-routing and exocytosis (Castro-Castro et al., 2012; Rey et al., 2011).  The growth of 
invadopodia and their extension deeper into the substratum is permitted by the infiltration 
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of microtubules, which in combination with an intact vimentin filament network support 
invadopodia elongation and stabilization (Schoumacher M et al., 2010 JBC). Interestingly, 
dynamic microtubules appear to be restricted to the base of invadopodia, while in the stem 
and apex they are stable (Schoumacher et al., 2010). It is feasible that GRK2-mediated 
regulation of HDAC6 contributes to gradient stability of invadopodial MTs. Moreover, 
up-regulation of vimentin caused by GRK2 could also favor invadopodia formation in 
mammary cells. Akin to vimentin, GIT-1 is up-regulated in cells with extra GRK2.  GIT 
has been reported to assemble lipid and protein kinases and small GTPase signaling 
complexes in podosomes (invadopodia-related structures) upon Src activation, an event 
necessary and sufficient for the induction of invadopodia and podosome formation.  In 
sum, we speculate that the positive effects of GRK2 in invasive motility of breast cancer 
cells could be mediated by HDAC6, GIT1 or Mdm2 activities.
Figure D.7. GRK2 contributes to different 
sequential steps of the metastatic cascade. 
First, GRK2 potentiates the adquisition of 
invasive capabilites in tumoural cells. Then, 
GRK2 favours invadopodia formation and 
matrix proteolytic activity to breach the 
basement membrane, followed by ECM 
remodeling, in which the kinase has also a 
positive role.
223
Discussion
Initial escape of metastatic cells from the tumour mass rely on an intrinsic cell-
autonomous altered behaviour, which is conditioned by extrinsic microenvironmental 
factors such as the interaction of malignant cells with the extracellular matrix (ECM) 
and with cellular components of the tumoural stroma that release signals responsible 
for fostering chemotaxis and invasiveness.  Our group has recently reported that GRK2 
levels might affect tumour progression by altering such interplay between malignant cells 
and their surrounding microenvironment. Transformed breast epithelial cells (with high 
levels of GRK2) can trigger in a paracrine way down-modulation of GRK2 specifically 
in the surrounding tumour endothelium, what results in vasculature dysfunction and 
more aggressive tumour progression (Rivas et al., 2013). Tumour-associated vessels with 
lower GRK2 content display deficient pericyte-endothelial attachment and increased 
permeability, blood leakage and tortuosity, leading to inefficient tissue oxygenation and 
nutrient supply. Notably, the increased hypoxic tumoural microenvironment induces 
infiltration of immune cells such as macrophages, which also contribute to increase 
angiogenesis by releasing endothelial activating factors. These features would escalate 
extravasation of immune cells, which positively contribute to tumour growth, but also 
intravasation of tumour cells. Moreover, the interplay between GRK2 and Mdm2 could 
be also relevant in angiogenesis, since up-regulation of Mdm2 in epithelial transformed 
cells stimulates the production and secretion of pro-angiogenic factors such as VEGF 
(Narasimhan et al., 2008; Inada et al., 1996). Therefore, concurrent and opposite changes 
of GRK2 in the epithelial (up-regulation) and stromal (down-modulation) components of 
breast tumours might act synergistically to develop tumour-promoting inflammation and 
genome instability, two characteristics that enable cancer cells the acquisition of hallmarks 
of cancer, and that finally results in tumour survival, growth, and dissemination (Hanahan 
& Weinberg, 2011). A better knowledge of the mechanisms underlying such cell type–
specific modulation and roles of GRK2 may help to understand its integrated role in cancer 
development and to design novel therapeutic strategies.
224
Discussion
 5. 
Future directions
Due to the overall integrative effect of GRK2 in the acquisition of tumoural features and its participation in the majority of hallmarks of cancer (Fig.D.8), we hypothesize a possible role of this kinase in the emerging attributes of cancer 
cells important for cancer development such as reprogramming energy metabolism. In 
this context, GRK2 is associated with insulin resistance and obesity (Garcia-guerra et al., 
2010), both risk factors in breast tumourigenesis, especially in post-menopausal women 
(Thomson et al., 2009). The metabolic context of obesity and diabetes as a risk factor of 
breast cancer involves the inhibition of p53 response. Moreover, p53 directly influence 
various metabolic pathways, including AMPK and mTOR signalling, carbohydrate and 
lipid metabolism, the regulation of autophagy, and the maintenance of mitochondrial 
integrity and REDOX balance enabling cells to respond to metabolic stress and 
counteracting many of the metabolic alterations associated with cancer development 
(Berkers et al., 2013). Interestingly, GRK2 diminishes glucose uptake and blocks insulin 
signalling through the phosphorylation and kidnapping of the insulin receptor substrate 
protein IRS1. Since Mdm2 mediates IRS1 degradation (Usui et al., 2004), we speculate a 
possible role of GRK2 in the Mdm2-mediated IRS1 degradation. However, GRK2 could 
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also impact on cell metabolism through the control of Mdm2-mediated regulation of p53. 
Overall, all these evidences put forward that the role of GRK2 in cancer progression could 
be more complex than expected and deserves a detailed characterization in each particular 
scenario.
Figure D.8. GRK2 favours the adquisition of hallmarks of cancer. Schematic representation of the 
role of GRK2 as a main contributor to the development of cancer.



CONCLUSIONS
1. La sobreexpresión de GRK2, HDAC6 y Mdm2 aparece como un módulo 
funcional común de cáncer de mama de tipo luminal.
2. Las principales vías oncogénicas responsables de la transformación tumoral 
luminal de mama son las responsables del aumento de GRK2 en este tipo de canceres. 
3. Mdm2 es un nuevo sustrato de GRK2. GRK2 fosforila Mdm2 en varios sitios. 
estabiliza la proteína Mdm2, promueve su localización nuclear y mejora la unión entre p53 
y la ligasa, regulando así la respuesta de p53 en una manera negativa.
4. GRK2 favorece la adquisición de las capacidades tumorales mediante el aumento 
de la proliferación celular y la supervivencia, la disminución de las respuestas de apoptosis 
mediada por p53 y mediante la promoción de la migración invasiva de las células tumorales 
de mama. Estos efectos de GRK2 implican la modulación de HDAC6 y / o procesos de 
Mdm2-dependientes.
5. GRK2 es un mediador clave del crecimiento tumoral “in vivo” promovido tanto 
por células de cáncer de mama p53 mutantes o p53 de tipo salvaje. 
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Conclusions
1. The overexpression of GRK2, HDAC6 and Mdm2 emerges as a common 
functional module of luminal breast cancer.
2. The main oncogenic pathways that trigger luminal breast tumour transformation 
increase GRK2 levels in these cancer types.
3. GRK2 is a new Mdm2-activating kinase. GRK2 phosphorylates Mdm2 at several 
sites, stabilizes the Mdm2 protein, promotes its nuclear localization and enhances the 
binding between p53 and the ligase, thus regulating the p53 response in a negative way.
4. GRK2 favours the acquisition of breast cancer hallmarks by enhancing cell 
proliferation and survival, by decreasing the p53-mediated apoptotic responses and by 
promoting the invasive migration of breast tumoural cells. These effects of GRK2 involve 
the modulation of HDAC6 and/or Mdm2-dependent processes.
5. GRK2 is a key mediator of “in vivo” tumour growth promoted by either wild-
type or mutated p53 transformed breast cancer cells. 

CONCLUSIONES EN CASTELLANO

235
Conclusiones en  castellano
1. La sobreexpresión de GRK2, HDAC6 y Mdm2 surge como un módulo funcional 
común en el cáncer de mama de tipo luminal.
2. Las principales vías de señalización oncogénicas responsables de la transformación 
tumoral de mama tipo luminal tales como receptores tirosina quinasa, el eje PI3K/AKT o 
receptores de estrógenos confluyen en el aumento de los niveles de GRK2 en este tipo de 
tumores. 
3. Mdm2 es un nuevo sustrato de GRK2. GRK2 fosforila a Mdm2 en múltiples 
residuos, aumenta la estabilidad de la ligasa, promueve su localización nuclear y facilita la 
unión Mdm2-p53, regulando de forma negativa la respuesta de p53.
4. GRK2 favorece la adquisición de capacidades tumorales mediante el aumento 
de la proliferación celular y la supervivencia, la disminución de las respuestas  apoptóticas 
mediadas por p53 y la promoción de la migración invasiva de las células tumorales de 
mama. Entre los mecanismos moleculares responsables del efecto de GRK2 en la progresión 
tumoral se encuentran la modulación de HDAC6 o la regulación del eje p53/Mdm2. 
5. GRK2 es un mediador clave del crecimiento tumoral “in vivo” , independientemente 
del estatus de p53.
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αARs alfa adrenergic receptors 
β-arr β-arrestin 
β1AR beta-1 adrenergic receptor 
β2AR beta-3 adrenergic receptor 
aa Amino acid 
ADH Atypical ductal hyperplasia 
ADP Adenosine diphosphate 
AKT  protein kinase B  
ATP Adenosine triphosphate 
AP1 Activator protein 1 
BM Basal membrane 
BRCA Breast Cancer Type 2 susceptibility protein 
BSA: Bovine serum albumin 
CAD Central acidic domain 
CCL21 Chemokine (C-C motif) ligand 21 
CDK2 Cyclin-dependent kinase 2 
CHX Cicloheximide 
CK1 Casein kinase 1 
CXCR C-X-C chemokine receptor type 
DAB Diaminobenzidine 
DAG Diacylglycerol 
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DCIS Ductal carcinoma in situ 
DMEM Dulbecco's Modified Eagle's medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
ECM Extracelular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
EGTA Ethylene glycol tetraacetic acid 
Elite ABC kit Avidin-biotinperoxidase complex 
ER Estrogen receptor 
ERK Extracellular signal-regulated kinases 
FBS Fetal bovine serum 
GAP GTPase-activating protein 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GEF Guanine-Nucleotide Exchange Factor 
GF Growth factor 
GIT G-protein-coupled receptor kinase-interacting protein 
GPCR G-Protein coupled receptor 
GRB2 Growth factor receptor-bound protein 2 
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Abbreviations
GRK G-protein coupled kinase 
GSK3 Glycogen synthase kinase 3 
GPR30 
GPER1 
G protein-coupled receptor for estrógeno 30 
G	  protein-­‐coupled	  estrogen	  receptor	  1 
HDAC6 Histone deacetylase 6 
HER2 Human Epidermal growth factor Receptor-type2 
HIF Hypoxia-inducible factors 
HS Horse serum 
HSP90 Heat shock protein 90 
IGFR Insulin-like growth factor 1 receptor 
IDC Infiltrating ductal carcinoma 
IP Immunoprecipitation 
IP3 Inositol trisphosphate 
Iso Isoproterenol 
LC/ MS   Liquid chromatography–mass spectrometry 
MAPK Mitogen-activated protein kinases 
MDM2 Murine double minute 2 
MMP Matrix metallopeptidase  
MT1-MMP Membrane type 1-matrix metalloproteinase 1 
mTOR Mammalian target of rapamycin 
NaVO3 Sodium orthovanadate 
NES Nuclear export signal 
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Abbreviations
NLS Nuclear localization sequence 
PDK1 
PDPK1 
Phosphoinositide-dependent kinase-1 
3-phosphoinositide-dependent protein kinase 1 
PCR Polymerase chain reaction 
PH domain Pleckstrin homology domain 
Pi Inorganic phosphate 
PI3K Phosphoinositide 3-kinase 
PIN1 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 
PIP2 Phosphoinositol biphosphate 
PTEN Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase 
PVDF  Polyvinylidene fluoride 
RGS Regulators of G protein signaling 
RING Really Interesting New Gene 
RNA Ribonucleic acid 
S1P Sphingosine-1-phosphate 
SDF1a Stromal cell-derived factor α 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
Ser Serine  
SH domain Src homology domain 
shRNA A small hairpin RNA or short hairpin RNA  
 siRNA  Small interfering RNA 
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SOS Son of sevenless 
S1P Sphingosine-1-phosphate 
TAE Tris base, acetic acid and EDTA 
TE Tris-EDTA 
TEMED Tetramethylethylenediamine 
TGF-β Transforming growth factor beta 
Thr Threonine 
TKR Tyrosine kinase receptors 
Tyr Tyrosine 
Ub Ubiquitin  
WB Western blot 
WT Wild-type 
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Phosphoinositide-dependent kinase-1 
3-phosphoinositide-dependent protein kinase 1 
PCR Polymerase chain reaction 
PH domain Pleckstrin homology domain 
Pi Inorganic phosphate 
PI3K Phosphoinositide 3-kinase 
PIN1 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 
PIP2 Phosphoinositol biphosphate 
PTEN Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase 
PVDF  Polyvinylidene fluoride 
RGS Regulators of G protein signaling 
RING Really Interesting New Gene 
RNA Ribonucleic acid 
S1P Sphingosine-1-phosphate 
SDF1a Stromal cell-derived factor α 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
Ser Serine  
SH domain Src homology domain 
shRNA A small hairpin RNA or short hairpin RNA  
 siRNA  Small interfering RNA 



